CA2440374A1 - A pharmaceutical composition for the treatment of depression comprising the ep1 antagonist as active ingredient - Google Patents

Abstract

Remedies and/or preventives for depression containing as the active ingredie nt a compound (an EP1 antagonist) having antagonism to EP1 receptor which is on e of prostaglandin E2 receptor subtypes. The EP1 antagonist is useful in treating depression (for example, endogenous depression, reactive depression , weatherproof depression, neurogenic depression, depression associating organ ic mental disorder).

Description

a SPECIFICATION
A pharmaceutical composition for the treatment of depression comprising the EPi antagonist as active ingredient Technical Field The present invention relates to a pharmaceutical composition for the treatment of depression comprising the EPi antagonist as active ingredient.
Background Prostaglandin Ez (PGE~ has been known as a metabolite in the arachidonic acid cascade. It has been known that PGEz possesses cyto-protective activity, uterine contractile activity, a pain-inducing effect, a promoting effect on digestive peristalsis, an awaking effect, a suppressive effect on gastric acid secretion, hypotensive activity, and diuretic activity.
In the recent study, it was found that PGEz receptor was divided into some subtypes, which possesses different physical roles from each other. At present, four receptor subtypes are known and they are called EPi, EPz, EPs and EPa respectively (Negishi M. et al, J. Lipid Mediators Cell Signaling 12, 379-391 (1995)].
PGEz has a broad range of a physiologically active, therefore it has a fault that an activity other than a purpose will become a side effect. However, it has been studied to overcome the fault by a reserch of each subtype role and a synthesis of compounds having an effective action for one subtype only.
Among these subtypes, it is known that EPi subtype relates to pain, fever, diuresis [Br. J. Pharmacol., 112, 735-40 (1994) European J. Pharmacol., 152, (1988) Gen Pharmacol., Sep 1992, 23(5), 805'809]. Therefor, it is believed that an antagonism for this receptor is useful as analgesics, antipyretic or a therapeutic agent of frequent urination.
Besides, it is known that EPi antagonists have an inhibitory activity of a formation of abnormal crypt in the lining of the large intestine and polyp in the intestine, and show an anticancer activity [see reference WO 00/69465].
Depression is led by various factors, and the pathological physiology is remained incompletely understood. Monoamine reuptake inhibitor and monoamine oxidase (MAO) inhibitor are showed an antidepressive activity, and it is consider that an r abnormal mono-aminergic neuron system plays a role in the development of depression.
As an antidepressant, MAO inhibitors including hydrazine derivatives, emotion stimulators such as a reuptake inhibitor of noradrenaline (NA) and 5-hydroxytryptamine (5-HT), emotion-regulators including benzodiazepine derivatives and psychostimulants including Meratoran are known. Then, MAO inhibitors are not used because of a serious hepatopathy and hypertensive crisis, and new type reuptake inhibitor of NA and 5-HT are used, that they are improved side effects such as dry mouth, drowsiness, dizziness, urinary disturbance that are side effects of tricyclic antidepressants as typified by imipramine.
On the other hand, it was not confirmed by an experiment that a relationship of EPi receptors and depression and antidepressive activity of EPi antagonist.
Disclosure of the Invention Energetic investigations about a role of EPi receptors in the brain by various experiments using EPA antagonists have been carried out. The present inventors have found that EPi antagonists have an antidepressive activity and accomplished the present invention. As mentioned above, it was known that an increase of dopamine in the brain on EPi receptor knockout mouse, however, it was not confirmed whether EPi antagonists have an antidepressive activity.
The present invention relates to a pharmaceutical composition for the treatment and/or prevention of depression, such as endogenous depression, reactive depression, weatherability depression, neurological depressed state, the depressed state of brain organic mental disorder, comprising an antagonist for EPi receptor, which is one subtype of PGEz receptor.
EPi antagonists of the present invention bond to EPi receptor, which is a subtype of PGEz receptor, and show an antagonistic action. More preferably EPi antagonists are specifically bond to EPi receptor and show an antagonistic action.
Known EPi antagonists and any EPi antagonists, which will be found in the future, are included in EPi antagonists of the present invention.
Any EPi antagonists are preferable and more preferable EPi antagonists are, for examp 1e, (1) in the specification of EP $78465, the compound of formula (IAA

,,vY.~COR~A

A1 RZA ~~ (IA) N \ ~~ RaA -0 S~Q R5A
wherein ,,,.

is ,,.. ,v ,,v (a) (b) (c) (d) (e) ,,.~ ,,.~ ,,~~ ,,,..
or (9) (h) (I) RIA is hydroxy, C 1-4 alkoxy or a group of formula ~R6AR7A
in which RsA and R7A each independently, is hydrogen or C1-4 alkyl, RZA is hydrogen or C 1-4 alkyl, R3A and R4A are C 1-4 alkyl, halogen atom or trifluoromethyl, R5A is hydrogen, C1-4 alkyl, halogen atom or trifluoromethyl, Y is cis-vinylene or trans-vinylene ~~ is a single bond or a double bond:
a non-toxic salt thereof or a cyclodextrin clathrate thereof (2) in the specification of WO 98/27053, the compound of formula (IB) (Ras) ~ Rze B2 (ZZ)t (/B) 2 Z3 N,-Z4-Zs Rae wherein A2 (A2 ring) T

and g2 (B2 ring) each independently, is C5-15 carbocyclic ring or 5-7 membered heterocyclic ring containing 1 or 2 of oxygens, sulfurs or nitrogens, Z1 is -COR1B, -C 1-4 alkylene-CORIB, ~CH=CH-COR~B, --C~C-COR1B, -0-C1-3 alkylene-COR1B, in which R1$ is hydroxy, C1-4 alkoxy or NRseR7B in which R~B and R~B each independently, is hydrogen or C 1-4 alkyh or ~C1-5 alkylene-OH, ZZ is hydrogen, C1-4 alkyl, C1-4 alkoxy, nitro, halogen atom, trifluoromethyl, trifluoromethoxy, hydroxy or CORiB in which R1B as hereinafter defined Z3 is a single bond or C 1-4 alkylene, Z4 is SOz or CO, Z5 15 (1) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (2) phenyl, C3-7 cycloalkyl or 5-7 membered heterocyclic ring containing 1-2 of oxygens, sulfurs or nitrogens, (3) C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl substituted by phenyl or C3-7 cycloalkyl, in the above (2) and (3), phenyl, C3-7 cycloalkyl and 5-? membered heterocyclic ring containing 1-2 of oxygens, sulfurs or nitrogens may be substituted by 1-5 of R5B in which multiple R5B each independently, is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, nitro, halogen atom, trifluoromethyl, trifluoromethoxy or hydroxyl RzB is CONRgB, NReBCO, CONReB-C1~4 alkylene, C1-4 alkylene-CONRBB, NReBCO-C1-4 alkylene, C 1-4 alkylene-NR8BC0, C 1-3 alkyleen-CONRBB-C 1-3 alkylene, C 1-3 alkylene-NRBBCO-C1-3 alkylene, in which R8B is hydrogen or C1-4 alkyh oxygen, sulfur, NZs in which Z6 is hydrogen or C 1-4 alkyh -Z~-C 1-4 alkylene, C 1-4 alkylene-Z~, C 1-3 alkylene-Z7-C1-3 alkylene in which Z~ is oxygen, sulfur or NZs in which Zs is as hereinbefore defined CO, CO-C 1-4 alkylene, C 1-4 alkylene-CO, C 1-3 alkylene-CO-C 1-3 alkylene, C2-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, R3B is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, nitro, halogen atom, trifluoromethyl, trifluoromethoxy, hydroxy or hydroxymethyl, s ' RrH is (1) hydrogen, (2) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (3) C1-6 alkyl substituted by 1-2 of COOZB, CONZsZIC, OZ8 in which Z8, Zs and Z1~ each independently, is hydrogen or C 1-4 alkyh and C 1-4 alkoxy-C 1-4 alkoxy, (4) C3-7 cycloalkyl, (5) C 1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl substituted by phenyl or C3-? cycloalkyl, in the above (4) and (5), phenyl, C3-7 cycloalkyl may be substituted by 1-5 of R5B in which R5B is as hereinbefore defined, n and t each independently, is 1-4, with the proviso that (1) RzB bond to atom of only 1-position in Bz ring and R3B bond to atom of only 2-position in Bz ring, (2) when Az ring is benzene and (Zz)c is not CORIB, then Zl bond only 3 or 4-position in benzene ofAz ring (3) in the specification of WO 92/19617, the compound of formula (IC) Zc w I / Roc (IC) ~Yc)'c ~.
p N (X )qc (CH2)mc H
wherein RIC is hydrogen, halogen atom or -CFs, Rzc is hydrogen, halogen atom, -OH or -OCHs, Zc is oxygen, sulfur, -S(0)- or -S(O)z- , Xc is -CH=CH-, -CFz-, -CHF-, -(CHzJn~- or -(CH~~-CH=CH-, Yc is -CH(OH)-, -NR3c-, sulfur, -S(0)-, -S(0)z- or oxygen , qcis0orl, rc is 0 or 1, with the proviso that in the case of following (1), (2) or (3), rc is not 0:
(1) Xc is -CH=CH-, -(CH~n~- or -(CHz)p~-CH=CH-, qc is 1 and Arc is imidazole or phenyl, (2) Xc is -(CH~"~-, qc is 1, nc is 1 and Arc is ethylphenyl substituted by halogen atom, methyl or alkoxy, (3) qc is 1, me is 1, 2, 3, 4, 5 or 6 and Arc is imidazole or phenyl, me is 0-6, with the proviso that when Xc is -(CHz)n~-, qc is 1, Yc is oxygen, sulfur, -S(O)-or -S(O)z- and Arc is phenyl, and then me is not 0, nc is 1-6 , p~ is 1-6 , R3C is hydrogen or t-butyloxycarbonyl, Are is aryl, alkyl-substituted aryl or aryl-substituted aiyh (4) in the specification of WO 96/06822, the compound of formula (ID) D (ID) A
~XD-DD
wherein AD is an optionally substituted: 8-10 membered bicyclic heteroaryl, 5-membered heteroaryl, naphthyl or phenyl, with the proviso that -OCH(R3o)- and -XD-linking group are positioned in a 1, 2 relationship to one another on ring carbon atoms, BD is an optionally substituted 5-6 membered heteroaryl ring system or optionally substituted phenyl, DD is optionally substituted: pyridyl, pyrazinyl, pyrimidyl, pyridazyl, pyrrolyl, thienyl, furyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl or phenyl, XD is -(CHR4D)"~- or -(CHR4D)pnCR4D=CR4D(CHR4o)qD-, in which nD is 1-3, and pD
and qD
are either both 0 or one of pD and qD is 1 and the other is 0, Rlo is positioned on ring BD in a 1, 3 or 1,4 relationship with the -OCH(R3D)-linking group in 6-membered rings and in a 1, 3 relationship with -OCH(R3D)- linking group in 5-membered rings and carboxy, carboxy-C 1-3 alkyl, tetrazolyl, tetrazolyl-C 1-3 alkyl, tetronic acid, hydroxamic acid or sulphonic acid, or R1D is -CONRaDRem in which RaD is hydrogen or C1-6 alkyl, Ram is hydrogen, or optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C3-7 cycloalkyl-C2-6 alkenyl, C3-7 cycloalkyl-C2-6 alkynyl, C5-7 cycloalkenyl, C3-7 cycloalkenyl-C1-6 alkyl, C5-7 cycloalkenyl-C2-6 alkenyl, C5-cycloalkenyl-C2-6 alkynyl, C 1-3 alkyl substituted by 5-6 membered saturated or partially saturated heterocyclic ring, 5-6 membered saturated or partially saturated heterocyclic ring or 5-6 membered heteroaryl, or RaD and RaiD together with the amide nitrogen to which they are attached (NR$DRem) form an amino acid residue or ester thereof, or R1D is -CONHSOzRbD in which RbD is optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl-C1-6 alkyl, C3-7 cycloalkyl-C2-6 alkenyl, C3-7 cycloalkyl-C2-6 alkynyl, C3-7 cycloalkenyl-C1-6 alkyl, C3-7 cycloalkenyl-C2-6 alkenyl, C3-7 cycloalkenyl-s C2-6 alkynyl, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-6 alkyl, phenyl, phenyl-C1-6 alkyl, 5-6 membered saturated or partially saturated hetrocyclic ring or 5-6 membered saturated or partially saturated hetrocyclic ring-C1-6 alkyl, R3D is hydrogen or C 1-4 alkyl, RED is hydrogen or C1-4 alkyl, with the proviso that 4-(2-benzyl-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid and 4-(2-(3-phenylprop-2-ene-1-yl)-3-hydroxy-4-formyophenoxymethyl-3-methoxybenzoic acid are excluded or N-oxide thereof, or S-oxide of sulfur containing rings, or a pharmaceutically acceptable salt thereof or in vivo hydrblyzable ester or amide thereof (5) in the specification of WO 97/00863, the compound of formula CIE) ~N_BE_R~E
AE CIE) ~-R4E
wherein AE is optionally substituted: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl or thiadiazolyl having at least two adjacent ring carbon atoms, with the proviso that -CH(R3E)N(R2E)BE-RiE and -OR4E are positioned in a 1, 2 relationship to one another on ring carbon atom and the ring atom position ortho to the OR4E linking group (and therefor in the 3-position relative to the -CHRsENR2E-linking group) is not substituted, BE is optionally substituted: phenyl, pyridyl, thiazolyl, oxazolyl, thienyl, thiadiazolyl, imidazolyl, pyrazinyl, pyridazinyl or pyrimidyl, R1E is positioned on ring BE in a 1, 3 or 1, 4 relationship with -CH(R3E)N(RzE)- linking group and is carboxy, carboxy-C1-3 alkyl, tetrazolyl, tetrazolyl-C1-3 alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R1E is -CONRaERaiE in which RaE is hydrogen or C1-6 alkyl, RaiE is hydrogen, C1-6 alkyl (optionally substituted by halogen atom, amino, C1-4 alkylamino, di-C1-4 alkylamino, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy or C1-4 alkoxycarbonyl), C2-6 alkenyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond is not in the 1-position), carboxyphenyl, 5-6 membered heterocyclyl-C1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, or RaE and RaIE together with the amide nitrogen to which they are attached (NReERaiE) form an amino acid residue or ester thereof, or R1E is -C~NHSOaRbE in which RbE is C1-6 alkyl (optionally substituted by halogen atom, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy, amino, Cl-4 alkylamino, di-C1-4 alkylamino or C 1-4 alkoxycarbonyl), C2-6 alkenyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond is not in the 1-position), 5-6 membered heterocyclyl-C 1-3 alkyl, 5-6 membered heteroaryl-C 1-3 alkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl or phenyl, wherein any heterocyclyl or heteroaryl group in ReiE is optionally substituted by halogen atom, hydroxy, nitro, amino, cyano, C1-6 alkoxy, C1-6 alkyl-S(O)pE- (pE is 0, 1 or 2), C1-6 alkylcarbamoyl, C1-4 alkylcarbamoyl, di(C1-4 alkyl)carbamoyl, C2-6 alkenyl, C2-alkynyl, Cl-4 alkoxycarbonylamino, C1-4 alkanoylamino, C1-4 alkanoyl(N-C1-4 alkyl)amino, C1-4 alkanesulfonamide, benzenesulfonamide, aminosulfonyl, C1-4 alkylaminosulfonyl, di(C1-4 alkyl)aminosulfonyl, C1-4 alkoxycarbonyl, C-4 alkanoyloxy, C 1-6 alkanoyl, formylC 1-4 alkyl, hydroxyimino-C 1-6 alkyl, C 1-4 alkoxyimino-C 1-6 alkyl or C1-6 alkylcarbamoylamino, or R1E is -SOaN(R~E)R~IE in which RAE is hydrogen or C1-4 alkyl and R~IE is hydrogen or C1-4 alkyl, or RIE is the formula (EA), (E$) or (Ec):
E
~X~dE ,,~YE .' ~ 'YE
O-N-R ''C~~N- ~~EY ~N-ZEY
i (E") RdE (Eel (E') wherein XE is CH or nitrogen, YE is oxygen or sulfur, Y'E is oxygen or NRaE and Z~ is CH2, NRdE or oxygen, with the proviso that there is no more than one ring oxygen and there are at least two ring heteroatoms and wherein RdE is hydrogen or C1-4 alkyl, R2E is hydrogen, C1-6 alkyl optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6 alkynyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond in not in the 1-position), phenyl-C1-3 alkyl or pyridyl-C1-3 alkyl, R3E is hydrogen, methyl or ethyl, R4E is optionally substituted: C1-6 alkyl, C3-7 cycloalkyl-C1-3 alkyl or C3-7 cycloalkyl, with the proviso that 2-(2-methoxybenzylamino]pyridine-5-carboxylic acid, 4-(2-methoxybenzylamino]benzoic acid, 5-(2, 3-dimethoxybenzylamino]-2-chloro-3-aminosulfonylbenzoic acid and 5-[2, 5-dimethoxybenzylamino]-2-hydroxybenzoic acid are excluded;
or N-oxide of -NR'=E-, or S-oxide of sulfur containing rings, or a pharmaceutically acceptable salt thereof or in vivo hydrolyzable ester or amide thereof (6) in the specification of WO 99/47497, the compound of formula CIF) R~ FRzFRsF-HETF
CAF O CIF) XF-BF ~ F
Z
wherein HETF is 5-12 membered mono- or bi-cyclic aromatic ring containing 0-3 heteroatoms selected from oxygen, S(O)nF and N(O)mF, in which mF is 0 or 1, nF
is 0, 1 or 2, AF is -WF-, 'C(O)', -C(R7F)-WF-, -WF-C(R7F)z-, -CR~F(ORZOF)-, -C(R~F)2', -C(R?F)a-C(OR20F)R7F- -C(R7F)2-C(R~F)2- or -CR~F=CR7F-, in which WF is oxygen, S(O)nF
or NR1~F, XF is 5-10 membered mono- or bi-cyclic aryl or heteroaryl having 1-3 heteroatoms selected from oxygen, , S(O)nF and N(O)mF, and optionally substituted by RIaF and R15F, and AF and BF are attached to the aryl or heteroaryl ortho relative to each other, YF' is O, S(O)nF, NR1~F, a bond or -CRiBF-CRIaF-;
BF is -(C(Ri$F)~pF-YF'-(C(R18F)a)qF-, in which pF and qF are independently 0-3, such that when YF is 0, S(O)nF, NR17F or -CRIBF=CR18F- pF+qF is 0-6, and when YF is a bond, pF+qF
is 1-6;
ZF is OH, NHSOzRISF ;
R1F, R2F and R3F each independently, is hydrogen, halogen atom, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl'HETF(RaF)a~s, '(C(CR4F)~pF)SRSF, '(C(R4F)a~pFOg,eF~ -(C(R4F)z)pFN(R6F)z, CN, NOx, '(C(R4F)2)pFC(R~F)3, -COORsF, -CON(R6F)z or -(C(R4F)2)pFS(0)nFRIOF
each R4F is hydrogen, F, CFs, lower alkyl or two R4F, taken together, is a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)nF and N(O)mF , each R5F is independently lower alkyl, lower alkenyl, lower alkynyl, CFs, lower alkyl-HETF, lower alkenyl-HETF, -(C(R18F)z)pFPh(RuF)o.a , each R6F is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CFs, Ph, Bn or two R6F together with N to which they are attached, is a ring of up to six atoms, optionally containing an additional heteroatom selected from 0, S(O)nF and N(O)mF , each R7F is independently hydrogen, F, CFs, lower alkyl, or two RAF taken together, is 3-fi membered aromatic or aliphatic ring containing 0-2 heteroatom selected from O, S(0)nF
and N(0)a,F , each RsF is hydrogen or R5F , each RoF is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn , each RioF is independently lower alkyl, lower alkenyl, lower alkynyl, CFs, Ph(R11F)o.s, CHzPh(RIiF)o.3 or N(RsF)z , , each RuF is independently lower alkyl, SRzoF, ORzoF~ N(RsF)z, -COORIZF, -CON(RsF)z, -COR12F, CN, CFs, NOz or halogen atom , each RIZF is independently hydrogen, lower alkyl or benzyl , each Ri3F is independentlyhydrogen, halogen atom, lower alkyl, O-lower alkenyl, Slower alkyl, N(RsF)z, COOR12F, CN, CFa or N02 , RiaF and R~SF are independently lower alkyl, halogen atom, CF3, ORISF, S(O)nFRISF or C(R16F)aORI~F
each RISF is independently hydrogen, lower alkyl, lower alkenyl, Ph, Bn or CFs , each R1~F is independently hydrogen, lower alkyl or Bn , each R18F is independently hydrogen, F or lower alkyl, or two R18F taken together, is 3-6 membered ring optionally containing one heteroatom selected from oxygen, S(O)"F and nitrogen , each RISF is independently lower alkyl, lower alkenyl, lower alkynyl, CFs, HET(RaF)4-s, lower alkyl-HET(RaF)a~s, lower alkenyl-HET(RaF)a-s, each RzoF is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CFs or P11~13F)2 ~
each RaF is independently selected from the following group:
hydrogen, hydroxy, halogen atom, CN, NOz, amino, C 1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C 1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, C 1-6 alkylamino, di(C 1-6 alkyl)amino, CFs, C(0)C1-6 alkyl, C(O)C2-6 alkenyl, C(O)C2-6 alkynyl, COOH, COO(C1-6)alkyl, COO(C2-6)alkenyl and C00(C2-6)alkynyl, said alkyl, alkenyl, alkynyl, and alkyl portions of alkylamino and dialkylamino being optionally substituted by 1-3 of hydroxy, halogen atom, aryl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, CF3, CO(C1-6)alkyl, CO(C2-6)alkenyl, CO(C2-6)alkynyl, COOH, C00(C1-6)alkyl, COO(C2-6)alkenyl, COO(C2-6)alkynyl NHz, NH(C1-6)alkyl and N(C1-6alkyl)z or a non-toxic salt thereof (7) in the specification of WO 2000/20371, the compound of formula (IG) A~~~-W~-ArZ~-X~-W~
wherein Ar~G is aryl or heteroaryl, optionally substituted by Rig or R3G, Rio is YGmc-RzG, YGmG-Ar3G, halogen atom, N(R5G)z, CN, NOz, C(RsG)s, CON(R5G)z, S(O)"cR~~ or hydroxy , Y~ is a linker between RzG or Ar3G and Arl~ containing 0-4 carbon atoms and not more than one heteroatom selected from oxygen, nitrogen and sulfur, said linker optionally containing CO, S(0)nc, -C=C- or acetylenic group, and said linker being optionally substituted by RzG , mGis0orl, n~is0, lor2, RzG is hydrogen, F, CHFz, CF3, lower alkyl or hydroxy(C1-6)alkyl, or two Rz~
taken together, is carbocyclic ring of up to six members, said ring containing not more than one heteroatom selected from oxygen, nitrogen or sulfur , Ar3G is aryl or heteroaryl, optionally substituted by R3c , R3o is Rio, halogen atom, halo(C1-6)alkyl, N(R6G)z, CN, NOz, C(RsG)3, CON(R.SG)z, OR4c, SR4~ or S(O)ncRT~ , R4G is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CHFz or CFs , R5G is R4o, Ph or Bn, or two RAG taken together, is a ring of up to six members containing carbon atoms and 0-2 heteroatoms selected from oxygen, nitrogen or sulfur , R6G is hydrogen, F, CFs or lower alkyl, or two R6~ taken together, is a ring of up to six members containing carbon atoms and 0-2 heteroatoms selected from oxygen, nitrogen or sulfur , R~~ is lower alkyl, lower alkenyl, lower alkynyl, CHFz, CFs, N(R5~)z, Ph(R8~)z or CH2Ph(R8G)z , R8o is R4o, OR~G, SR4o or halogen atom , WG is a 3-6 membered linking group containing 0-2 heteroatoms selected from oxygen, nitrogen and sulfur, said linking group optionally containing CO, S(O)mc, C=C, acetylenic group, and optionally being substituted by R9c , R9~ is R=G, lower alkyl, lower alkynyl, OR4G or SR4c , Arz~ is aryl or heteroaryl, optionally substituted by R3c , R,ioc is R4G , halogen atom, N(R6G)z, CN, NOz, C(RsG)s, OR4G, SR4G or S(O)r,GR~~ , X~ is a linker which is attached to ArzG ortho to the attachment of W~, said linker containing 0-4 carbon atoms and not more than one heteroatom selected from oxygen, nitrogen and sulfur, said linker further optionally containing CO, S(O)ac, C=C
or acetylenic group, and said linker being optionally substituted by R11G , R11G is RAG , QG is a member selected from the group consisting of COOH, tetrazole, S03H, hydroxamic acid, CONHSOzRIZG and SOzNHCORIZG , RIZG is a member selected from the group consisting of CF3, lower alkyl, lower alkenyl, lower alkynyl and ZGAr4G , ZG is a linker containing 0-4 carbon atom, optionally substituted by R13G , R13G iS R9G , Ar4G is aryl or heteroaryl, optionally substituted by RIaG
R14G iS RIOG or NHCOMe or an non-toxic salt thereof (8) in the specification of WO 2001/19814, the compound of formula (IH) ~H R3H
R S.
R2H ('y~ZH (R4H~2 1H ~ / ~ /1 RaH
R O
'(RSH)3 wherein yH and zH are independently 0-2, with the proviso that yH + zH = 2 , RaH iS
1) heteroaryl, wherein heteroaryl is selected from the group (a) - (n):
(a) fury, (b) diazinyl, triazinyl or tetrazinyl, (c) imidazolyl, (d) isoxazolyl, (e) isothiazolyl, (t) oxadiazolyl, (g) oxazolyl, (h) pyrazolyl, (i) pyrrolyl, (j) thiadiazolyl, (k) thiazolyl, (1) thienyl, (m) triazolyl and (n) tetrazolyl, wherein heteroaryl is optionally substituted by one or more substituents independently selected from Rlls and C1-4 alkyh 2) -CORsx, 3) -NR~HRsH, 4) -SOzR9H, 5) hydroxy, 6) C1-6 alkoxy, optionally substituted by one or more substituents independently selected from Rllx and l2 7) C 1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, optionally substituted by one or more substituents independently selected from R1H, and further substituted by 1-3 substituents independently selected from the group of (a) - (h):
(a) -CORoH, (b) -NR~HRBH, (c) -SOzR~H, (d) hydroxy, (e) C1-6 alkoxy or haloCl-6 alkoxy, and (~ heteroaryl RaH is positioned on the phenyl ring to which it is bonded in a 1, 3 or l, 4 relationship relative to the thienyl group of formula (IH), g,iH~ R,zx~ R9H~ RaH and R5H are independently selected from the following group:
1) hydroxy, 2) halogen atom, 3) C 1-6 alkyl, 4) C 1-6 alkoxy, 5) C 1-6 alkylthio, 6) vitro, 7) carboxy, and 8) CN, wherein groups of 3) - 5) are optionally substituted by one or more substituents independently selected from Rux , R6H is hydrogen, hydroxy, C1-6 alkyl, C1-6 alkoxy and NR~HReH, wherein C1-6 alkyl and C 1-6 alkoxy are optionally substituted by one or more substituents independently selected from R~lx , RAH and RaH are independently selected from the group: 1) hydrogen, 2) hydroxy, 3) SOaRoH, 4) C1-6 alkyl, 5) C1-6 alkoxy, 6) phenyl, 7) naphthyl, 8) furyl, 9) thienyl and 10) pyridyl, wherein groups of 4) - 5) are optionally substituted by one or more substituents independently selected from R11H, and groups of 6) - 10) are optionally substituted by one or more substituents independently selected from Rlx or C1-4 alkyl , R9H is selected from the group:
1) hydroxy, 2) N(Rlox)2, 3) C1-6 alkyl, optionally substituted by one or more substituents independently selected from R1~H, 4) phenyl, 5) naphthyl, 6) furyl, 7) thienyl, and 8) pyridyl, groups of 4) - 8) are optionally substituted by one or more substituents independently selected from RIyH and C1-4 alkyl, RioH is hydrogen or C1-6 alkyl, RlH is halogen atom, hydroxy, C1-3 alkoxy, vitro, N(RIOH)z, and pyridyh or a pharmaceutically acceptable salt, hydrate or ester thereof (9) in the specification of WO 2001/19819, the compound of formula (IJ) r S
R~JI 1y dl )zJ 1R~12 1J ( / ~ ~~~ RaJ (1J) R O
~RsJls wherein yJ and zJ are independently 0-2, with the proviso that yJ + zJ = 2 , R~ is 1) heteroaryl, wherein heteroaryl is selected from the group (a) - (n):
(a) fury, (b) diazinyl, triazinyl or tetrazinyl, (c) imidazolyl, (d) isoxazolyl, (e) isothiazolyl, (~ oxadiazolyl, (g)oxazolyl, (h) pyrazolyl, (i) pyrrolyl, (j) thiadiazolyl, (k) thiazolyl, (1) thienyl, (m) triazolyl and (n) tetrazolyl, wherein heteroaryl is optionally substituted by one or more substituents independently selected from Rlia and C1-4 alkyh 2) -CORD, 3) -NR~JR~, 4) -SO2R9J, 5) hydroxy, 6) C 1-6 alkoxy, optionally substituted by one or more substituents independently selected from R11J, and 7) C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, optionally substituted by one or more substituents independently selected from R1H, and further substituted by 1-3 substituents independently selected from the group of (a) - (~:
(a) -CORD, (b) -NR7JR~, (c) -SOaR9J, (d) hydroxy, (e) C1-6 alkoxy or haloCl-6 alkoxy, and (~ heteroaryl, RaJ is positioned on the pyridyl ring to which it is bonded in a l, 3 or 1, 4 relationship relative to the thienyl group of formula (IJ), Ria R,za~ R,3J~ RA.t and R5J are independently selected from the following group:
1) hydroxy, 2) halogen atom, 3) C 1-6 alkyl, 4) C 1-6 alkoxy, 5) C 1-6 alkylthio, 6) nitro, 7) carboxy, and 8) CN, wherein groups of 3) - 5) are optionally substituted by one or more substituents independently selected from RIiJ , R~ is hydrogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy and NR~JR~, wherein C 1-6 alkyl and C 1-6 alkoxy are optionally substituted by one or more substituents independently selected from Rlia , R~J and R8J are independently selected from the group: 1) hydrogen, 2) hydroxy, 3) SOzRoJ, 4) C1-6 alkyl, 5) C1-6 alkoxy, 6) phenyl, 7) naphthyl, 8) furyl, 9) thienyl and 10) pyridyl, wherein groups of 4) - 5) are optionally substituted by one or more substituents independently selected from R11J, and groups of 6) - 10) are optionally substituted by one or more substituents independently selected from RuJ or C1-4 alkyl , R9J is selected from the group:
1) hydroxy, 2) N(Rloa)a, 3) C1-6 alkyl, optionally substituted by one or more substituents independently selected from R11J, 4) phenyl, 5) naphthyl, 6) furyl, 7) thienyl, and 8) pyridyl, groups of 4) - 8) are optionally substituted by one or more substituents independently selected from Rlia and C1-4 alkyl, RIOJ is hydrogen or C1-6 alkyl, Rica is halogen atom, hydroxy, C1-3 alkoxy, nitro, N(RIOJ)z, and pyridyh or a pharmaceutically acceptable salt, hydrate or ester thereof (10) N-phenyl-aryl-sulfonamide compound of formula (IK~
R~K
RSK O~ ~ ~nK
(1K) R N ArK
wherein R1K is COOH, hydroxymethyl, 5-tetrazolyl, 5-oxo-1,2,4-oxadiazolyl or 5-oxo-1,2,4-thiadiazolyl, R2K is hydrogen, methyl, methoxy or chloro, R3K and R4K are a combination of (1) methyl and methyl, (2) methyl and chloro, (3) chloro and methyl, or (4) trifluoromethyl and hydrogen or R3 and R4 are taken together with the carbon to which R3 and R4 are attached to form (5) cyclopentene, (6) cyclohexene or (7) benzene ring, R~K is isopropyl, isobutyl, 2-methyl-2-propenyl, cyclopropylmethyl, methyl, ethyl, propyl, 2-propenyl or 2-hydroxy-2-methylpropyl, ArK is thiazolyl optionally substituted with methyl, pyridyl or 5-methyl-2-furyl, nK is 0 or 1, with the proviso that when R1K is 5-tetrazolyl, 5-oxo-1,2,4-oxadiazolyl or 5-oxo-1,2,4-thiadiazolyl, and then n is 0, an alkyl ester thereof or a non-toxic salt thereof.

s ' The above compound of formula (IA) - (IK~ may be converted into a corresponding pharmaceutically acceptable salt by known methods. Non-toxic salts and water-soluble salts are preferred.
Appropriate salts are salts of alkali metals (e.g. potassium, sodium), salts of alkaline-earth metals (e.g. calcium, magnesium), ammonium salts (e.g.
tetramethylammonium), salts of pharmaceutically acceptable organic amines (e.g.
triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine, N-methyl-D-glucamine).
Non-toxic and water-soluble acid addition salts are preferable. Appropriate acid addition salts are, salts of inorganic acids, such as hydrochloride, hydrobromide, sulfate, phosphate, nitrate salts of organic acid, such as acetate, triffuoroacetate, lactate, tartrate, oxalate, fumarate, maleate, citrate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, toluenesulphonate, isethionate, glucuronate, gluconate.
The compound of the present invention and a non-toxic salt thereof may be converted into the corresponding a hydrate thereof by conventional means.
The compound of the present invention, a non-toxic salt thereof or a hydrate thereof may be converted into the corresponding a cyclodextrin clathrate thereof by conventional means.
As the concretely compound of formula (IA) - (IJ) in the present invention, compounds described in the specification in WO 98/27053, EP 878465, WO
92/1961?, WO
96/06822, WO 9?/00863, WO 99/4?497, WO 00/20371, WO 2001119814, WO 2001/19819, for example, compounds described in Examples are preferable.
As the concretely compound of formula (III, the compound described in Examples of this specification are preferable.
In the compounds described in the above specification, compounds which bond to EPi receptor and show an antagonistic action are preferable. More preferably, compounds which specifically bond to EPA receptor and show an antagonistic action.
The compound of formula (IA) - (IK~ may be prepared by method described in each corresponding published International application, published European patent application or the specification of Japanese application.
In the present invention, EPi antagonists are not limited in order to achieve the object that is treatment and/or prevention depression. Especially, following compounds are preferable.
In the compound of formula (IA) - (III, the compound of formula (IA), (I8) and (III are preferable.
1) In the compound of formula (IA), the compound in which ,, ,, A1 (a) is , is preferable.
2) In the compound of formula (IB), the compound in which and are C5-15 carbocyclic ring, Z5 is 5-7 membered heterocyclic ring containing 1 or 2 oxygens, sulfurs or nitrogens, which ring may be substituted by 1-5 of R5B in which multiple R5B each, independently, is hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylthio, nitro, halogen atom, trifluoromethyl, trifluoromethoxy or hydroxyl is preferable.
3) In the compound of formula (III, all compounds are preferable, especially, the compound in which Ark is 5-methyl-2-furyl, 2-thiazolyl, 5-methyl-2-thiazolyl, 2-pyridyl, 3-pyridyl is preferable. Concretely, following compounds are preferable.
(1) 4-[2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (2) 4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (3) 4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (4) 4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (5) 4-(2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (6) 4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (7) 3-methyl-4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chloro phenoxymethyl]benzoic acid, ($) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-fmylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (9) 3-chloro-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (10) 3-chloro-4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (11) 3-methoxy-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (12) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (13) 3-methoxy-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (14) 3-methoxy-4-(2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (15) 3-methoxy-4-[2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (16) 3-chloro-4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (17) 3-chloro-4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (18) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid, (19) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (20) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (21) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (22) 3-methyl-4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (23) 3-methyl-4-[2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (24) 3-methyl-4-[2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (25) 3-methyl-4-(2-[N-isobutyl-N-(5-methyl-2-fuiylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (26) 4-[2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethyl phenoxymethyl]cinnamic acid, (27) N-[4-chloro-5-methyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (28) 3-methoxy-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (29) N-[4, 5-dimethyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (30) N-[4, 5-dimethyl-2-[2-methyl-4-(5-tetrazolyDphenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide, (31) N-(4-chloro-5-methyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (32) N-[4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide, (33) N-[4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (34) 4-(6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (35) 4-[6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (36) 4-[7-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaphtharen-6-yloxymethyl]benzoic acid, (37) 4-[7-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaphtharen-6-yloxymethyl]benzoic acid, (38) N-[4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide, (39) N-[4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (40) N-(4, 5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide, (41) N-[4, 5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (42) N-[4, 5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (43) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-fmylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (44) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl) phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide, (45) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl) phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide, (46) 4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
cinnamic acid, (4~) 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (48) 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyDamino]indan-5-yloxymethyl]cinnamic acid, (49) 4-[2-[N-(2-methyl-2-propenyl)-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (50) 3-methyl-4-[6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (51) 3-methyl-4-[6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (52) 4-[6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (53) 4-[3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]'2-naphthyloxymethyl]
benzoic acid, (54) 3,5-dimethyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (55) 3-methyl-4-[6-[N-(2-methyl-2-propenyl)-N-(5-methyl-2-furylsulfonyl)amino]
indan-5-yloxymethyl]benzoic acid, (56) 4-[6-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzoic acid, (57) 4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzylalcohol, (58) 3-methyl-4-[6-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (59) 4-[6-[N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzoic acid, (60) 4-(6-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (61) 4-[6-[N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (62) 4-[6-[N~propyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (63) 4-[4~ 5-dimethyl-2-[N-(2-methyl-2-propenyl)-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid, (64) 4-[S-[N-(2-methyl-2-propenyl)-N-(5-methyl-2-furylsulfonyDamino]indan-5-yloxymethyl]cinnamic acid;
(65) 4-[6-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (66) 4-[6-[N-(2-propenyl)-N-(5-methyl-2-furylsulfonyDamino]indan-5-yloxymethyl]cinnamic acid, (67) 3-methyl-4-[6-(N-propyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (68) 3-methyl-4-[6-[N-(2-propenyl)-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (69) 4-[4, 5-dimethyl-2-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxy methyl]benzoic acid, (70) 4-[4, 5-dimethyl-2-[N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxy methyl]benzoic acid, (71) 4-[4, 5-dimethyl-2-[N-(5-methyl-2-furylsulfonyl)-N-propylamino]phenoxy methyl]benzoic acid, (72) 4-(3-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]-3-methylbenzoic acid, (73) 4-(3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]-3-methylbenzoic acid, (74) 4-(3-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (75) 4-[3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (76) 3-methyl-4~[3-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (7?) 3-methyl-4-(3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (78) 4-(4, 5-dimethyl-2-[N-[(5-methyl-2-furyl)sulfonyl]-N-2-propenylamino]
phenoxymethyl]benzoic acid, (79) 4-(4, 5-dimethyl-2-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (80) 4-[4, 5-dimethyl-2-(N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid, (81) 4-[4, 5-dimethyl-2-[N-(5-methyl-2-furylsulfonyl)-N-propylamino)phenoxymethyl]-3-methylbenzoic acid, (82) 4-[4, 5-dimethyl-2=[N-(5-methyl-2-furylsulfonyl)-N-(2-propenyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (83) 4-(4, 5-dimethyl-2-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl) amino]phenoxymethyl]-3-methylbenzoic acid, (84) 4-(6-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzoic acid, (85) 4-[4, 5-dimethyl-2-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl) amino]phenoxymethyl]benzoic acid, (86) 4-[4, 5-dimethyl-2-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl) amino]phenoxymethyl]benzoic acid, (87) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyDamino]indan-yloxymethyl]cinnamic acid, (88) 4-[4, 5-dimethyl-2-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid.
(89) 4-[2-(N-isopropyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
benzoic acid, (90) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
benzoic acid, (91) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
cinnamic acid, (92) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
cinnamic acid, (93) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (94) 4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (95) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxy methyl]benzoic acid, (96) N-(4-trifluoromethyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-thiazolylsulfonylamide, (9?) N-(4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylaulfonylamide, (98) N-(4-trifluoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylsulfonylamide, (99) N-[4-trifluoromethyl-2-(4-(5-oxo-1,2,4-thiadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylsulfonylamide, (100) 4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (101) 4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (102) 3-chloro-4-[2-(N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (103) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (104) 3-methyl-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (105) 3-methoxy-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (106) 3-methoxy-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (107) N-(4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (108) N-[4-trifluoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (109) N-[4-trifluoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (110) 4-(2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (111) 3-chloro-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (112) 3-methoxy-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (113) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (114) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (115) 3-methyl-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (116) 3-methoxy-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (11?) 3-chloro-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (118) 3-chloro-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (119) 4-[2-(N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (120) 4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (121) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid, (122) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (123) 3-chloro-4-(2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (124) 3-methyl-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (125) 3-methyl-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (126) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (12?) 3-methyl-4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (128) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid, (129) N-[4-chloro-5-methyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (130) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (131) 4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (132) N-[4-trifluoromethyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (133) N-(4-trifluoromethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (134) 3-chloro-4-(2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyDamino]-4, 5-dimethylphenoxymethyl]c'innamic acid, (135) N-[4, 5-dimethyl-2'(2-methyl-4-(5-tetrazolyl)phenylmethyloxylphenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (136) N-[4, 5-dimethyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (137) N-(4, 5-dimethyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (138) N-(4, 5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (139) N-[4-chloro-5-methyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (140) N-[4-chloro-5-methyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyDsulfonylamide, (141) N-(4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (142) N-(4-chloro-5-methyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (143) 3-methoxy-4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (144) N-(4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3~y1)phenyl methyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (145) N-[4, 5-dimethyl-2-(2-methyl-4-(5-oxo-1,2,4-oxadiazol-3~y1)phenylmethyloxy]
phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (146) N-(4, 5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (147) N-[4, 5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N~

isobutyl-(4-methyl-2-thiazolyl)sulfonylamide, (148) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
p henyl]-N-isopr opyl-(4-methyl-2 ~thiazolyl)sulfonylarnide, (149) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylrnethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide, (150) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (151) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (152) 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (153) 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)aminolindan-5-yloxymethyl]cinnarnic acid, (154) 3-methyl-4-[2-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)aminol-4-chloro-5-methylphenoxymethyl]benzoic acid, (155) 4-[2-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (156) 3-methyl-4-[2-[N-(2-methyl-2-propenyD-N-(4-methyl-2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (157) 3-methyl-4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxyrnethyl]benzoic acid, (158) 3-methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (159) 3-methyl-4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (160) 4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (161) 4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (162) 4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (163) 4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (164) 3-methyl-4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (165) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dirnethylphenoxymethyl]
benzoic acid, (166) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]
benzoic acid, (167) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]
cinnamic acid, (168) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]
cinnamic acid, (169) 4-[6-[N-isopropyl-N~(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (170) 4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (171) 3-methyl-4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (172) 3-methyl-4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (173) 3-methyl-4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (174) 3-methyl-4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (175) 3-methyl-4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (176) 3-methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (1?7) 4-[3-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]benzoic acid, (178) 4-[3-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]benzoic acid, (179) 4-[3-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]-3-methylbenzoic acid, (180) 4-I3-[N-isopropyl-N-[2-(4-methylthiazolyl)sulfonyl]amino]naphtharen-2-yloxymethyl]-3-methylbenzoic acid, (181) 4-[3-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (182) 4-[3-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]cinnamic acid, (183) 4-[4, 5-dimethyl-2-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (184) 4-[4, 5-dimethyl-2-(N-ethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (185) 4-(4, 5-dimethyl-2-[N-propyl-N-(4-methyl-2-thiazolylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (186) 4-(4, 5-dimethyl-2-(N-(2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (187) 4-(4, 5-dimethyl-2-(N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid, (188) 4-[4, 5-dimethyl-2-[N-(2-hydroxy-2-methylpropyl)-N-(4-methyl-2-thiazoly1 sulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid, (189) 4-[6-(N-(2-methyl-2-propenyl?-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (190) 4-[6-(N-(4-methyl-2-thiazolylsulfonyl)-N-(2-propenyDamino]indan-5-yloxymethyl]benzoic acid, (191) 4-[6-[N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (192) 4-[3-(N-isobutyl-N-[2-(4-methylthiazolyl)sulfonyl]amino]naphtharen-2-yloxymethyl]benzoic acid, (193) 4-(3-(N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphtharen-2-yloxymethyl]-3-methylbenzoic acid, (194) 4-[6-(N-ethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (195) 4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-propylamino]indan-5-yloxymethyl]benzoic acid, (196) 4-[6-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, (197) 3-methyl-4-(6-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (198) 4-(6-(N-ethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]-methylcinnamic acid, (199) 3-methyl-4-[6-(N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyD
amino]indan-5-yloxymethyl]cinnamic acid, (200) 4-(6-(N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]-3-methylcinnamic acid, (201) 3-methyl-4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yloxymethyl]cinnamic acid, (202) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]-3-methylcinnamic acid, (203) 3-methyl-4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-propylamino]indan-5-yloxymethyl]cinnamic acid, (204) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(4-methyl-2-thiazalylsulfony1) amino]indan-5-yloxymethyl]benzoic acid, (205) 4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (206) 4-[2-[N-isobutyl-N~(3-pyridylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (207) 3-chloro-4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (208) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (209) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid, (210) 3-methyl-4-[2-[N-isobutyl~N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (211) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-3-pyridylsulfonylamide, (212) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenylj-N-isobutyl-3-pyridylsulfonylamide, (213) 4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (214) 3-chloro-4'[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (215) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (216) 3-methoxy-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4, 5-dimethyl phenoxymethyl]benzoic acid, (217) 3-methoxy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4, 5-dimethyl phenoxymethyl]benzoic acid, (218) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4, 5-dimethyl phenoxymethyl]benzoic acid, (219) 3-methyl-4-[2-(N-isobutyl-N-(2-pyridylsulfonyl)amino]-4, 5-dimethyl phenoxymethyl]benzoic acid, (220) N-(4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide, (221) N-(4-trifluoromethyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (222) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid, (223) 4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]
benzoic acid, -(224) N-[4-triffuoromethyl-2-(4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenylJ-N-isobutyl-2-pyridylsulfonylamide, (225) 4-(2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (226) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid, (227) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (228) 4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (229) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (230) N-[4-trifluoromethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide, (231) 3-chloro-4-[2-(N-isobutyl-N-(3-pyridylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]cinnamic acid, (232) N-[4, 5-dimethyl-2-(2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (233) N-[4, 5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide, (234) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide, (235) N-[4, 5-dimethyl-2-[2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (236) N-[4, 5-dimethyl-2-[2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-3-pyridylsulfonylamide, (237) N-[4, 5-dimethyl-2-[2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide, (238) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid, (239) N-[4, 5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-pyridylsulfonylamide, (240) N-[4, 5-dimethyl-2-[4-(5-tetrazolyDphenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (241) N-[4, 5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide, (242) 3-chloro-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid, (243) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide, (244) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (245) N-[4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isopropyl-2-pyridylsulfonylamide, (246) N-[4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isobutyl-3-pyridylsulfonylamide, (247) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide, (248) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide, (249) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isobutyl-2-pyridylsulfonylamide, and (250) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]
phenyl]-N-isopropyl-2-pyridylsulfonylamide.
In the compound of formula (I~ - (III, most preferable EPi antagonists are following compounds.
1) 6-[(2S, 3S)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)-bicyclo[2.2.2]
octan-2-yl]-5Z-hexenoic acid (the compound ~, 2) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid (the compound B), 3) 4-[2-(N-isobutyl-2-furanylsulfonylamino)-5-trifluoromethylphenoxymethyl]
cinnamic acid (the compound C), 4) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid (the compound D), 5) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid (the compound E), 6) 4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
cinnamic acid (the compound F), ?) 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiaolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid (the compound G), 8) 4-[4, 5-dimethyl-2-[N-(5-methyl-2-furylsulfonyl)-N-propylamino]
phenoxymethyl]benzoic acid (the compound H), 9) 4-[5-trifluoromethyl-2-[N-(5-methyl-2-furylcarbonyl)-N-isopropylamino]
phenoxymethyl]cinnamic acid (the compound J) and 10) 4-[6-[N-isobutyl-N-(4-methyl-2-thizolylsulfonyDamino]indan-5-yloxymethyl]
benzoic acid (the compound K).
The compound A was described in the specification of EP 878465 as Example 2c.
The compound C was described in the specification of WO 98/27053 as Example 18(9).
The compounds B, D, E, F, G, H, J and K are contained in the compound of formula (IK). These compounds were also contained in the compound of formula (IB), but they were not specifically described in the specification of WO 98/27053.
Although the chemical structures of all compounds were different each other, these compounds had this activity in common, and so, it became clear that an antagonism for EPi receptor lead to the treatment and/or prevention of depression.
It have been known that EPi antagonist could be used as an analgesic, an antipyretic, a therapeutic agent of frequent urination, and an anticancer agent by antagonizing EPi, however it have not been known that EPi antagonists have an antidepressive activity, and it was firstly demonstrated by this invention.
The depression in this invention is contained depression and a depressed state, for example, endogenous depression, reactive depression, weatherability depression, and neurological depressed state, the depressed state of brain organic mental disorder.

(Process for the preparation of the present invention]
The compound of formula (IA), SIB), (IC), (ID), CIE), CIF), (IG), (IH) and (IJ) may be prepared by each method described in the specification of W098/27053, EP878465, W092/19617, W096/06822, W09?/00863, W099/47497, W000120371, W02001/19814 and W02001/ 19819.
The compound of formula (IK~ may be prepared by a method described in the specification of W098/27053, or by a following method. A detailed process for the preparation is described hereinafter.
In the scheme, R is C 1-4 alkyl, Tf is triffuoromethanesulfonyl, the other symbols are as hereinbefore defined.
R: C 1-4 alkyl, Ms: mesyl, TfzO: trifluoromethanesulfonic acid anhydrous, Et: ethyl, TCDI: 1,1'-thiocarbonyldiimidazole.

Scheme A
Rz \ COOR
\ ~n Rz / \ COOR
n R~ OH Ms0 K CO (V) R \ O .~ \ /

4\~
R NOz 4 Fe R NOz (VI) (IV) Rz Rz '\, COOR / \ COOR
\ /n R3 O ~ n R3 \ O \
\ O O
a-~ (~1) ~ (VIII) R N Ar R NHz X Ar H (IX) pyridine Rz \ COOR
R51 (X) 3 ~ ~ ~n CsC03 R \ O \
O (1-A) R N Ar ~5 R
NaOH reduction Rz / \ COOH Rz / \
n 'OH
Ra \ O \ ~ R3 \ O
~ O'S ~O 1-B 4 ~ / O ~ O
R N Ar ( ) R N Ar (1-C) is is R R

Scheme(B) RZ / COOH Z O
1) (COCI)2, DMF - R / ~ NH2 I
R \ O O 2) NHS R3 \ O
4~ / i ~ ~ O~ ~O
R N Ar I_B1 ( ) R N~~Ar (XI) Ra Tf20 R / CN
Pyridine R3 \ \\
O (X11) N_N
R RS ~Ar Me3SnN3 Rz \ I N,N
I H
R \ O /
4 I / O~O
R N Ar 1) NHZOH HCI Rs (I D) EtyN
'' O
1) NHZOH HCI ~
2) TCDI CI "O
3) BF3 OEtZ
_O
RZ \ N N~O
Rs \ O I / H
N-S 4 ~ / O~\O
R2 I ~O R R Ar (1_E1 'H
R3 \ O
,~O ~O
R4 / N' ~Ar R (1F) s Concretely, the compound B, the compound D, the compound E, the compound F, the compound G, the compound H, the compound J and the compound K were prepared by a method described in following Example.
The compound B : Example 2(2), the compound D : Example 2(6), the compound E
Example 2, the compound F : Example 2(32), the compound G : Example 2(74), the compound H : Example 5(30), the compound J : Example 7, the compound K :
Example 2(71).
[Pharmacological Activities]
It was confirmed by the following experiments that the compounds of formula of (IA) - (IK) could be useful for the treatment of depression. The following paper can be referred to about a tail-suspension test and its testing system in mice.
1) Psychopharmacology (1985) 85: 367-370 2) Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1987 Vol. 11, 659-671 (1) Tail-suspension test in mice The test compound (10 mg/kg animal body weight) was administered orally to male ddy mice weighing around 30 g 1 hour before the beginning of measurement.
The mice were suspended by their tail on the hook of Tail Suspension TEST System (Neuroscience, Inc., Model NS-TSTOI-SS2) using adhesive tape. The subsequent immobility time for 10 miautes was measured. If the mice have none of administration, they get about 300 seconds as an immobility time in this experiment.
Generally, the medicine having an anti-depressive action shortens this immobility time.
The result was as follows. In addition, in any case, ten animals were used for each group.
Table 1 Compounds Immobility time Inhibition (sec.) (%) Vehicle 290133 0.0 Compound A 202120 30t7*

Compound B 194123 3518**

Compound C 212120 23t7*

Compound D 217124 27t8*

Compound E 185136 38t12*

Compound F 160126 4719**

Compound G 206135 31f12*

(*~ p<0.05, **: p<0.01, ***: p<0.001 vs. vehicle / Student's t test) (Discussion) Immobility time in compounds A, B, C, D, E, F and G were shortened as compared with that in the vehicle treated group, and each rate of inhibition was statistically significant. Although the chemical structures of these compounds were different structure each other, all of them had EPi receptor antagonistic activity, and shortened the immobility state induced by tail-suspension, and these results clearly indicate that compounds having EPi antagonistic activity have an action increasing mobility, namely an anti-depressive action.

(2) Forced swim test in rats The seven-week old male SD (IGS) rat freely fed was solely put into the forced swimming equipment (the cylinder (Neuroscience, Inc.) of diameter of inner 19 cm, and height 40 cm, depth-sounding 1? cm, water temperature of 23~ 1 °C) manufactured with the transparent acrylics board, and let it swim for 15 minutes. The rat was immediately dried after the end of trial and was returned to the home cage. At the same time of the next day the rats were exposed to the same conditions, and behavior of rats were observed for 5 minutes. In this time, the behavior of pat is distinguished by immobile state, struggling, submerging and swimming. The immobility time, period that rats were floating on the water by taking their head outside of the water without stroking by both legs, were measured. In addition, the water in equipment was exchanged for every trial. Moreover, one trial was conducted for each animal.
The test compound was administered orally by 5 mL/kg dosage immediately after the end of the examination on the 1st, and 1 hour before the examination on the 2nd.
And, the positive control compound (desipramine~ selective serotonin reuptake inhibitor) was similarly administered intraperitoneally by 2 mL/kg dosage immediately after the end of the examination on the 1st, and 1 hour before the examination on the 2nd.
The result was as follows. In addition, in any case, twelve animals were used for each group.
Table 2 Compounds Immobility time Inhibition (sec. ) Vehicle 23614 0t6 Desipramine 11215 536***

Compound B 16321 31g***

Compound G 19313 lg5*

Compound H 15621 35g**

Compound J 194-!-16 207*

Compound K 172-x-17 297**

(*: p<0.05, **: p<0.01, ***: p<0.001 vs. vehicle / Student's t test) (Discussion) Immobility time in compounds B, G, H, J and K group were shortened as compared with that in the vehicle treated group, and each rate of inhibition was statistically significant. Although the chemical structures of these compounds were different structure each other, all of them had EPi receptor antagonistic activity, and so, it became clear that these compounds shortened the immobility state induced by forced swim by antagonizing to EPi receptor, and showed the action to increase the mobility, namely an anti-depressive action.
(Toxicity]
The toxicity of the compounds of the present invention is very low and therefore, it is confirmed that these compounds are safe for use as medicine. For example, LDso values of the compound A and B of the present invention by oral administration to mouse are 2000 mg/kg and over.
Industrial Applicability (Application for Pharmaceuticals]
The compounds of the formula (IA) - (IK) or a non-toxic salt thereof have EPi receptor antagonistic activity, therefor, they are useful as antidepressant.
For the purpose described above, the compounds of formula (IA) - (IK) of the present invention or a non-toxic salt thereof may be normally administered systemically or topically, usually by oral or parenteral administration.
The compound of formula (IA) - (III or a non-toxic salt thereof may be administered in combination with other medicaments for the purpose of 1) complement and/or enhancement of preventing andlor treating effect, 2) improvement of dynamics and absorption of the compound, and lowering of dose, and/or 3) alleviation of side effect of the compound.
The compound of formula (IA) - (III may be administered in combination with other medicaments as a composition in one drug product comprising these components, or may be administered separately. When they are administered independently, they may be administered simultaneously or with time lag. Administering with time lag includes the method of administering the compound of formula (IA) - (IK~ before other medicaments and vice versa, and they may be administered in the same route or not.
The above combination takes effects on whichever disease treating and/or preventing effect of the compound of formula (IA) - (IK~ is complemented and/or enhanced.

As other medicaments to complement and/or to enhance the preventing and/or treating effect of an EPi antagonist of formula (IA) - (IK) for depression, for example, antianxiety agent such as series of benzodiazepine, thienodiazepine or non-benzodiazepine~ antidepressant such as monoamine releasing agent, monoamine oxidase inhibitor, monoamine reuptake inhibitor (e.g. SNRI (Serotonin-Noradrenaline Reuptake Inhibitor), SSRI (Selective Serotonin Reuptake Inhibitor)), dopamine (D~
antagonist, CRF antagonist, his agonist, neurotensin antagonist, NKi antagonist, tricyclic antidepressant, tetracyclic antidepressant anticholinergic agent, affinity polyacryl resin, obstipant, mucosal paralyzant, bulk cathartic, saline purgative, fibrillose preparation, drug for controlling intestinal function, automatic nervous regulator, calcium antagonist, phosphodiesterase inhibitor, serotonin antagonist (e.g. 5-HTs antagonist, 5-HTa antagonist), serotonin agonist (e.g. 5-HTa agonist, 5-HTiA
agonist), gastrointestinal regulator (e.g. CCK-A antagonist, ps agonist, neurotensin antagonist, opioid agonist, NKi antagonist, NKa antagonist, S~HTxn agonist, muscarine agonist, 5-lipoxygenase inhibitor, CRF antagonist) are given.
As antianxiety agent, for example, alprazolam, oxazepam, oxazolam, tandospirone citrate, cloxazolam, clotiazepam, clorazepate dipotassium, chlordiazepoxide, diazepam, tofisopam, prazepam, fludiazepam, flutazolam, flutoprazepam, bromazepam, mexazolam, medazepam, ethyl loflazepate, lorazepam are given.
As antidepressant, for example, dosulepin hydrochloride, ethyl loflazepate, progabide, etizolam, setiptiline maleate, minaprine dihydrochloride, amoxapine, lofepramine hydrochloride, maprotiline hydrochloride, mianserin hydrochloride, 6-34586, MD-690276, FCE-20124, modafinil, RV-12309, 5-1574, bupropion, venlafaxine hydrochloride, tandospirone citrate, paroxetine hydrochloride, trazodone hydrochloride, risperidone, milnacipran hydrochloride, citalopram hydrobromide, ffuvoxamine maleate, mirtazapine, topiramate, nefazodone hydrochloride, moclobemide, sertraline hydrochloride, OR-611, lamotrigine, olanzapine, pramipexole hydrochloride, ffuoxetine hydrochroride, LU-26~054, tomoxetine hydrochloride, BMY 13805-1, duloxetine hydrochloride, MD-370503, BIM~17, CP-93393, L-759274, LAX-lOlc are given.
As SSRI (Selective Serotonin Reuptake Inhibitor), for example, minaprine dihydrochloride, sibutramine hydrochloride, tramadol hydrochloride, venlafaxine hydrochloride, WY 45030, paroxetine hydrochloride, milnacipran hydrochloride, citalopram hydrobromide, fluvoxamine maleate, nefazodone hydrochloride, sertraline hydrochloride, fluoxetine hydrochroride, LU-26-054, duloxetine hydrochloride are given.
As dopamine antagonist, for example, amoxapine, etizolam, spiperone, sulpiride, timiperone, domperidone, nemonapride, haloperidol, fluphenazine, prochlorperazine, propericiazine, bromperidol, risperidone, clebopride malate, itopride hydrochloride, sultopride hydrochloride, tiapride hydrochloride, mosapramine hydrochloride, oxypertine, zotepine, pimozide, mazindol, indeloxazine hydrochloride, dosulepine hydrochloride, mazaticol hydrochloride are given.
As CRF antagonist, for example, DPC-368, NBI-34041, NBI-37582 are given.
As (is agonist, for example, SR-58611A, AJ-9677, KUL-7211, SB-418790, GW-427353, N-5984 are given.
As NKi antagonist, for example, ezlopitant, MK-869, CP-122721, DNK-333, L-758298, NKP-608, SR-140333, TAK-63?, CS-003 are given.
As NKz antagonist, for example, saredutant, nepadutant, DNK-333, CS-003 are given.
As tricyclic antidepressant, for example, amoxapine, setiptiline maleate, trimipramine maleate, amitriptyline hydrochloride, imipramine hydrochloride, clomipramine hydrochloride, desipramine hydrochloride, dosulepine hydrochloride, nortriptyline hydrochloride, mianserin hydrochloride, lofepramine hydrochloride are given.
As tetracyclic antidepressant, for example, mianserin hydrochloride, setiptiline maleate, maprotiline hydrochloride are given.
As anticholinergic agent, for example, aniracetam, etomidoline, tofisopam, dimetotiazine mesylate, scopolamine butylbromide, oxapium iodide, diphenylpiperidinomethyldioxolane iodide, tiemonium iodide, scopolia extract, trospium chloride, oxyphencyclimine hydrochloride, cyclopentolate hydrochloride, dicycloverine hydrochloride, trihexyphenidyl hydrochloride, pirenzepine hydrochloride, piroheptine hydrochloride, propiverine hydrochloride, mazaticol hydrochloride, metixene hydrochloride, ipratropium bromide, pipethanate ethobromide, oxitropium bromide, glycopyrronium bromide, tiquizium bromide, timepidium bromide, scopolamine butylbromide, butropium bromide, prifinium bromide, ffutropium bromide, propantheline bromide, anisotropine methylbromide, methylbenactyzium bromide, mepenzolate bromide, scopolamine hydrobromide, homatropine hydrobromide, N-methylscopolamine sulfate, atropine sulfate are given.
As obstipant, for example, albumin tannate, bismuth subnitrate, bismuth subgallate are given.
As mucosal paralyzant, for example, oxethazaine, strocain, topicain are given.
As bulk cathartic, for example, carmellose sodium (carboxy methylcellulose sodium) is given.
As saline purgative, magnesium oxide, magnesium sulfate, magnesium carbonate are given.
As calcium antagonist, for example, verapamil, nifedipine, diltiazem, nicardipine, nilvadipine are given.
As phosphodiesterase inhibitor, for example, cilostazol, amrinone, anagrelide hydrochloride, enoxymon, olprinone hydrochloride, pimobendan, milrinone, doxofyline, sildenafil citrate, mopidamol, toborinone, tadalafil, vardenafil, MCI-154, cilomilast, roflumilast are given.
As serotonin antagonist, for example, ketanserin tartarate, mosapramine hydrochloride, zotepine, ondansetron hydrochloride, tropisetron hydrochloride, risperidone, granisetron hydrochloride, sarpogrelate hydrochloride, perospirone hydrochloride hydrate, mirtazapine, ramosetron hydrochloride, azasetron hydrochloride, nefazodone hydrochloride, olanzapine, quetiapine fumarate, ziprasidone hydrochloride hydrate, dolasetron mesylate, clozapine, alosetron hydrochloride, indisetron hydrochloride, RS-25259-197, HP-873, EGIS-3886, itasetron hydrochloride, KC-9946, F-0930-RS, blonanserin, BIMT-1? are given.

As serotonin agonist, for example, buspirone hydrochloride, tandospirone citrate, sumatriptan succinate, mosapride citrate, naftopidil, LAS-17177, mirtazapine, naratriptan hydrochloride, zolmitriptan, rizatriptan benzoate, eletriptan hydrobromide, LAS~31416, tegaserod maleate, VML-251, BMY 13805-1, xaliproden hydrochloride, repinotan hydrochloride are given.
As CCK-A antagonist, for example, loxiglumide, dexloxiglumide, lintitript, devacard, 2-203 are given.
As 5-lipoxygenase inhibitor, for example, oxatomide, diruton, ML-3000, darbufelone mesylate, DUP-654, LDP-977 are given.
Weight ratio of the compound of formula (IA) - (IK~ and other medicaments is not limited.
A combination of any two or more of other medicaments may be administered.
A combination of any two or more of the compound of formula (IA) - (IK) may be administered.
In other medicaments to complement and/or to enhance the preventing and/or treating effect of the compound of formula (IA) - (III, medicaments that not only exist now but also may be found in the future on the basis of above mechanisms are included.
For the purpose described above, the compound of formula (IA) - (IK) or a salt thereof of the present invention or a concomitant drug combined the compound of formula (IA) - (IK) with other medicaments may be normally administered systemically or topically, usually by oral or parenteral administration.
The doses to be administered are determined depending upon, for example, age, body weight, symptom, the desired therapeutic effect, the route of administration, and the duration of the treatment , etc. In the human adult, the doses per person at a time are generally from 1 mg to 1000 mg, by oral administration, up to several times per day, and from 1 mg to 100 mg, by parenteral administration (preferably intravenous administration), up to several times per day, or continuous administration between 1 and 24 hours per day into vein.
As mentioned above, the doses to be used depend upon various conditions.
Therefore, there are cases wherein doses lower than or greater than the ranges specified above may be used.
The compound of formula (I~ - (IKa or a salt thereof or concomitant drug combined the compound of formula (IA) - (III with other medicaments may be administered in the composition of, for example, solid compositions, liquid compositions or other compositions each for or al administration, or injections, liniments or suppositories, each for parenteral administration.
Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders and granules.
Capsules include hard capsules and soft capsules.
In such solid forms, one or more of the active compounds may be admixed with vehicles such as lactose, mannitol, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium aluminometasilicate. The compositions may comprise, in accordance with the conventional process, additives other than the inert diluent, for example, lubricants such as magnesium stearate~
disintegrants such as cellulose calcium glycolate~ stabilizer such as lactose and solubilizing agent such as glutamic acid or aspartic acid. Tablets or pills may be coated with a film of a gastric soluble or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxypropyl methylcellulose phthalate, or with two or more layers, if necessary.
Furthermore, capsules made of a substance which can be absorbed in the body, for example, gelatin, are included.
Liquid forms for oral administration include pharmaceutically acceptable solutions, suspensions and emulsions, syrups and elixirs. In such forms, one or more of the active compounds may be dissolved, suspended or emulsified into diluents commonly used in the art (such as purified water, ethanol). Besides such liquid forms may also comprise some additives, such as wetting agents, suspending agents, sweetening agents, flavoring agents, aroma or preservative.
The other compositions for oral administration include sprays which comprise one or more active compounds and are formulated in a manner known per se in the art.
The compositions may comprise, in addition to an inert diluent, a stabilizer such as sodium bisulfite and a tonicity agent such as sodium chloride, sodium citrate or citric acid.
The preparation process of sprays is described in detail in, for example, U.S.
Patent Nos.
2,868,691 and 3,095,355.
In the present invention, injections for parenteral administration include sterile aqueous and/or non-aqueous solutions, suspensions and emulsions. The aqueous solutions or suspensions include, for example, distilled water for injection and saline.
The non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohol such as ethanol and Polysorbate $0 (trade mark).
Furthermore, sterile aqueous and non-aqueous solutions, suspensions, and emulsions may be used in combination. Such compositions may additionally comprise adjuvants such as antiseptic, humectant, emulsifier, dispersant, stabilizer (such as lactose) and solubilizing agent (such as glutamic acid and aspartic acid). They are sterilized by filtration through a bacteria retaining filter, the addition of a fungicide, or irradiation.
Also, a sterile solid composition is prepared and then, for example, a freeze-dried product may be dissolved in sterilized or sterile distilled water for injection or another sterile solvent before use.
The other compositions for parenteral administration include liquids for external use, ointments, endermic liniments, suppositories for intrarectal administration and pessaries for vaginal administration which comprise one or more of the active substances and may be prepared by methods known per se.
The compounds of the present invention may be administered in the form of, for example, solid compositions, liquid compositions or other compositions for oral administration, injections, liniments or suppositories for parenteral administration.
Solid compositions for oral administration include compressed tablets, pills, capsules, dispersible powders and granules. Capsules include hard capsules and soft capsules.
In such solid forms, one or more of the active compounds) may be admixed with vehicles (such as lactose, mannitol, mannit, glucose, hydroxypropyl cellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone or magnesium aluminometasilicate). The compositions may comprise, in accordance with the conventional process, additives other than the inert diluent, for example, lubricants such as magnesium stearate, disintegrants such as cellulose calcium glycolate, and solubilizing agent such as glutamic acid or aspartic acid. Tablets or pills may be coated with a film of a gastric soluble or enteric substance such as sucrose, gelatin, hydroxypropyl cellulose or hydroxypropyl cellulose phthalate, or with two or more layers, if necessary.
Furthermore, capsules made of a substance which can be absorbed in the body, for example, gelatin, are included.
Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, syrups and elixirs. Such liquid compositions comprise one or more of the active substances) and an ordinarily employed inert diluent(s) (such as purified water or ethanol) dissolving the substances) therein. The compositions may comprise, in addition to the inert diluent, an adjuvant such as humectants or suspending agents, sweetening agents, flavoring agents, aromatic agents and antiseptics.
The other compositions for oral administration include sprays which comprise one or more active substances and are formulated in a manner known per se in the art.
The compositions may comprise, in addition to an inert diluent, a stabilizer such as sodium bisulfite and a tonicity agent such as sodium chloride, sodium citrate or citric acid.
The preparation process of~sprays is described in detail in, for example, U.S.
Patent Nos.
2,868,691 and 3,095,355.
In the present invention, injections for parenteral administration include sterile aqueous and/or non-aqueous solutions, suspensions and emulsions. The aqueous solutions or suspensions include, for example, distilled water for injection and saline.
The non-aqueous solutions or suspensions include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohol such as ethanol and Polysorbate 80 (trade mark).
Furthermore, sterile aqueous and non-aqueous solutions, suspensions, and emulsions may be used in combination. Such compositions may additionally comprise adjuvants such as antiseptic, humectant, emulsifier, dispersant, stabilizer and solubilizing agent (such as glutamic acid and aspartic acid). They are sterilized by filtration through a bacteria retaining filter, the addition of a fungicide, or irradiation. Also, a sterile solid composition is prepared and then, for example, a freeze-dried product may be dissolved in sterilized or sterile distilled water for injection or another sterile solvent before use.
The other compositions for parenteral administration include liquids for external use, ointments, endermic liniments, suppositories for intrarectal administration and pessaries for vaginal administration which comprise one or more of the active substances and may be prepared by methods known per se.
Best mode for carrying out the invention The following Reference examples and Examples are intend to illustrate, but not to limit the present invention.
The solvents in parentheses at chromatographic separations section show the developing or eluting solvents and the ratios of the solvents used are indicated by volume.
Without special explanation, NMR data was determined in CDCIa solution. And the solvents in parentheses at NMR data section show solvents used in determination.

Reference example 1 4-(2-nitro-4,5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester H3C ~ O
H C' v 'NO

Under atmosphere of argon, a mixture of 2-nitro-4,5-dimethylphenol (4 g), DMF
(100 ml), potassium carbonate (6.6 g) and 4-mesyloxymethyl-3-methylbenzoic acid methyl ester (6.8 g) were stirred for 15 minutes at 60 °C. After the termination of reaction, the mixture was cooled and poured into iced water. The mixture was extracted with ethyl acetate - hexane. The organic layer was washed, dried, concentrated under reduced pressure to give the title compound (7.22 g) having the following physical data.
TLC : Rf 0.24 (n-hexane : ethyl acetate = 4 : 1).
Reference example 2 4-(2-amino-4,5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester H3C ~ O
H3C~NHz A mixture of 4-(2-nitro-4,5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester prepared in reference example 1 (?.21 g), acetic acid (88 ml) and water (8.8 ml) was stirred at 50 °C. To the reaction solution, iron powder (6.11 g) was gradually added, and the mixture was stirred for 1 hour at 50 °C. After cooling, the mixture was filtered and the filtrate was concentrated and azeotroped with toluene. To the residue, ethyl acetate - water (100 ml - 100 ml) was added and the mixture was filtrated over Celite (registered trademarl~. The organic layer was washed, dried, concentrated under reduced pressure to give the title compound (4.66 g) having the following physical data.
TLC : Rf 0.51 (n-hexane : ethyl acetate = 2 : 1).
Reference example 3 3-methyl-4-(2-(N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid methyl ester H3C ~ O
H C ~ ~ N'S~O 0 a H ~CH3 /
A solution of 4-(2~amino-4,5-dimethylphenoxymethyl)-3-methylbenzoic acid methyl ester prepared in reference example 2 (632 mg) in pyridine (4 ml) was cooled to.
0°C, then 5-methylfuran-2-sulfonyl chloride (490 mg) was added dropwise thereto. After the solution was stirred for 1 hour at room temperature, the reaction mixture was diluted by ethyl acetate, and poured into water. The organic layer was washed, dried, concentrated under reduced pressure. The residue was washed by mixed solvent of diisopropylether and hexane to give the title compound (875 mg) having the following physical data.
TLC : Rf 0.42 (n-hexane : ethyl acetate = 2 : 1).
Example 1 3-methyl-4-(2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid methyl ester Na''° o J I / cH3 To a solution of 3-methyl-4-(2-[N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid methyl ester prepared in reference example 3 (870 mg) in N,N-dimethylacetamide (2 ml), cesium carbonate (1.3? g) and isobutyl iodide (0.36 ml) were added and the mixture was stirred for 1 hour at 100 °C. The reaction mixture was allowed to cool and poured into ethyl acetate - water (40 ml - 40 ml). The organic layer was washed, dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (toluene - ethyl acetate) to give the title compound (855 mg) having the following physical data.
TLC : Rf 0.51 (n-hexane : ethyl acetate = 2 : 1)~
NMR : 8 7.87 (d, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 7.04 (s, 1H), 6.70 (m, 2H), 5.93 (m, 1H), 4.91 (brs, 2H), 3.92 (s, 3H), 3.48 (m, 2H), 2.34 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.09 (s, 3H), 0.90 (brs, 6H).

Example 2 3-methyl-4-[2-[N-isobutyl~N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid H3C ~ O
H C~N~O O
3 ~ ~ CH3 H3C\ J
'C~H3 To a solution of 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid methyl ester prepared in example 1 (850 mg) in dioxane (10 ml), 2N aqueous sodium hydroxide (2.5 ml) and methanol (4 ml) were added, and the mixture was stirred for 30 hours at room temperature. To the mixture, hydrochloric acid was added, then ethyl acetate - water (30 ml - 15 ml) was also added.
The organic layer was washed, dried and concentrated under reduced pressure.
The residue was dissolved in hot ethanol (40 ml) and added by hot water (40 ml), then allowed to cool. Precipitation was filtrated, and dried to give the title compound (755 mg) having the following physical data.
TLC : Rf 0.78 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 7.94 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.04 (s, 1H), 6.74-6.70 (m, 2H), 5.94 (dd, J = 3.3, 0.9 Hz, 1H), 4.94 (br, 2H), 3.48 (d, J = 6.6 Hz, 2H), 2.37 (s, 3H), 2.24 (s, 3 H), 2.19 (s, 3H), 2.11 (s, 3H), 1.68 (sep, J = 6.6 Hz, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Example 2(1) ~ Example 2(124) By the same procedures as described in reference example 1 -~ reference example 2 -~ reference example 3 -> example 1 -~ example 2 using corresponding compounds, the title compounds having the following physical data were obtained.
Example 2(1) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-triffuoromethylphenoxymethyl]
cinnamic acid ~N.S~O O

H3~, J
TLC : Rf 0.51 (n-hexane : ethyl acetate : acetic acid = 1 : 1 : 0.02) NMR : 8 7.80 (d, J = 16.2 Hz, 1H), 7.59 (d, J = 8.0 Hz, 2H), 7.45 - 7.36 (m, 3H), ?.26 (dd, J
= 8.2, 1.8 Hz, 1H), 7.18 (d, J = 1.8 Hz, 1H), 7.00 - 5.00 (br, 1H), 6.75 (d, J
= 3.4 Hz, 1H), 6.49 (d, J = 16.2 Hz, 1H), 5.98 (dq, J = 3.4, 0.8 Hz, 1H), 5.05 (brs, 2H), 3.51 (d, J = 7.4 Hz, 2H), 2.16 (s, 3H), 1.75 - 1.50 (m, 1H), 0.88 (d, J = 6.8 Hz, 6H).
Example 2(2) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyDamino]-5-trifluoromethylphenoxymethyl]
benzoic acid COOH
F3C ~ O
/ N~O O

HgC"CH3 TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR : b 8.16 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.21-7.26 (m, 3H), 6.84 (d, J =
3.2 Hz, 1H), 6.05 (m, 1H), 5.21 (m, 2H), 4.49 (m, 1H), 2.33 (s, 3H), 1.10 (d, J = 6.6 Hz, 6H).
Example 2(3) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
benzoic acid / COOH
F3C ~ O
/ N~O O

TLC : Rf 0.46 (chloroform : methanol = 9 : 1)~
NMR : 8 8.15 (d, J = 8.6 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 7.41 (m, 1H), ?.29 (m, 1H), ?.18 (m, 1H), 6.76 (d, J = 3.4 Hz, 1H), 5.98 (m, 1H), 5.10 (s, 2H), 3.51 (d, J =
6.2 Hz, 2H), 2.16 (s, 3H), 1.64 (m, 1H), 0.90 (d, J = 6.8 Hz, 6H).
Example 2(4) 4-[2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]
TLC : Rf 0.30 (chloroform : methanol = 9 : 1)~
NMR : b 8.12 and 7.46 (each d, J = 8.1 Hz, each 2H), 7.20 (s, 1H), 6.81-6.75 (m, 2H), 6.01-5.98 (m, 1H), 5.12-4.98 (m, 2H), 3.45 (d, J = 7.5 Hz, 2H), 2.34 and 2.19 (each s, each 3H), 1.75-1.59 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).
Example 2(5) 4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid / COOH
H3C ~ O
H3C I / N:S~O O

H3C"CH3 TLC : Rf 0.38 (chloroform : methanol = 10 : 1)~
NMR : 8 8.12-8.09 (m, 2H), 7.56 (d, J = 8.4 Hz, 2H), 6.81 (s, 1H), 6.79 (d, J
= 3.3 Hz, 1H), 6.75 (s, 1H), 6.02 (dd, J = 3.3, 1.2 Hz, 1H), 5.10 (s, 2H), 4.48 (m, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.17 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H).
Example 2(6) 4-(2-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid TLC : Rf 0.38 (chloroform : methanol = 10 : 1)~
NMR : 8 8.12-8.08 (m, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.03 (s, 1H), 6.71 (d, J
= 3.3 Hz, 1H), 6.68 (s, 1H), 5.92 (dd, J = 3.3, 0.9 Hz, 1H), 5.00 (brs, 2H), 3.52-3.46 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.68 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
benzoic acid Example 2(7) 3-methyl-4-[2-(N-isobutyl-N-(5-methyl-2-fuiylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid c1 CHa TLC : Rf 0.42 (chloroform : methanol = 9 : 1)~
NMR : 8 8.00-7.89 (m, 2H), 7.41 (d, J = 8.4 Hz, 1H), 7.16 (s, 1H), 6.95 (s, 1H), 6.74 (d, J =
3.3 Hz, 1H), 5.96 (m, 1H), 4.94 (s, 2H), 3.47 (d, J = 6.3 Hz, 2H), 2.37 (s, 3H), 2.30 (s, 3H), 2.11 (s, 3H), 1.64 (m, 1H), 0.90 (d, J = 6.6 Hz, 6H).
Example 2(8) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid HOC / COOH
H3C ~ O
CI I ~ N'S~0 O

'C~H3 TLC : Rf 0.58 (chloroform : methanol = 9 : 1)~
NMR : b 7.96 (d, J = ?.5 Hz, 1H), 7.94 (s, 1H), 7.47 (d, J = ?.5 Hz, 1H), 7.20 (s, 1H), 6.81 (s, 1H), 6.77 (d, J = 3.3 Hz, 1H), 6.03-5.97 (m, 1H), 4.99 (brs, 2H), 3.44 (d, J =
7.5 Hz, 2H), 2.39 (s, 3H), 2.36 (s, 3H), 2.17 (s, 3H), 1.75-1.60 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Example 2(9) 3-chloro-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid TLC : Rf 0.38 (chloroform : methanol = 9 : 1)~
NMR : 8 8.13 (d, J = 1.5 Hz, 1H), 8.02 (dd, J = 8.4, 1.5 Hz, 1H), 7.58 (d, J =
8.4 Hz, 1H), 7.15 (s, 1H), 6.94 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 5.98 (m, 1H), 5.25-4.90 (br, 2H), 3.48 (d, J = 6.6 Hz, 2H), 2.31 (s, 3H), 2.16 (s, 3H), 1.64 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).
Example 2(10) 3-chloro-4-[2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-acid TLC : Rf 0.38 (chloroform : methanol = 9 : 1)~
NMR : 8 8.12 (d, J = 1.5 Hz, 1H), 8.07 (dd, J = 8.4, 1.5 Hz, 1H), 7.88 (d, J =
8.4 Hz, 1H), 6.99 (s, 1H), 6.95 (s, 1H), 6.85 (d, J = 3.3 Hz, 1H), 6.06 (m, 1H), 5.20 (d, J
= 14.4 Hz, 1H), 5.15 (d, J = 14.4 Hz, 1H), 4.48 (m, 1H), 2.33 (s, 3H), 2.30 (s, 3H), 1.11 (d, J = 6.3 Hz, 3H), 1.09 (d, J = 6.3 Hz, 3H).
Example 2(11) 3-methoxy-4-[2-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid ci Na''° o CHs TLC : Rf 0.49 (chloroform : methanol = 9 : 1)~
NMR : 8 7.78 (dd, J = 8.1, 1.5 Hz, 1H), 7.76 (d, J = 1.5 Hz, 1H), 7.59 (d, J =
1.5 Hz, 1H), 7.01 (s, 1H), 6.96 (s, 1H), 6.83 (d, J = 3.3 Hz, 1H), 6.05- 6.00 (m, 1H), 5.11 (d, J = 14.1 Hz, 1H), 5.07 (d, J = 14.1 Hz, 1H), 4.55-4.40(m, 1H), 3.94 (s, 3H), 2.30 (s, 3H), 2.29 (s, 3H), 1.12 (d, J = 6.9 Hz, 6H).
Example 2(12) 3-methoxy-4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid H3C ~ O
H C I ~ N'S~O O
3 , ~ CHs H3C"CH3 TLC : Rf 0.44 (chloroform : methanol = 9 : 1);

NMR : 8 7.77 (dd, J = 8.1, 1.2 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), ?.58 (d, J =
1.2 Hz, 1H), 6.84 (s, 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.78 (s, 1H), 6.05- 6.00 (m, 1H), 5.09 (s, 2H), 4.60-4.40 (m, 1H), 3.94 (s, 3H), 2.29 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H), 1.12 (d, J = 6.9 Hz, 6H).
Example 2(13) 3-methoxy-4-[2-[N-isobutyl~N-(5-methyl-2-furylsulfonyl)amino] ~4, 5-nzoic acid TLC : Rf 0.45 (chloroform : methanol = 9 : 1);
NMR : b 7.73 (dd, J = 8.1, 1.2 Hz, 1H), 7.58 (d, J = 1.2 Hz, 1H), 7.40 (d, J =
8.1 Hz, 1H), 7.07 (s, 1H), 6.75-6.70 (m, 2H), 5.95-5.90 (m, 1H), 5.15-4.85 (m, 2H), 3.94 (s, 3H), 3.51 (br, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.11 (s, 3H), 1.80-1.60 (m, 1H), 0.94 (br, 6H).
Example 2(14) 3-methoxy-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid H3~ \ o ~ 1 cWN'~~ °

TLC : Rf 0.46 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 13.02 (s, 1H), ?.58-7.50 (m, 3H), 7.24 (s, 1H), 6.98 (s, 1H), 6.94 (d, J =
3.3 Hz, 1H), 6.25 (m, 1H), 5.10 (d, J = 13.5 Hz, 1H), 5.04 (d, J = 13.5 Hz, 1H), 4.24 (m, 1H), 3.87 (s, 3H), 2.34 (s, 3H), 2.27 (s, 3H), 0.99 (d, J = 6.6 Hz, 3H), 0.98 (d, J
= 6.6 Hz, 3H).
Example 2(15) 3-chloro-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR : 8 8.12 (d, J = 1.8 Hz, 1H), 8.02 (dd, J = 8.1, 1.8 Hz, 1H), 7.61 (d, J =
8.1 Hz, 1H), ?.03 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.70 (s, 1H), 5.96 (m, 1H), 5.25-4.85 (br, 2H), 3.50 (d, J = 6.6 Hz, 2H), 2.24 (s, 3H), 2.19 (s, 3H), 2.16 (s, 3H), 1.79 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Example 2(16) 3-chloro-4-(2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid CI / COOH
H3C ~ O
H C ~ ~ N'~O O
3 ~ ~ CH3 H3C"CH3 TLC : Rf 0.39 (chloroform : methanol = 9 : 1)~
NMR : b 8.11 (d, J = 1.8 Hz, 1H), 8.06 (dd, J = 8.1, 1.8 Hz, 1H), ?.90 (d, J =
8.1 Hz, 1H), 6.86-6.80 (m, 2H), 6.75 (s, 1H), 6.05 (m, 1H), 5.17 (s, 2H), 4.51 (m, 1H), 2.32 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Example 2(17) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-chloro-5-1]cinnamic acid c1 H3C\ J
'C~H3 TLC : Rf 0.37 (chloroform : methanol = 9 : 1)>
NMR(CDsOD) : b 7.63 (d, J = 16.2 Hz, 1H), ?.45 (s) and 7.44 (d, J = 8.1 Hz) total 2H, 7.34 (d, J = 8.1 Hz, 1H), 7.1? (s, 1H), 7.10 (s, 1H), 6.72 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 16.2 Hz, 1H), 6.08 (dd, J = 3.3, 1.2 Hz, 1H), 4.98 (brs, 2H), 3.44 (d, J = 6.9 Hz, 2H), 2.37 (s, 3H), 2.35 (s, 3H), 2.10 (s, 3H), 1.60 (m, 1H), 0.87 (d, J = 6.6 Hz, 6H).

Example 2(18) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4~methyl-5-chlorophenoxymethyl]cinnamic acid ~ COOH
CI ~ O
H C~N'~O O

TLC : Rf 0.31 (chloroform : methanol = 9 : 1)~
NMR : b ?.?3 (d, J = 15.9 Hz, 1H), 7.57 and 7.49 (each d, J = 8.1 Hz, each 2H), 6.98 and 6.92 (each s, each 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.03 (d, J = 3.3 Hz, 1H), 5.05 (s, 2H), 4.50-4.38 (m, 1H), 2.30 and 2.28 (each s, each 3H), 1.10 and 1.09 (each d, J = 6.6 Hz, each 3H).
Example 2(19) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]
cinnamic acid ~ COOH
CI ~ O
H3C~ / N'~O O

H3C' J
~CH3 TLC : Rf 0.31 (chloroform : methanol = 9 : 1)~
NMR : 8 7.77 (d, J = 15.9 Hz, 1H), 7.56 and 7.35 (each d, J = ?.8 Hz, each 2H), 7.14 and 6.92 (each s, each 1H), 6.72 (d, J = 3.6 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.95 (d, J = 3.6 Hz, 1H), 5.00-4.88 (m, 2H), 3.52-3.42 (m, 2H), 2.29 and 2.13 (each s, each 3H), 1.72-1.60 (m, 1H),0.90 (d, J = 6.3 Hz, 6H).
Example 2(20) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
cinnamic acid ~ COOH
H3C ~ O
~O~ ,O
H3C~N:~ O

HgC"CH3 TLC : Rf 0.39 (chloroform : methanol = 9 : 1).
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.50 (d, J = 8.4 Hz, 2H), 6.80 (s, 1H)~ 6.79 (d, J = 3.3 Hz, 1H), 6.76 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.01 (m, 1H), 5.06 (s, 2H), 4.47 (sept, J = 6.6 Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.16 (s, 3H), 1.1l and 1.10 (each d, J = 6.6 Hz, each 3H).
Example 2(21) 3-methyl-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid H3C / ~ COOH
P3C ~ O
/ N~O O
CH3 .
H3C"CH3 TLC : Rf 0.42 (chloroform : methanol = 9 : 1);
NMR(DMSO-ds) : b 12.36 (br s, 1H), 7.61-7.52 (m, 5H), 7.38 (d, J = 8.0 Hz, 1H), ?.24 (d, J
= 8.0 Hz, 1H), 6.96 (d, J = 3.5 Hz, 1H), 6.54 (d, J = 16.0 Hz, 1H), 6.28 (d, J
= 3.5 Hz, 1H), 5.24 (d, J = 13.0 Hz, 1H), 5.18 (d, J = 13.0 Hz, 1H), 4.26 (septet, J = 6.5 Hz, 1H), 2.35 (s, 3H), 2.30 (s, 3H), 0.9? (d, J = 6.5 Hz, 6H).
Example 2(22) 3-methyl-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid H3C ~ 0 ~ I
H C I ~ N'~O 0 3 ~ ~ CH3 H3C"CH3 TLC : Rf 0.28 (n-hexane : ethyl acetate = 1 : 1);
NMR : b 7.97 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.65 (d, J = 7.8 Hz, 1H), 6.82 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.77 (s, 1H), 6.01 (dd, J = 3.3, 1.2 Hz, 1H), 5.08 (d, J =
13.2 Hz, 1H), 5.02 (d, J = 13.2 Hz, 1H), 4.47 (quint, J = 6.6 Hz, 1H), 2.40 (s, 3H), 2.29 (s, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.11 (d, J = 6.6 Hz, 6H).
Example 2(23) 3-methyl-4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid N:~O O

TLC : Rf 0.30 (n-hexane : ethyl acetate = 1 : 2)~
MS (FAB, Pos.) : 498 (M + H)+.
Example 2(24) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid H3C / ~ COOH
H3C ~ O
H3C~N~0 O

H3C_ J
~CH3 TLC : Rf 0.26 (n-hexane : ethyl acetate = 1 : 2)~
MS (FAB, Pos.) : 512 (M + H)+.
Example 2(25) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid / ~ COOH
H3C ~ O
HsC ~ / IV:S~O O

H3Cw TLC : Rf 0.47 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 ?.69 (d, J = 8.1 Hz, 2H), ?.58 (d, J = 16.2 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 6.93 (s, 1H), 6.90 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.54 (d, J = 16.2 Hz, 1H), 6.13 (m, 1H), 5.10-4.80 (m, 2H), 3.40- 3.20 (m, 2H, covered with Ha0 in DMSO-d~, 2.18 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 1.58-1.42 (m, 1H), 0.82 (d, J = 6.6 Hz, 6H).
Example 2(26) 3-methoxy-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid OOH
CI
H3C~N~0 O CH

TLC : Rf 0.30 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), ?.30 (d, J = 8.1 Hz, 1H), ?.26 (s, 1H), 7.20 (d, J = 8.1 Hz, 1H), 7.04 (s, 1H), 6.96 (s, 1H), 6.72 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 6.00-5.90 (m, 1H), 4.95 (brs, 2H), 3.91 (s, 3H), 3.48 (brs, 2H), 2.29 (s, 3H), 2.13 (s, 3H), 1.75-1.60 (m, 1H), 0.91 (brd, J = 6.6 Hz, 6H).
Example 2(27) 4-(6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : 8 8.11 (d, J = 8.1 Hz, 2H), ?.43 (d, J = 8.1 Hz, 2H), 7.12 (s, 1H), 6.7?
(s, 1H), 6.?3 (d, J = 3.3 Hz, 1H), 5.94 (m, 1H), 5.15-4.85 (br, 2H), 3.60-3.40 (br, 2H), 2.86 (t, J = 7.2 Hz, 4H), 2.14 (s, 3H), 2.13-2.00 (m, 2H), 1.68 (m, 1H), 1.02-0.82 (br, 6H).
Example 2(28) 4-(6-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid COOH
O
//N.S~O O

H3C"CH3 TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : 8 8.12 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 6.83 (s, 1H), 6.81 (d, J = 3.3 Hz, 1H), 6.02 (m, 1H), 5.1?-5.05 (m, 2H), 4.49 (m, 1H), 2.93-2.?9 (m, 4H), 2.31 (s, 3H), 2.15-2.00 (m, 2H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Example 2(29) 4-(7-(N~isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaphthalen-6-yloxymethyl]benzoic acid Na''o 0 J I / cH3 TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : b 8.10 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H)> 6.95 (s, 1H), 6.73 (d, J = 3.3 Hz, 1H), 6.57 (s, 1H), 5.93 (m, 1H), 5.15-4.82 (br, 2H), 3.48 (d, J = 7.2 Hz, 2H), 2.77-2.60 (m, 4H), 2.13 (s, 3H), 1.82-1.60 (m, 5H), 0.92 (d, J = 6.6 Hz, 6H).
Example 2(30) 4- [7-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-1,2,3,4-tetrahydronaphthalen-6-yloxymethyl]benzoic acid / COOH
O
O O

H3C"CH3 TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : b 8.12 (d, J = 8.4 Hz, 2H), 7.56 (d, J = 8.4 Hz, 2H), 6.80 (d, J = 3.3 Hz, 1H), 6.74 (s, 1H), 6.64 (s, 1H), 6.02 (m, 1H), 5.16-5.04 (m, 2H), 4.48 (m, 1H), 2.77-2.58 (m, 4H), 2.30 (s, 3H), 1.82-1.69 (m, 4H), 1.12 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Example 2(31) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4-methyl-5-1]cinnamic acid TLC : Rf 0.30 (chloroform : methanol = 9 : 1)~
NMR(CDsOD) : 8 7.65 (d, J = 15.9 Hz, 1H), 7.46 (s) and 7.44 (d, J = 7.8 Hz) total 2H, 7.34 (d, J = 7.8 Hz, 1H), 7.18 (s, 1H), 7.14 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 6.50 (d, J = 15.9 Hz, 1H), 6.07 (dd, J = 3.3, 0.9 Hz, 1H), 4.95 (m, 2H), 3.44 (d, J = 7.5 Hz, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 2.09 (s, 3H), 1.61 (m, 1H), 0.87 (d, J = 6.6 Hz, 6H).

Example 2(32) 4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid ~N.S~O O

H3~, J
TLC : Rf 0.42 (chloroform : methanol = 9 : 1);
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H), 7.11 (s, 1H), 6.78 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 6.4? (d, J = 15.9 Hz, 1H), 5.93 (m, 1H), 5.10-4.80 (br, 2H), 3.60-3.40 (br, 2H), 2.86 (t, J = 7.5 Hz, 4H), 2.14 (s, 3H), 2.08 Cm, 2H), 1.68 (m, 1H), 1.00-0.82 (br, 6H).
Example 2(33) 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.33 (chloroform : methanol = 10 : 1);
NMR(CDC13 + 1 drop of CDsOD) : 8 7.89 (d, J = 8.4 Hz, 1H), 7.88 (s, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.12 (s, 1H), 6.?9 (s, 1H), 6.71 (d, J = 3.3 Hz, 1H), 5.94 (m, 1H), 5.06-4.74 (m, 2H), 3.60-3.37 (m, 2H), 2.92-2.82 (m, 4H), 2.34 (s, 3H), 2.172.03 (m, 2H), 2.10 (s, 3H), 1.69 (m, 1H), 1.01-0.80 (m, 6H).
Example 2(34) 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.30 (chloroform : methanol = 10 : 1);
benzoic acid cinnamic acid NMR : b 7.78 (d, J = 15.9 Hz, 1H), 7.42-7.36 (m, 3H), 7.10 (s, 1H), 6.80 (s, 1H), 6.72 (d, J =
3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.94 (m, 1H), 5.04-4.77 (m, 2H), 3.59-3.3? (m, 2H), 2.91-2.82 (m, 4H), 2.34 (s, 3H), 2.14-2.05 (m, 2H), 2.12 (s, 3H), 1.68 (m, 1H), 1.00-0.82 (m, 6H).
Example 2(35) 4-[2-[N-(2-methyl-2-propenyl)-N-(5-methyl-2-furylsulfonyl)amino]-4,5-acid TLC : Rf 0.42(chloroform : methanol = 10 : 1)~
NMR : 8 8.11 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.02 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.6? (s, 1H), 6.00-5.95 (m, 1H), 5.00 (brs, 2H), 4.77 (s, 2H), 4.26 (brs, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.13 (s, 3H), 1.78 (s, 3H).
Example 2(36) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid / COOH
~I
/ N~O N
H3C"CH3 TLC : Rf 0.58 (ethyl acetate) NMR(CDsOD) : 8 8.03 (d, J = 8.7 Hz, 2H), 7.92 (d, J = 3.3 Hz, 1H), 7.82 (d, J
= 3.3 Hz, 1H), 7.54 (d, J = 8.4 Hz, 2H), 7.43 (brs, 1H), 7.37 (d, J = 8.1 Hz, 1H), 7.30 (brd, J = 8.1 Hz, 1H), 5.23 (ABd, J = 12.6 Hz) and 5.14 (ABd, J = 12.6 Hz) total 2H, 4.64 (sept, J =
6.9 Hz, 1H) , 1.15 (d, J = 6.9 Hz) and 1.14 (d, J = 6.9 Hz) total 6H.
Example 2(37) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid / COOH
F3C ~ O
I / O:S~O N
N

TLC : Rf 0.60 (ethyl acetate) NMR(CDsOD) : 8 8.02 (d, J = 8.7 Hz, 2H), 7.74 (m, 2H), 7.52 (d, J = 7.2 Hz, 1H), 7.38 (d, J
= 8.? Hz) and 7.3? (s) total 3H, 7.32 (brd, J = 7.2 Hz, 1H), 5.02 (br, 2H), 3.60 (brd, J = 7.5 Hz, 2H), 1.70-1.58 (m, 1H), 0.92 (d, J = 6.9 Hz, 6H).
Example 2(38) 4-[2-(N-isopropyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
cinnamic acid / ~ COOH
P3C ~ 0 I
/ N~O N
H3C"CH3 TLC : Rf 0.42 (chloroform : methanol = 9 : 1).
NMR(CDsOD) : b 7.91 (d, J = 3 Hz, 1H), 7.81 (d, J = 3 Hz, 1H), 7.69 (d, J =
15.9 Hz, 1H), 7.63 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), 7.42 (s, 1H), ?.36 (d, J =
8.1 Hz, 1H), 7.29 (brd, J = 8.1 Hz, 1H), 6.52 (d, J = 15.9 Hz, 1H), 5.18 (ABd, J = 12.3 Hz) and 5.09 (ABd, J =
12.3 Hz) total 2H, 4.63 (sept, J = 6.6 Hz, 1H), 1.15 (d, J = 6.6 Hz) and 1.13 (d, J = 6.6 Hz) total 6H.
Example 2(39) 4-[2-(N-isobutyl-N-(2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid / ~ COOH
F3C ~ 0 / N~S'O N

TLC : Rf 0.42 (chloroform : methanol = 9 : 1)~
NMR(CDsOD) : b 7.76-7.70 (m, 2H), 7.64 (s) and 7.63 (d, J = 15.9 Hz) total 3H, 7.52 (d, J =
8.1 Hz, 1H), 7.38-7.28 (m, 4H), 6.53 (d, J = 15.9 Hz, 1H), 5.04-4.90 (m, 2H), 3.60 (brd, J =
6.9 Hz, 2H), 1.72-1.56 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).

Example 2(40) 4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
TLC : Rf 0.42 (chloroform : methanol = 9 : 1)~
NMR(CDsOD) : 8 8.03 (d, J = 8.4 Hz, 2H), ?.53 (d, J = 8.1 Hz, 1H), 7.42-7.30 (m) and 7.27 (s) total 5H, 5.18-4.90 (m, 2H), 3.63-3.58 (m, 2H), 2.23 (d, J = 0.9 Hz, 3H), 1.66 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Example 2(41) 4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
cinnamic acid / ~.,, COOH
F3C ~ O
/ N~0 N

TLC : Rf 0.32 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.70 (d, J = 8.1 Hz, 2H), 7.60 (d, J = 15.9 Ha, 1H), ?.56-7.46 (m, 3H), 7.38 (d, J = 8.7 Hz, 1H), ?.29 (d, J = 8.1 Hz, 2H), 6.56 (d, J = 15.9 Hz, 1H), 5.20-4.85 (m, 2H), 3.49 (d, J = 6.9 Hz, 2H), 2.21 (s, 3H), 1.53 (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Example 2(42) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl)benzoic acid / COOH
H3C ~ O
~ ~I
CI~N~O N
H3C"CH3 TLC : Rf 0.39 (chloroform : methanol = 9 : 1)~
NMR : b 8.13 (d, J = 8.1 Hz, 2H), 7.91 (d, J = 3.0 Hz, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.50 (d, benzoic acid J = 3.0 Hz, 1H), 7.10 (s, 1H), 6.85 (s, 1H), 5.09 (s, 2H), 4.67 (m, 1H), 2.36 (s, 3H); 1.16 (d, J
= 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Example 2(43) 4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid COOH
H3C \ O
CI~N~O N
~~CH3 H3C~CH3 ~ , TLC : Rf 0.39 (chloroform : methanol = 10 : 1)~
NMR : 8 8.13 (d, J = 8.1 Hz, 2H), ?.52 (d, J = 8.1 Hz, 2H), 7.09 (s, 1H), 7.04 (m, 1H), 6.85 (s, 1H), 5.10 (s, 2H), 4.68 (m, 1H), 2.49 (d, J = 0.6 Hz, 3H), 2.36 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H).
Example 2(44) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid COOH
HsC \ O \
CI~N~O N
~CH3 TLC : Rf 0.40 (chloroform : methanol = 10 : 1)~
NMR : 8 8.12 (d, J = 7.5 Hz, 2H), ?.37 (d, J = 7.5 Hz, 2H), 7.27 (d, J = 1.2 Hz, 1H), 6.96 (m, 1H), 6.78 (s, 1H), 5.10-4.78 (m, 2H), 3.57 (brs, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 1.70 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H).
Example 2(45) 3-chloro-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid CI / COOH
H3C \ O
CI~N~O N
~~CH3 HgC~CH ~3 TLC : Rf 0.69 (chloroform : methanol : water = 8 : 2 : 0.2)~

NMR : b 8.12 (d, J = 1.5 Hz, 1H), 8.06 (dd, J = 8.1, 1.5 Hz, 1H), 7.83 (d, J =
8.1 Hz, 1H), ?.117.10 (m, 2H), 6.86 (s, 1H), 5.23 (d, J = 14.4 Hz, 1H), 5.15 (d, J = 14.4 Hz, 1H), 4.71 (quint, J = 6.6 Hz, 1H), 2.52 (d, J = 1.2 Hz, 3H), 2.38 (s, 3H), 1.56 (d, J =
6.6 Hz, 3H), 1.34 (d, J = 6.6 Hz, 3H).
Example 2(46) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid F3C ~ O

N ~CH3 HaC ~ ~

TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR : 8 7.96 (d, J = 8.4 Hz, 1H), 7.95 (s, 1H), 7.48 (d, J = 8.1 Hz, 1H), 7.35 (d, J = 8.4 Hz, 1H), 7.32-7.24 (m, 1H), 7.20 (s, 1H), 6.98 (s, 1H), 5.06-4.85 (m, 2H), 3.70-3.50 (m, 2H), 2.39 (s, 3H), 2.34 (s, 3H), 1.75-1.59 (m, 1H), 0.91 (d, J = 6.6 Hz, 6H).
Example 2(47) 3-methyl-4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid H3C ~ O
/ O'S~ J'~
CI N ~CH3 TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.79 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.29 (s, 1H), 7.27 (d, J = 8.1 Hz, 1H), 7.23 (s, 1H), 5.20-4.65 (m, 2H), 3.55-3.35 (m, 2H), 2.36 (s, 3H), 2.31 (s, 3H), 2.21 (s, 3H), 1.65-1.4? (m, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Example 2(48) 3-methoxy-4-[2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]benzoic acid TLC : Rf 0.48 (chloroform : methanol = 9 : 1)~
NMR : 8 7.74 (dd, J = 7.8, 1.2 Hz, 1H), 7.59 (d, J = 1.2 Hz, 1H), 7.31 (d, J =
7.8 Hz, 1H), ?.30 (s, 1H), 6.94 (s, 1H), 6.81 (s, 1H), 5.10-4.70 (m, 2H), 3.94 (s, 3H), 3.59 (br, 2H), 2.35 (s, 3H), 2.34 (s, 3H), 1.80-1.60 (m, 1H), 1.12 (d, J = 6.9 Hz, 6H).
Example 2(49) 3-methoxy-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-triffuoromethylphenoxymethyl]benzoic acid N~~N
J s~cHa TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR : 8 7.73 (dd, J = 8.1, 1.5 Hz, 1H), 7.60 (d, J = 1.5 Hz, 1H), 7.50 (d, J =
8.1 Hz, 1H), 7.34-7.19 (m, 3H), 6.95 (m, 1H), 5.12-4.80 (m, 2H), 3.95 (s, 3H), 3.77-3.48 (m, 2H), 2.34 (s, 3H), 1.77-1.60 (m, 1H), 0.94 (d, J = 6.6 Hz, 6H).
Example 2(50) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid COOH
CI ~ O
H C I ~ N'S~O N
~~CH3 H3C\ J S
'C~Hg TLC : Rf 0.38 (chloroform : methanol = 9 : 1)~
NMR : 8 8.11 and 7.33 (each d, J = 8.4 Hz, each 2H), 7.22 (s, 1H), 6.92 and 6.91 (each s, each 1H), 5.10-4.70 (m, 2H), 3.74-3.42 (m, 2H), 2.31 and 2.30 (each s, each 3H), 1.78-1.62 (m, 1H), 1.05-0.83 (m, 6H).
Example 2(51) 3-chloro-4~[2-[N~isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid w CI / COOH
CI ~ O ~
H C I ~ N~Y0 N
3 ~~CH3 H3C\ J S
~C'H3 TLC : Rf 0.28 (chloroform : methanol = 9 : 1)~
NMR : 8 8.11 (s, 1H), 8.02 and ?.45 (each d, J = 8.1 Hz, each 1H), 7.21 (s, 1H), 6.97 (s, 1H), 6.94 (s, 1H), 5.12-4.74 (m, 2H), 3.75-3.45 (m, 2H), 2.32 and 2.31 (each s, each 3H), 1.80-1.62 (m, 1H), 1.05-0.82 (m, 6H).
Example 2(52) 3-methoxy-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid CI ~ O
H3C~ / N'S'O N
~~CH3 H3C~ ~S

TLC : Rf 0.35 (chloroform : methanol = 9 : 1)~
NMR : 8 7.73 (d, J = 7.8 Hz, 1H), 7.59 (s, 1H), 7.30-7.20 (m, 2H), 6.95 (s, 1H), 6.91 (s, 1H), 5.09-4.62 (m, 2H), 3.94 (s, 3H), 3.78-3.45 (m, 2H), 2.31 (s, 6H), 1.79-1.63 (m, 1H), 1.08-0.85 (m, 6H).
Example 2(53) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid TLC : Rf 0.76 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : b 7.93 (d, J = 8.1 Hz, 1H), 7.92 (s, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.08 (s, 1H), 6.90 (d, J = 0.9 Hz, 1H), 6.71 (s, 1H), 4.91 (br, 1H), 4.79 (br, 1H), 3.65 (br, 1H), 3.56 (br, 1H), 2.35 (s, 3H), 2.30 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 1.71 (sep, J =
6.9 Hz, 1H), 1.03-0.92 (br, 6H).
Example 2(54) 3-methyl-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid HaC ~ O
H C~N~YO N~,--3 ~~CH3 H3C"CH3 TLC : Rf 0.78 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 7.95 (d, J = 8.1 Hz, 1H), ?.93 (s, 1H), 7.54 (d, J = 8.1 Hz, 1H), 6.98 (d, J = 0.9 Hz, 1H), 6.86 (s, 1H), 6.78 (s, 1H), 5.03 (d, J = 13.2 Hz, 1H), 4.98 (d, J = 13.2 Hz, 1H), 4.69 (quint, J = 6.6 Hz, 1H), 2.46 (d, J = 0.9 Hz, 3H), 2.39 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.17 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H).
Example 2(55) 3-methoxy-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-nzoic acid TLC : Rf 0.39 (chloroform : methanol = 9 : 1)~
NMR : 8 7.72 (dd, J = 8.1, 1.2 Hz, 1H), 7.57 (d, J = 1.2 Hz, 1H), 7.26 (d, J =
8.1 Hz, 1H), 7.11 (s, 1H), 6.87 (s, 1H), 6.71 (s, 1H), 4.95 (br, 1H), 4.75 (br, 1H), 3.93 (s, 3H), 3.69 (br, 1H), 3.56 (br, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 2.19 (s, 3H), 1.80-1.65 (m, 1H), 0.97 (br, 6H).
Example 2(56) 3-chloro-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid CI / COOH
H3C ~ O
~O~ ~O
H3C~N~ iN

TLC : Rf 0.36 (chloroform : methanol = 9 : 1);
NMR : b 8.11 (d, J = 1.8 Hz, 1H), 8.01 (dd, J = 8.1, 1.8 Hz, 1H), 7.49 (d, J =
8.1 Hz, 1H), 7.08 (s, 1H), 6.95 (d, J = 0.6 Hz, 1H), 6.69 (s, 1H), 5.20-4.70 (br, 2H), 3.80-3.45 (br, 2H), 2.32 (d, J = 0.6 Hz, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 1.75 (m, 1H), 1.07-0.85 (br, 6H).
Example 2(57) 3-chloro-4-[2-[N-isopropyl-N-(4-methyl-2=thiazolylsulfonyl)amino]-4,5-~nzoic acid TLC : Rf 0.36 (chloroform : methanol = 9 : 1);
NMR(CDCIs + CDsOD) : b 8.06 (d, J = 1.8 Hz, 1H)> 7.98 (dd, J = 8.1, 1.8 Hz, 1H), 7.70 (d, J
= 8.1 Hz, 1H), 7.05 (d, J = 0.6 Hz, 1H), 6.86 (s, 1H), 6.76 (s, 1H), 5.14 (d, J = 14.1 Hz, 1H), 5.08 (d, J = 14.1 Hz, 1H), 4.70 (m, 1H), 2.47 (d, J = 0.6 Hz, 3H), 2.25 (s, 3H), 2.1? (s, 3H), 1.17 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Example 2(58) 4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid / COOH
H3C ~ O
H3C ~ / N.S~~ N
~~CH3 H3C~CH ~3 TLC : Rf 0.45 (chloroform : methanol = 10 : 1);
NMR : 8 8.11-8.08 (m, 2H), 7.49 (d, J = 8.4 Hz, 2H), 6.9? (d, J = 0.9 Hz, 1H), 6.86 (s, 1H), 6.75 (s, 1H), 5.06 (d, J = 12.9 Hz, 1H), 5.04 (d, J = 12.9 Hz, 1H), 4.? 1 (m, 1H), 2.46 (d, J =
0.9 Hz, 3H), 2.23 (s, 3H), 2.16 (s, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J
= 6.6 Hz, 3H).
Example 2(59) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid / COOH
H3C ~ O
~~I
H C~N~O N

H3C\ J S

TLC : Rf 0.43 (chloroform : methanol = 10 : 1)~
NMR : 8 8.09 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 7.08 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.68 (s, 1H), 5.08-4.68 (m, 2H), 3.75-3.45 (m, 2H), 2.30 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 1.71 (m, 1H), 1.04-0.83 (m, 6H).
Example 2(60) 4-(2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid TLC : Rf 0.22 (chloroform : methanol = 9 : 1);
NMR(CDsOD) : 8 7.69 (d, J = 16.2 Hz, 1H), ?.61 (d, J = 8.1 Hz, 2H), 7.32-7.24 (m) and 7.29 (d, J = 8.1 Hz) total 4H, ?.05 (s, 1H), 6.52 (d, J = 16.2 Hz, 1H), 5.05-4.70 (m, 2H, covered with Hz0 in CDsOD), 3.63-3.50 (m, 2H), 2.37 (s, 3H), 2.22 (d, J = 0.9 Hz, 3H), 1:65 (m, 1H), 0.93 (d, J = 6.3 Hz, 6H).
Example 2(61) 3-methyl-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid H3C / ~ COOH
F3C ~ 0 / N~0 N
~CH3 TLC : Rf 0.37 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.45-7.35 (m, 2H), 7.32-7.23 (m, 2H), 7.20 (m, 1H), 6.98 (s, 1H), 6.48 (d, J = 16.2 Hz, 1H), 5.03-4.82 (m, 2H), 3.?0-3.50 (m, 2H), 2.36 (s, 3H), 2.34 (s, 3H), 1.74-1.58 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).

Example 2(62) 3-chloro-4-(2-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid CI / ~ COOH
F3C ~ O
N~O N
~CH3 TLC : Rf 0.28 (n-hexane : ethyl acetate = 1 : 2)~
NMR : 8 7.71 (d, J = 16.2 Hz, 1H), 7.58 (s, 1H), 7.52-7.44 (m, 3H), 7.29 (d, J
= 8.1 Hz, 1H) 7.19 (s, 1H), 7.01 (d, J = 0.9 Hz, 1H), 6.50 (d, J = 16.2 Hz, 1H), 5.02 (br, 2H), 3.62 (d, J =
6.6 Hz, 2H), 2.35 (s, 3H), 1.68 (sep, J = 6.6 Hz, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Example 2(63) 3-methyl-4-[2-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid H3C / ~ COOH
H3C ~ O
H C I / NCYO N~,---H3C"CH3 TLC : Rf 0.20 (n-hexane : ethyl acetate = 1 : 2)~
MS (FAB, Post : 515(M + H)+.
Example 2(64) 3-methyl-4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid H3C / ~ COOH
H3C ~ O
H C I / NCO N
s ~~CH3 H3C\ J S
'C~Hg TLC : Rf 0.22 (n-hexane : ethyl acetate = 1 : 2)~
MS (FAB, Pos.) : 529(M + H)+.
Example 2(65) 4-(2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid ~ COOH
CI ~ O ~
H C~N~YO N~,-~~CH3 H3C\ J S
'C~H3 TLC : Rf 0.31 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.56 and 7.27 (each d, J = 8.1 Hz, each 2H), 7.21 (s, 1H), 6.95-6.88 (m, 2H), 6.48 (d, J = 15.9 Hz, 1H), 5.00-4.65 (m, 2H), 3.72-3.42 (m, 2H), 2.33-2.22 (m, 6H), 1.?8-1.60 (m, 1H), 1.05-0.83 (m, 6H).
Example 2(66) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid H3C / ~ COOH
CI ~ O
H C I ~ N'SrYO N
a I J CHa H3C\ J S
'C~H3 TLC : Rf 0.30 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.42-?.3? (m, 2H), ?.30-7.15 (m, 2H), 6.98-6.89 (m, 2H), 6.47 (d, J = 16.2 Hz, 1H), 4.95-4.67 (m, 2H), 3.?2-3.40 (m, 2H), 2.38-2.22 (m, 9H), 1.7?-1.61 (m, 1H), 1.05-0.82 (m, 6H).
Example 2(67) 3-methyl-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]cinnamic acid H3C / ~ COOH

CI ~ ~ N'S~O N

TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : b ?.76 (d, J = 16.2 Hz, 1H), 7.39 (d, J = 8.4 Hz, 1H), 7.38 (s, 1H), 7.27 (d, J = 8.4 Hz, 1H), ?.23 (s, 1H), 6.97 (s, 1H), 6.81 (s, 1H), 6.47 (d, J = 16.2 Hz, 1H), 5.04-4.66 (m, 2H), 3.65-3.39 (m, 2H), 2.36 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H), 1.75-1.61 (m, 1H), 0.92 (d, J = 6.6 Hz, 6H).

Example 2(68) 4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
TLC : Rf 0.33 (chloroform : methanol = 10 : 1)~
MS (APCI, Neg. 20V) : 513 (M - H)'.
Example 2(69) 3-chloro-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyDamino]-4,5-dimethylphenoxymethyl]cinnamic acid TLC : Rf 0.17 (chloroform : methanol = 9 : 1)~
NMR(CD30D) : 8 ?.69 (d, J = 1.8 Hz, 1H), 7.65 (d, J = 15.9 Hz, 1H), 7.59 (dd, J = 8.1, 1.5 Hz, 1H), 7.35 (d, J = 8.1 Hz, 1H), 7.29 (d, J = 1.2 Hz, 1H), 7.04 (s, 1H), 6.88 (s, 1H), 6.57 (d, J = 15.9 Hz, 1H), 5.10-4.60 (m, 2H), 3.63-3.50 (m, 2H), 2.28 (s, 3H), 2.21 (d, J = 1.2 Hz) and 2.20 (s) total 6H, 1.66 (m, 1H), 1.03-0.85 (m, 6H).
Example 2(70) 3-methoxy-4-[2-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid H3C0 / ~ COOH
H3C ~ O
H C I ~ N'~O N
~CH3 H3~ Y

TLC : Rf 0.40 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Pos.) : 545 (M + H)+.

cinnamic acid Example 2(? 1) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.43 (chloroform : methanol = 9 : 1)~
NMR : 8 8.10 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), ?.16 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.76 (s, 1H), 5.06-4.70 (br, 2H), 3.78-3.45 (br, 2H), 2.87 (t, J = 7.5 Hz, 4H), 2.31 (d, J =
0.9 Hz, 3H), 2.09 (m, 2H), 1.74 (m, 1H), 1.04-0.86 (br, 6H).
Example 2(72) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid / \ COOH
\ O
/ N~O N
~CH3 TLC : Rf 0.42 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 7.15 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.77 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.05-4.60 (br, 2H), 3.78-3.45 (br, 2H), 2.86 (t, J = 7.8 Hz, 4H), 2.30 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H), 1.73 (m, 1H), 1.06-0.83 (br, 6H).
Example 2(73) 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1)~
NMR : 8 7.95-7.92 (m, 2H), ?.31 (d, J = 7.8 Hz, 1H), 7.16 (s, 1H), 6.91 (brs, 1H), 6.79 (s, benzoic acid 1H), 4.93 (brs, 1H), 4.73 (brs, 1H), 3.75-3.45 (m, 2H), 2.92-2.84 (m, 4H), 2.34 (s, 3H), 2.31 (d, J = 0.6 Hz, 3H), 2.10 (m, 2H), 1.74 (m, 1H), 1.08-0.80 (brs, 6H).
Example 2(74) 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
cinnamic acid HsC / \
o ~I
/ N~O N

H3C~ J
Hy TLC : Rf 0.32 (dichloromethane : methanol = 19 : 1)~
NMR : b 7.76 (d, J = 15.9 Hz, 1H), 7.40-?.36 (m, 2H), 7.25 (m, 1H), 7.14 (s, 1H), 6.91 (brs, 1H), 6.80 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 4.90 (brs, 1H), 4.69 (brs, 1H), 3.75-3.43 (m, 2H), 2.95-2.80 (m, 4H), 2.31 (s, 6H), 2.09 (m, 2H), 1.72 (m, 1H), 1.05-0.85 (brs, 6H).
Example 2(75) 4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]cinnamic acid / ~ COOH
F3C ~ O
I / N'S~O Nw TLC : Rf 0.37 (chloroform : methanol = 9 : 1)~
NMR.(CDsOD) : 8 8.39 (ddd, J = 4.5, 1.5, 0.9 Hz, 1H), 7.82 (dt, J = 7.5, 1.5 Hz, 1H), 7.72-7.64 (m, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.53 (d, J = 7.5 Hz, 1H), ?.38 (ddd, J
= 7.5, 4.5, 0.9 Hz, 1H), 7.34-7.22 (m,4H), 6.54 (d, J = 15.9 Hz, 1H), 4.95-4.78 (m, 2H), 3.61 (d, J = 6.6 Hz, 2H), 1.60 (m, 1H), 0.91 (d, J = 6.9 Hz, 6H).
Example 2(76) 4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino)-5-trifluoromethylphenoxymethyl]benzoic acid / COOH
F3C ~ O
~N~O ~N

TLC : Rf 0.2? (chloroform : methanol = 9 : 1)~
NMR(CDsOD) : 8 8.63 (m, 1H), 8.53 (dd, J = 5.1, 1.8 Hz, 1H), 7.99 (d, J = 8.4 Hz) and 7.94 (m) total 3H, 7.56 (d, J = 7.5 Hz, 1H), 7.40-7.29 (m, 3H), 7.23 (d, J = 8.4 Hz, 2H), 5.10-4.80 (m, 2H), 3.58-3.40 (m, 2H), 1.61 (m, 1H), 0.92 (brd, J = 6 Hz, 6H).
Example 2(77) 3-chloro-4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]
benzoic acid CI / COOH
H3C ~ O
CI~N~O N\
H3C"CH3 J
TLC : Rf 0.43 (chloroform : methanol = 9 : 1)~
NMR(CDsOD) : s 8.63 (m, 1H), 8.02 (d, J = 1.8 Hz, 1H), 7.98-7.84 (m, 3H), 7.70 (d, J = 8.1 Hz, 1H), 7.50 (m, 1H), ?.11 (s, 1H), 7.09 (s, 1H), 5.16 (ABd, J = 13.5 Hz) and 5.08 (ABd, J
= 13.5 Hz) total 2H, 4.61 (sept, J = 6.6 Hz, 1H), 2.39 (3, 3H), 1.12 (d, J =
6.6 Hz) and 1.10 (d, J = 6.6 Hz) total 6H.
Example 2(78) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino-4-chloro-5-methylphenoxymethyl]
TLC : Rf 0.37 (chloroform : methanol = 10 : 1);
NMR : 8 8.52 (m, 1H), 7.94-7.92 (m, 2H), 7.77-7.68 (m, 2H), 7.31-7.24 (m, 3H), 6.?6 (s, 1H), 4.83 (brs, 2H), 3.65-3.50 (m, 2H), 2.34 (s, 6H), 1.66 (m, 1H), 0.91 (d, J =
6.6 Hz, 6H).

benzoic acid Example 2(79) 3-methyl-4-(2-(N-isobutyl-N~(3-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]
benzoic acid H3C~ ~ O
~0~0 CI//~~/ ..N~ ~ ~N
HsC J /

TLC : Rf 0.16 (dichloromethane : methanol = 20 : 1).
NMR : s 12.90 (s, 1H), s.s7 (d, J = 1.s Hz, 1H>, 8.62 (dd, J = 4.8, 1.8 Hz, 1H), 7.94 (dt, J =
8.1, 1.8 Hz, 1H), ?.74 (s, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.37 (dd, J = 8.1, 4.8 Hz, 1H), 7.27 (s, 1H), ?.24 (s, 1H), 7.01 (d, J = 8.1 Hz, 1H), 4.95 (br, 1H), 4.76 (br, 1H), 3.45-3.30 (m, 2H), 2.34 (s, 3H), 2.24 (s, 3H), 1.49 (sept, J = 6.6 Hz, 1H), 0.90-0.70 (br, 6H).
Example 2(80) 3-methyl-4-(2-(N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]
TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR : 8 8.50-8.40 (m, 1H), 7.95-7.85 (m, 2H), 7.75-7.60 (m, 2H), 7.30-7.20 (m, 3H), 6.89 (s, 1H), 4.76 (br, 2H), 3.61 (br, 2H), 2.31 (s, 3H), 2.29 (s, 3H), 1.75-1.55 (m, 1H), 1.00-0.80 (m, 6H).
Example 2(81) 4-(2-(N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]benzoic acid / COOH
CI~ ~ O
~O,~O
H3CJJ~~/ N ~ ~ N

TLC : Rf 0.31 (chloroform : methanol = 9 : 1)~
NMR : b 8.83 (d, J = 2.4, 0.6 Hz, 1H), 8.61 (dd, J = 5.1, 1.8 Hz, 1H), 8.10 (d, J = 8.4 Hz, benzoic acid 2H), ?.78-7.71 (m, 1H), 7.36 (s, 1H), 7.29-7.22 (m, 1H), 7.08 (d, J = 8.4 Hz, 2H), 6.90 (s, 1H), 4.94-4.72 and 4.50-4.25 (each m, each 1H), 3.75-3.56 and 3.45-3.24 (each m, each 1H), 2.36 (s, 3H), 1.79-1.63 (m, 1H), 1.16-0.80 (m, 6H).
Example 2(82) 3-chloro-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]
benzoic acid ci ci H3C~N~ I ~N

TLC : Rf 0.29 (chloroform : methanol = 9 : 1)~
NMR : b 8.87 (d, J = 1.8 Hz, 1H), 8.63 (dd, J = 5.1, 1.8 Hz, 1H), 8.13 (d, J =
1.8 Hz, 1H), 8.03 (dd, J = 8.1, 1.8 Hz, 1H), 7.73-7.66 (m, 1H), 7.40 (s, 1H), 7.36 (dd, J =
8.1, 5.1 Hz, 1H), 7.05 (d, J = 8.1 Hz, 1H), 6.96 (s, 1H), 4.92-4.74 and 4.54-4.34 (each m, each 1H), 3.72-3.63 and 3.50-3.33 (each m, each 1H), 2.39 (s, 3H), 1.84-1.68 (m, 1H), 1.20-0.92 (m, 6H).
Example 2(83) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyDamino]-5-trifluoromethylphenoxymethyl]
cinnamic acid ~N~O Nw HsC

TLC = Rf 0.32 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 12.39 (br s, 1H), 8.51 (d, J = 4.5 Hz, 1H), ?.90 (dd, J =
?.5, 7.5 Hz, 1H), 7.70 (d, J = 7.5 Hz, 1H), 7.55 (d, J = 16.0 Hz, 1H), 7.53-7.46 (m, 5H), 7.35 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.55 (d, J = 16.0 Hz, 1H), 5.00 (br s, 2H), 3.49 (d, J = 7.0 Hz, 2H), 2.25 (s, 3H), 1.45 (triple septet, J = 7.0, 7.0 Hz, 1H), 0.78 (d, J = ?.0 Hz, 6H).
Example 2(84) 3-methoxy-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid TLC : Rf 0.38 (chloroform : methanol = 9 : 1)~
NMR : b 8.47 (d, J = 4.8 Hz, 1H), 7.75-7.60 (m, 3H), 7.56 (d, J = 1.5 Hz, 1H), 7.20-7.15 (m, 2H), 7.12 (s, 1H), 6.65 (s, 1H), 4.84 (br, 1H), 4.66 (br, 1H), 3.92 (s, 3H), 3.61 (br, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 1.80-1.60 (m, 1H), 0.96 (br, 6H).
Example 2(85) 3-methoxy-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid H3C .~ O
/ O~O
H3C N I ~ N
H3C, TLC : Rf 0.35 (chloroform : methanol = 9 : 1)~
NMR : 8 8.86 (dd, J = 2.1, 0.9 Hz, 1H), 8.57 (dd, J = 5.1, 1.5 Hz, 1H), 7.75-7.65 (m, 2H), 7.61 (d, J = 1.5 Hz, 1H), 7.30-7.20 (m, 2H), 6.92 (d, J = 7.8 Hz, 1H), 6.72 (s, 1H), 4.75 (d, J
= 12.3 Hz, 1H), 4.43 (d, J = 12.3 Hz, 1H), 3.93 (s, 3H), 3.75-3.60 (m, 1H), 3.45-3.35 (m, 1H), 2.29 (s, 3H), 2.25 (s, 3H), 1.85-1.65 (m, 1H), 1.09 (d, J = 6.3 Hz, 3H), 0.92 (d, J = 6.3 Hz, 3H).
Example 2(86) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid H3C ~ O
/ O~O
H3C N ~ ~ N
HsC\J /

TLC : Rf 0.61 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : b 12.8? (brs, 1H), 8.64 (d, J = 1.8 Hz, 1H), 8.59 (dd, J = 4.8, 1.8 Hz, 1H), 7.91 (dt, J = 8.1, 1.8 Hz, 1H), 7.73 (s, 1H), 7.67 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 8.1, 4.8 Hz, 1H), 7.04-6.96 (m, 3H), 4.92 (br, 1H), 4.66 (br, 1H), 3.48-3.22 (br, 2H), 2.23 (s, 3H), 2.22 (s, 3H)> 2.15 (s, 3H), 1.49 (sep, J = 6.9 Hz, 1H), 0.98-0.75 (m, 6H).
Example 2(87) 3-methyl-4-[2-(N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid H3C \ 0 ~
H3C I / N~0 N\
HsC ~ /

TLC : Rf 0.66 (chloroform :.methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : 8 12.88 (s, 1H), 8.47 (d, J = 4.5 Hz, 1H), 7.87 (dt, J = 1.5, 7.8 Hz, 1H), 7.?5 (s, 1H), 7.71 (d, J = 7.8 Hz, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.42 (ddd, J
= ?.8, 4.5, 1.5 Hz, 1H), 7.16 (d, J = 7.8 Hz, 1H), 6.93 (s, 1H), 6.91 (s, 1H), 4.80 (br, 2H), 3.57 (d, J = 6.6 Hz, 2H), 2.25 (s, 3H), 2.18 (s, 3H), 2.09 (s, 3H), 1.49 (sept, J = 6.6 Hz, 1H), 0.81 (d, J = 6.6 Hz, 6H).
Example 2(88) 3-methyl-4-(2-(N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]
benzoic acid H
TLC : Rf 0.31 (chloroform : methanol = 9 : 1)~
NMR : 8 8.83 (d, J = 1.8 Hz, 1H), 8.61 (dd, J = 5.4, 1.8 Hz, 1H), 7.93 (d, J =
8.1 Hz, 1H), ?.92 (s, 1H), 7.78 (dt, J = 8.1, 1.8 Hz 1H), ?.34 (s, 1H), 7.23 (dd, J = 8.1, 5.4 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 6.94 (s, 1H), 4.88-4.65 and 4.54-4.34 (each m, each 1H), 3.71-3.53 and 3.43-3.24 (each m, each 1H), 2.36 (s, 3H), 2.27 (s, 3H), 1.78-1.63 (m, 1H), 1.08-0.79 (m, 6H).
Example 2(89) 4-(2-(N-isobutyl-N-(2-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid / COOH
H3C ~ O
H C~N~O N\

HsC I /

TLC : Rf 0.33 (chloroform : methanol = 10 : 1)~
NMR : 8 8.46 (m, 1H), 8.09-8.05 (m, 2H), 7.71-?.60 (m, 2H), 7.28-7.25 (m, 2H), 7.20 (m, 1H), 7.09 (s, 1H), 6.62 (s, 1H), 5.02-4.50 (m, 2H), 3.83-3.43 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 1.67 (m, 1H), 1.04-0.82 (m, 6H).
Example 2(90) 4-[2-[N-isopropyl-N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]cinnamic acid / ~ COOH
CI ~ O
H C ~ / N~O N\

H3C~CH~
TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR : b 8.70-8.60 (m, 1H), 7.84 (d, J = ?.5 Hz, 1H), 7.79 (d, J = 15.9 Hz, 1H), 7.? 1 (dt, J =
1.8, 7.5 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.39 (d, J = 8.4 Hz, 2H), 7.35-7.25 (m, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 4.96 (d, J = 12.3 Hz, 1H), 4.92 (d, J = 12.3 Hz, 1H), 4.75-4.60(m, 1H), 2.26 (s, 3H), 1.14 (d, J = 6.9 Hz, 3H), 1.11 (d, J
= 6.9 Hz, 3H).
Example 2(91) 3-methyl-4-[2-[N-isobutyl-N-(2-pyridylsulfonyl)amino]-4-methyl-5-chlorophenoxymethyl]
TLC : Rf 0.37 (chloroform : methanol = 9 : 1)~
NMR : 8 8.50-8.40 (m, 1H), 7.77 (d, J = 15.9 Hz, 1H), 7.?5-?.60 (m, 2H), 7.40-?.35 (m, 2H), 7.25-7.20 (m, 2H), 7.15 (d, J = 8.4 Hz, 1H), 6.90 (s, 1H), 6.49 (d, J = 15.9 Hz, 1H), 4.73 (br, 2H), 3.60 (br, 2H), 2.29 (s, 3H), 2.28 (s, 3H), 1.70-1.55 (m, 1H), 0.91 (d, J
= 6.6 Hz, 6H).

cinnamic acid Example 2(92) 3-methyl-4-[2-[N-isobutyl-N-(2'pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
cinnamic acid H3C / ~ COOH
H3C ~ p ~
H C~N~O N~

TLC : Rf 0.36 (dichloromethane : methanol = 20 : 1)~
MS (FAB, Pos.) : 509 (M + H)+.
Example 2(93) 4-(2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid N~ I ~N
TLC : Rf 0.27 (chloroform : methanol = 10 : 1)~
MS (APCI, Neg. 20~ : 493 (M - H)'.
Example 2(94) 3-methyl-4-(2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
cinnamic acid TLC : Rf 0.33 (dichloromethane : methanol = 20 : 1)~
MS (FAB, Pos.) : 509 (M + H)+.
Example 2(95) 3-chloro-4-(2-(N-isobutyl-N-(3-pyridylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
cinnamic acid TLC : Rf 0.43 (chloroform : methanol = 3 : 1)~
NMR : 8 8.88-8.82 (m, 1H), 8.61-8.52 (m, 1H), 7.75-7.68 (m, 1H), 7.61 (d, J =
15.9 Hz, 1H), 7.52 (d, J = 1.5 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), ?.32-7.20 (m, 2H), 6.97 (d, J = 8.1 Hz, 1H), 6.70 (s, 1H), 6.50 (d, J = 15.9 Hz, 1H), 4.88-4.75 and 4.53-4.41(each m, each 1H), 3.74-3.58 and 3.48-3.32 (each m, each 1H), 2.29 and 2.25 (each s, each 3H), 1.82-1.63 (m, 1H), 1.15-0.82 (m, 6H).
Example 2(96) 3-methyl-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-4-chloro-5-methylphenoxymethyl]
TLC : Rf 0.36 (chloroform : methanol = 9 : 1);
NMR(DMSO-ds) : 8 8.65 (m, 2H), 7.94 (m, 1H), 7.54 (d, J = 16.2 Hz) and 7.51 (s) total 2H, 7.43 (d, J = 8.1 Hz, 1H), 7.38 (dd, J = 8.1, 4.8 Hz, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 6.98 (d, J
= 8.1 Hz, 1H), 6.53 (d, J = 16.2 Hz, 1H), 5.00-4.85 (m, 2H), 3.48-3.10 (m, 2H, covered with Hz0 in DMSO-ds), 2.34 (s, 3H), 2.21 (s, 3H), 1.48 (m, 1H), 0.93 (m, 6H).
Example 2(97) 3-chloro-4-[2-[N-isobutyl-N-(3-pyridylsulfonyl)amino]-5-triffuoromethylphenoxymethyl]
cinnamic acid CI / ~ COOH
F3C ~ O
/ O~O
N I ~N

TLC : Rf 0.25 (chloroform : methanol = 10 : 1)~
MS (APCI, Neg. 20V) : 567 (M - H)'.

cinnamic acid Example 2(98) 3-methyl-4-(6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
benzoic acid 0 \
N:S~O O

H3C"CH3 TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.79 (s, 1H), 7.75 (d, J = 8.0 Hz, 1H), 7.59 (d, J = 8.0 Hz, 1H), 7.11 (s, 1H), 6.90 (d, J = 3.3 Hz, 1H), 6.82 (s, 1H), 6.30-6.20 (m, 1H), 5.08 (s, 2H), 4.30-4.20 (m, 1H), 2.87 (t, J = 7.5 Hz, 2H), 2.79 (t, J = ?.5 Hz, 2H), 2.35 (s, 3H), 2.28 (s, 3H), 2.10-1.95 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H).
Example 2(99) 3-methyl-4-(6-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]
cinnamic acid H3C / \ COOH
\ O \
/ N~0 O
CHg H3C"CH3 TLC : Rf 0.50 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.60-7.50 (m, 4H), 7.11 (s, 1H), 6.89 (d, J = 3.3 Hz, 1H), 6.80 (s, 1H), 6.52 (d, J = 16.2 Hz, 1H), 6.30-6.20 (m, 1H), 5.04 (d, J = 13.5 Hz, 1H), 5.01 (d, J = 13.5 Hz, 1H), 4.30-4.20 (m, 1H), 2.87 (t, J = ?.2 Hz, 2H), 2.78 (t, J = ?.2 Hz, 2H), 2.32 (s, 3H), 2.28 (s, 3H), 2.10-1.95 (m, 2H), 0.97 (d, J = 6.6 Hz, 6H).
Example 2(100) 4-[6-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid / \ COOH
\ O \
/ N~O O

H3C"CH3 TLC : Rf 0.42 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 16.2 Hz, 1H), 7.57 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 6.89 (s, 1H), 6.84 (s, 1H), 6.80 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 16.2 Hz, 1H), 6.02 (m, 1H), 5.14-5.00 (m, 2H), 4.46 (m, 1H), 2.91-2.80 (m, 4H), 2.31 (s, 3H), 2.14-2.02 (m, 2H), 1.11 (d, J =

6.6 Hz, 3H), 1.10 (d, J = 6.6 Hz, 3H).
Example 2(101) 3-methyl-4-[2-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]-4-chloro-5-methylphenoxymethylJbenzoic acid H3C ~ O
CI I / NCO N
~~CHg H,~_ J
TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.79 (s, 1H), 7.?7 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.28 (d, J = 8.4 Hz, 1H), 7.27 (s, 1H), 7.23 (s, 1H), 4.97 (m, 2H), 4.77 (m, 1H), 4.72 (m, 1H), 4.21 (m, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 2.22 (s, 3H), 1.68 (s, 3H).
Example 2(102) 4-[2-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]-5-trifluoromethyl phenoxymethyl]cinnamic acid / ~ COOH
F3C ~ O
/ N~O N
~CH3 CHz TLC : Rf 0.43 (chloroform : methanol = 9 : 1)~
NMR : 8 7.80 (d, J = 15.9 Hz, 1H), 7.58 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.33 (d, J = 8.4 Hz, 2H), 7.30-7.20 (m, 1H), 7.15 (s, 1H), 6.99 (s, 1H), 6.50 (d, J =
15.9 Hz, 1H), 4.97 (s, 2H), 4.77 (s, 1H), 4.72 (s, 1H), 4.37 (s, 2H), 2.35 (s, 3H), 1.77 (s, 3H).
Example 2(103) 3-methyl-4-[2-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]-4,5-~nzoic acid TLC : Rf 0.24 (dichloromethane : methanol = 19 : 1)~

NMR(DMSO-ds) : b 7.77-7.73 (m, 2H), 7.50 (brs, 1H), 7.23 (d, J = 6.9 Hz, 1H), 6.99 (s, 1H), 6.96 (s, 1H), 4.8? (brs, 2H), 4.?4 (brs, 1H), 4.?1 (brs, 1H), 4.20 (brs, 2H), 2.28 (s, 3H), 2.19 (s, 3H), 2.16 (d, J = 0.6 Hz, 3H), 2.11 (s, 3H), 1.68 (s, 3H).
Example 2(104) 3-methyl-4-[6-[N-isopropyl-N-(2-thiazolylsulfonyDamino]indan-5-yloxymethyl]benzoic acid O \ I
~~ I
~N.S~~ N
H3C"CH3 TLC : Rf 0.43 (chloroform : methanol = 9 : 1)~
NMR : 8 '7.96 (d, J = 8.1 Hz, 1H), 7.93 (s, 1H), 7.89 (d, J = 3.0 Hz, 1H), 7.58 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 3.0 Hz, 1H), 6.95 (s, 1H), 6.86 (s, 1H), 5.05 and 4.99 (each d, J = 13.5 Hz, each 1H), 4.69 (sept, J = 6.6 Hz, 1H), 2.94-2.79 (m, 4H), 2.39 (s, 3H), 2.16-2.02 (m, 2H), 1.18 and 1.15 (each d, J = 6.6 Hz, each 3H).
Example 2(105) 3-methyl-4-[6-[N~isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid \ O \
N~O N

TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : 8 7.93 (d, J = 8.4 Hz, 1H), 7.92 (s, 1H), 7.71 (d, J = 3.0 Hz, 1H), 7.35 (d, J = 3.0 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.15 (s, 1H), 6.77 (s, 1H), 5.02-4.64 (m, 2H), 3.81-3.43 (m, 2H), 2.95-2.76 (m, 4H), 2.34 (s, 3H), 2.17-2.01 (m, 2H), 1.82-1.64 (m, 1H), 1.08-0.83 (m, 6H).
Example 2(106) 3-methyl-4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
benzoic acid O
~N~O N
~~CH3 H3C~CH3 TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1);
NMR : 8 7.97 (d, J = 8.1 Hz, 1H), 7.94 (s, 1H), 7.57 (d, J = 8.1 Hz, 1H), 7.00 (brs, 1H), 6.94 (s, 1H), 6.86 (s, 1H), 5.05 (d, J = 13.5 Hz, 1H), 4.99 (d, J = 13.5 Hz, 1H), 4.70 (m, 1H), 2.92-2.81 (m, 4H), 2.47 (s, 3H), 2.39 (s, 3H), 2.09 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Example 2(10?) 4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid COOH
O
~ N
H3C"CH S
TLC : Rf 0.37 (chloroform : methanol = 10 : 1);
NMR : 8 8.13 (d, J = 8.1 Hz, 2H), 7.88 (d, J = 3.3 Hz, 1H), 7.51 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 3.3 Hz, 1H), 6.95 (s, 1H), 6.84 (s, 1H), 5.06 (d, J = 13.5 Hz, 1H), 5.05 (d, J = 13.5 Hz, 1H), 4.71 (m, 1H), 2.92-2.78 (m, 4H), 2.14-2.02 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.16 (d, J
= 6.6 Hz, 3H).
Example 2(108) 4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid COOH
O
~~ N

TLC : Rf 0.35 (chloroform : methanol = 10 : 1);
NMR : 8 8.11 (d, J = 8.1 Hz, 2H), 7.? 1 (d, J = 3.3 Hz, 1H), 7.35 (d, J = 3.3 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 7.15 (s, 1H), 6.75 (s, 1H), 4.97 (m, 1H), 4.77 (m, 1H), 3.80-3.4? (m, 2H), 2.89-2.82 (m, 4H), 2.15-2.01 (m, 2H), 1.73 (m, 1H), 1.05-0.85 (m, 6H).
Example 2(109) 4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : S 8.11 (d, J = 8.4 Hz, 2H), ?.50 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 0.9 Hz, 1H), 6.94 (s, 1H), 6.84 (s, 1H), 5.11-5.00 (m, 2H), 4.71 (m, 1H), 2.91-2.79 (m, 4H), 2.47 (d, J = 0.9 Hz, 3H), 2.15-2.03 (m, 2H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Example 2(110) 4-(6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid / \ COOH
\ O \
/ N~O N
~~CH3 H3C~CH ~3 TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 6.98 (d, J = 0.6 Hz, 1H), 6.92 (s, 1H), 6.85 (s, 1H), 6.4? (d, J = 15.9 Hz, 1H), 5.06-4.95 (m, 2H), 4.70 (m, 1H), 2.92-2.78 (m, 4H), 2.46 (d, J = 0.6 Hz, 3H), 2.16-2.01 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H).
Example 2(111) 3-methyl-4-(6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
cinnamic acid H3C / \ COOH
\ O \ I
/ NCO N
Y~CH3 H3C~CH ~3 TLC : Rf 0.30 (dichloromethane : methanol = 19 : 1)~
NMR(DMSO-ds) : 8 12.38 (brs, 1H), 7.57 (brs, 1H), 7.56 (d, J = 15.9 Hz, 1H), 7.53 (s, 1H), 7.49 (brd, J = 8.1 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 7.13 (s, 1H), 6.83 (s, 1H), 6.53 (d, J =
15.9 Hz, 1H), 4.99 (brs, 2H), 4.47 (m, 1H), 2.87 (m, 2H), 2.77 (m, 2H), 2.37 (d, J = 0.9 Hz, 3H), 2.30 (s, 3H), 2.02 (m, 2H), 1.04 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H).

Example 2(112) 4-(2-(N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid TLC : Rf 0.57 (chloroform : methanol = 9 : 1)~
NMR : 8 8.10 (d, J = 8.1 Hz, 2H), ?.86 (d, J = 3.0 Hz, 1H), ?.49 (d, J = 8.1 Hz, 2H), ?.43 (d, J = 3.0 Hz, 1H), 6.85 (s, 1H), 6.75 (s, 1H), 5.04 (s, 2H), 4.72 (sept, J = 6.9 Hz, 1H), 2.23 (s, 3H), 2.15 (s, 3H), 1.19 (d, J = 6.9 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H).
Example 2(113) 4-[2-(N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid / COOH
H3C ~ O
H C ~ / N'S/O N

TLC : Rf 0.56 (chloroform : methanol = 9 : 1)~
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.70 (d, J = 3.0 Hz, 1H), 7.36-7.32 (m, 3H), ?.07 (s, 1H), 6.66 (s, 1H), 5.10-4.65 (m, 2H), 3.80-3.45 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 1.71 (sept, J =
6.9 Hz, 1H), 1.15-0.95 (m, 6H).
Example 2(114) 4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid / ~ COOH
H3C ~ O
H3C ~ / N~~ N
H3C"CH3 TLC : Rf 0.56 (chloroform : methanol = 9 : 1) NMR : 8 7.86 (d, J = 3.0 Hz, 1H), 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 3.0 Hz, 1H), 6.84 (s, 1H), 6.76 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.04 (d, J = 11.? Hz, 1H), 4.98 (d, J = 11.7 Hz, 1H), 4.71 (sept, J = 6.6 Hz, 1H), 2.23 (s, 3H), 2.13 (s, 3H), 1.18 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).

Example 2(115) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]cinnamic acid ~ COOH
H3C ~ O
H C~N~O N
3 , H3C\ J SJ
'C~H3 TLC : Rf 0.58 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), ?.67 (d, J = 3.0 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 3.0 Hz, 1H), 7.27 (d, J = 8.4 Hz, 2H), 7.05 (s, 1H), 6.67 (s, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.00-4.62 (m, 2H), 3.80-3.45 (m, 2H), 2.22 (s, 3H), 2.17 (s, 3H), 1.70 (sept, J = 6.6 Hz, 1H), 1.10-0.96 (m, 6H).
Example 2(116) 4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid N~~N
_..S~
TLC : Rf 0.39 (chloroform : methanol = 10 : 1)~
NMR : 8 7.87 (d, J = 3.3 Hz, 1H), 7.80 (d, J = 15.9 Hz, 1H), ?.56 (d, J = 7.8 Hz, 2H), 7.45 (d, J = ?.8 Hz, 2H), 7.44 (d, J = 3.3 Hz, 1H), 6.94 (s, 1H), 6.85 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 5.01 (d, J = 13.2 Hz, 1H), 5.00 (d, J = 13.2 Hz, 1H), 4.70 (m, 1H), 2.91-2.79 (m, 4H), 2.14-2.01 (m, 2H), 1.17 (d, J = 6.6 Hz, 3H), 1.15 (d, J = 6.6 Hz, 3H).
Example 2(117) 4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid TLC : Rf 0.40 (chloroform : methanol = 10 : 1)~
NMR : 8 7.80 (d, J = 15.9 Hz, 1H), 7.69 (d, J = 3.3 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.34 (d, J = 3.3 Hz, 1H), 7.2? (d, J = 8.4 Hz, 2H), 7.14 (s, 1H), 6.75 (s, 1H), 6.48 (d, J = 15.9 Hz, 1H), 4.92 (m, 1H), 4.70 (m, 1H), 3.78-3.46 (m, 2H), 2.90-2.80 (m, 4H), 2.14-2.01 (m, 2H), 1.72 (m, 1H), 1.02-0.83 (m, 6H).
Example 2(118) 3-methyl-4-[2-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid HaC \ O \
H C~N~O N

H3CI 'CH3 TLC : Rf 0.27 (chloroform : methanol = 9 : 1)~
NMR : 8 8.00-7.90 (m, 2H), 7.87 (d, J = 3.0 Hz, 1H), 7.55 (d, J = 7.8 Hz, 1H), 7.44 (d, J =
3.0 Hz, 1H), 6.85 and 6.77 (each s, each 1H), 5.09-4.92 (m, 2H), 4.78-4.62 (m, 1H), 2.39 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.19 and 1.15 (each d, J = 6.6 Hz, each 3H).
Example 2(119) 3-methyl-4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid H
TLC : Rf 0.27 (chloroform : methanol = 9 : 1)~
NMR : b 7.95-7.89 (m, 2H), 7.70 and 7.34 (each d, J = 3.3 Hz, each 1H), 7.32-7.29 (m, 1H), 7.06 and 6.69 (each s, each 1H), 5.00-4.68 (m, 2H), 3.?8-3.48 (m, 2H), 2.34 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 1.80-1.65 (m, 1H), 1.08-0.82 (m, 6H).
Example 2(120) 3-methyl-4-[2-[N-isopropyl-N-(2~thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
cinnamic acid H3C / ~ COOH
H3C \ O \
H C ~ ~ N'S/O N

H3C"CHj TLC : Rf 0.25 (chloroform : methanol = 9 : 1)~
NMR : b 7.87 (d, J = 3.0 Hz, 1H), 7.77 (d, J = 16.2 Hz, 1H), 7.52-7.32 (m, 4H), 6.83 and 6.79 Leach s, each 1H), 6.46 (d, J = 16.2 Hz, 1H), 5.05-4.87 (m, 2H), 4.75-4.62 (m, 1H), 2.36 (s, 3H), 2.25 (s, 3H), 2.15 (s, 3H), 1.17 and 1.13 (each d, J = 6.6 Hz, each 3H).
Example 2(121) 3-methyl-4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
TLC : Rf 0.25 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.69 (d, J = 3.0 Hz, 1H), 7.42-7.35 (m, 2H), ?.34 (d, J =
3.0 Hz, 1H), 7.25-7.19 (m, 1H), ?.05 and 6.70 (each s, each 1H), 6.47 (d, J =
16.2 Hz, 1H), 4.95-4.62 (m, 2H), 3.?5-3.48 (m, 2H), 2.31 (s, 3H), 2.24 (s, 3H), 2.18 (s, 3H), 1.78-1.62 (m, 1H), 1.78-1.62 (m, 6H).
Example 2(122) 3-methyl-4-[6-[N-isopropyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid H3C / ~ COOH
O
N~O N
HgC"CH3 TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR : 8 7.88 (d, J = 3.0 Hz, 1H), 7.7? (d, J = 16.2 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.45 (d, J = 3.0 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.38 (s, 1H), 6.93 (s, 1H), 6.87 (s, 1H), 6.46 (d, J =
16.2 Hz, 1H), 5.02 and 4.95 (each d, J = 12.9 Hz, each 1H), 4.68 (sept, J =
6.6 Hz, 1H), 2.94-2.78 (m, 4H), 2.36 (s, 3H), 2.16-2.02 (m, 2H), 1.17 and 1.14 (each d, J =
6.6 Hz, each 3H).
Example 2(123) 3-methyl-4-[6-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid cinnamic acid ~N.~~N
H3c~ J s~

TLC : Rf 0.39 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.98 (d, J = 3.0 Hz, 1H), 7.87 (d, J = 3.0 Hz, 1H), 7.56 (d, J = 16.2 Hz, 1H), 7.52 (s, 1H), ?.50 (d, J = 8.1 Hz, 1H), ?.18 (d, J = 8.1 Hz, 1H), 7.06 (s, 1H), 7.00 (s, 1H), 6.54 (d, J = 16.2 Hz, 1H), 5.04-4.66 (m, 2H), 3.57-3.37 (m, 2H), 2.93-2.68 (m, 4H), 2.27 (s, 3H), 2.11-1.93 (m, 2H), 1.64-1.46 (m, 1H), 0.94-0.74 (m, 6H).
Example 2(124) 4-[3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-2-naphthyloxymethyl]benzoic acid ~N:S'O O

H3~, J
TLC : Rf 0.33 (chloroform : methanol = 9 : 1);
NMR(CDsOD) : 8 8.05 (d, J = 8.4 Hz, 2H), ?.82-7.75 (m, 3H), ?.53 (d, J = 8.4 Hz, 2H), 7.51-7.35 (m, 3H), 6.71 (d, J = 3.3 Hz, 1H), 6.05 (m, 1H), 5.42-4.95 (br, 2H), 3.62 (d, J = 7.5 Hz, 2H), 2.13 (s, 3H), 1.?9-1.61 (m, 1H), 0.94 (d, J = 6.3 Hz, 6H).
Reference example 4 N-[4,5-dimethyl-2-(2-methyl-4-cyanophenylmethyloxy)phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide H3C ~ O
H C I ~ NCO O
3 ~ ~ CH3 H3C\ J

Under atmosphere of argon, a solution of 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid prepared in example 2 (178 mg) in dichloromethane (1.5 ml) was cooled to 0°C, then oxalyl chloride (48 p1) and a catalytic amount of N,N-dimethylformamide was added thereto. After the solution was stirred for 1 hour at room temperature, the reaction mixture was concentrated under reduced pressure, and azeotroped with toluene. Under atmosphere of argon, the residue was dissolved in dichloromethane (1.5 ml), and cooled to 0°C. The solution was added by 28% aqueous ammonia (1m1) and stirred for 5 minutes. The solution was added by water and ethyl acetate. The organic layer was washed, dried and concentrated under reduced pressure. Under atmosphere of argon, the residue was dissolved in dichloromethane (1.5 ml), and cooled to 0°C. The solution was added by pyridine (0.18 ml) and trifluoromethanesulfonic acid anhydride (0.12 ml) and stirred for 50 minutes.
The reaction mixture was poured into water, then it was added by ethyl acetate.
The organic layer was washed, dried and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane - ethyl acetate) to give the title compound (149 mg) having the following physical data.
TLC : Rf 0.74 (n-hexane ~ ethyl acetate = 1 : 1).
Example 3 N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2~furyl)sulfonylamide To N-[4,5-dimethyl-2-(2-methyl-4-cyanophenylmethyloxy)phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide prepared in reference example 4 (79 mg), trimethyltin azide (43 mg) was added, and mixture was refluxed for 7 hours, then stirred for 1 day at room temperature. The reaction mixture was added by methanol (3 ml) and 2N
hydrochloric acid (2 ml), then stirred for 2 hours. The solution was added by water and ethyl acetate.
The organic layer was washed, dried and concentrated under reduced pressure.
The residue was washed by hexane - ethyl acetate to give the title compound (81 mg) having the following physical data.
TLC : Rf 0.52 (chloroform : methanol : water = 8 : 2 : 0.2)~
MS (FAB, Pos.) : 510 (M + H)+.
Example 3(1) ~ Example 3(38) By the same procedures as described in reference examples 1 - 3 and example 3, the title compounds having the following physical data were obtained.

Example 3(1) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-TLC : Rf 0.40 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Pos.) : 530 (M)+.
Example 3(2) N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyDphenylmethyloxy]phenyl]-N-isoprnpyl-(5-methyl-2-furyl)sulfonylamide NINN

HaC \ O \ ~ H
H3C~N~0 O

H3C"CH3 TLC : Rf 0.52 (chloroform : methanol : water = 8 : 2 : 0.2)~
MS (FAB, Pos.) : 496 (M + H)+.
Example 3(3) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide N NN
/ N
CI \ O \ I H
H3C~N~0 O

H3C\ J
'C~H3 TLC : Rf 0.39 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 8.05 (d, J = 8.1 Hz, 2H), ?.47 (d, J = 8.1 Hz, 2H), ?.08 (s, 1H), 6.93 (s, 1H), 6.80 (d, J = 3.3 Hz, 1H), 6.01 (m, 1H), 5.15-4.80 (br, 2H), 3.46 (d, J = 7.2 Hz, 2H), 2.2? (s, 3H), 2.19 (s, 3H), 1.64 (m, 1H), 0.88 (d, J = 6.9 Hz, 6H).
methyl-2-fuiyl)sulfonylamide Example 3(4) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide N'NN
/ N
HOC \ p \ I H
H C I / N~0 C
3 ~ ~ CH3 H3C"CH3 TLC : Rf 0.41 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : 8 8.04 (d, J = 8.1 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), ?.O1 (s, 1H), 6.91 (d, J = 3.3 Hz, 1H), 6.76 (s, 1H), 6.29-6.23 (m, 1H), 5.18 and 5.12 (each d, J =
13.5 Hz, each 1H), 4.30 (sept, J = 6.6 Hz, 1H), 2.30 (s, 3H), 2.23 (s, 3H), 2.14 (s, 3H), 1.02 and 1.00 (each d, J = 6.6 Hz, each 3H).
Example 3(5) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide NW
I
/~ ~N
H
H3C~ /W ~~~
H3C~N~O ~ CH3 TLC : Rf 0.37 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : 8 8.04 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 8.4 Hz, 2H), 6.96 (s, 1H), 6.92 (s, 1H), 6.82 (d, J = 3.3 Hz, 1H), 6.19-6.13 (m, 1H), 5.28-4.82 (m, 2H), 3.38 (d, J = 6.9 Hz, 2H), 2.21 (s, 3H), 2.14 (s, 6H), 1.64-1.44 (m, 1H), 0.85 (d, J = 6.6 Hz, 6H).
Example 3(6) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-thiazolylsulfonylamide N NON
N
FsC ~ p ~ I H
N~O N

TLC : Rf 0.46 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 8.09 (d, J = 8.4 Hz, 2H), 7.?6 (d, J = 2.7 Hz, 1H), 7.49-7.44 (m, 4H), 7.27 (m, 1H), ?.19 (s, 1H), 5.01 (br, 2H), 3.63 (d, J = ?.2 Hz, 2H), 1.67 (m, 1H), 0.97 (d, J = ?.2 Hz, 6H).
Example 3(7) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylsulfonylamide -NINN
H
F3C ~ O
I / N~0 N
H3C"CH3 TLC : Rf 0.31 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : b 8.07 (d, J = 8.1 Hz, 2H), 7.94 (d, J = 3.3 Ha, 1H), 7.60 (d, J = 8.1 Hz, 2H), 7.56 (d, J = 3.3 Hz, 1H), 7.36-7.20 (m, 3H), 5.1? and 5.13 (each d, J = 12.0 Hz, each 1H), 4.68 (sept, J = 6.6 Hz, 1H), 1.15 and 1.14 (each d, J = 6.6 Hz, each 3H).
Example 3(8) N-(4-trifluoromethyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide TLC : Rf 0.31 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 8.04 (d, J = 8.1 Hz, 2H), 7.42 (d, J = 8.1 Hz, 1H), ?.37 (d, J = 8.1 Hz, 2H), 7.23 (m, 1H), 7.16 (s, 1H), 6.99 (s, 1H), 4.95 (br, 2H), 3.56 (d, J = 6.6 Hz, 2H), 2.26 (s, 3H), 1.59 (sept, J = 6.6 Hz, 1H), 0.84 (d, J = 6.6 Hz, 6H).
Example 3(9) N-(4-trifluoromethyl-2-(4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide N.N,N
N
FsC \ 0 \ I "
N\S~0 N
~~CH3 _ H3C~CH ~3 TLC : Rf 0.42 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 7.93 (d, J = 8.1 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), ?.24-7.16 (m, 3H), 7.02 (s, 1H), 5.10-4.92 (m, 2H), 4.5? (quint, J = 6.6 Hz, 1H), 2.39 (s, 3H), 1.04 (d, J =
6.6 Hz, 3H), 1.02 (d, J = 6.6 Hz, 3H).
Example 3(10) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide N NN
HgC / N
CI \ O \ ' "
~O~ ~
H3C / N~ ~~CH3 H3C~ S
'C~H3 TLC : Rf 0.24 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Pos.) : 54? (M)+.
Example 3(11) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide c1, ~ ,o, w ~J "
N~~N
~CH3 _ ~S
TLC : Rf 0.24 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Post : 533 (M)+.
Example 3(12) N~ [4-trifluoromethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide F
NON
N
H

TLC : Rf 0.38 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : b 7.91 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.64 (d, J = ?.8 Hz, 1H), 7.33-7.20 (m, 3H), 7.12 (s, 1H), 5.11 (s, 2H), 4.65 (sept, J = 6.6 Hz, 1H), 2.49 (s, 3H), 2.43 (s, 3H), 1.12 (d, J =
6.6 Hz, 6H).
Example 3(13) N-[4-trifluoromethyl-2-[2-methyl-4-(5-tetrazolyDphenylmethyloxy]phenyl]-N-isobutyl-(4-methyl H
N~~N
S ~CH3 TLC : Rf 0.34 (chloroform : methanol : water = 8 : 2 : 0.2)a NMR : 8 ?.97 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.48-7.38 (m, 2H), 7.34-7.18 (m, 2H), 7.05 (s, 1H), 5.12-4.84 (m, 2H), 3.59 (d, J = 7.2 Hz, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.74-1.58 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Example 3(14) N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-amide TLC : Rf 0.46 (chloroform : methanol : water = 8 : 2 : 0.2).
MS (FAB, Pos.) : 527 (M + H)+.

Example 3(15) N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide H
HaC~N~~~~CH

H3C~CH /3 TLC : Rf 0.52 (chloroform : methanol : water = 8 : 2 : 0.2);
MS (FAB, Pos.) : 513 (M + H)+.
Example 3(16) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide m H3C' 'CH3 TLC : Rf 0.29 (chloroform : methanol = 5 : 1);
MS (tIPCI, Neg. 20V) : 49? (M - H)-.
Example 3(1?) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide N NON
N
HsC \ 0 \ ~ H
H3C~N~C~N
~~CH3 H3C~ ~S

TLC : Rf 0.26 (chloroform : methanol = 5 : 1);
MS (APCI, Neg. 20V) : 511 (M - H)'.
Example 3(18) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide AI
113C- _CH3 TLC : Rf 0.31 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 8.02 (d, J = 8.4 Hz, 2H), ?.51 (d, J = 8.4 Hz, 2H), 7.10 (s, 1H), 6.98 (s, 2H), 5.03 and 4.95 (each d, J = 12.6 Hz, each 1H), 4.65 (sept, J = 6.6 Hz, 1H), 2.46 (s, 3H), 2.26 (s, 3H), 1.13 and 1.12 (each d, J = 6.6 Hz, each 3H).
Example 3(19) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide CI

TLC : Rf 0.29 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-d~ : b 8.05 (d, J = 8.4 Hz, 2H), 7.52 (s, 1H), 7.45 (d, J = 8.4 Hz, 2H), ?.26 (s, 1H), 7.25 (s, 1H), 5.25-4.73 (m, 2H), 3.62-3.40 (m, 2H), 2.26 (s, 3H), 2.22 (s, 3H), 1.66-1.50 (m, 1H), 0.88 (d, J = 6.6 Hz, 6H).
Example 3(20) N-[4,5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazoly ~~N
N
H
H3C~N~O N CH3 H3C"CH3 TLC : Rf 0.31 (chloroform : methanol = 5 : 1)~
NMR(CDCIs + 1 drop of CDaOD) : 8 7.71 (d, J = 7.5 Hz, 1H), 7.70 (d, J = 1.5 Hz, 1H), 7.51 (dd, J = 7.5, 1.5 Hz, 1H), 7.07 (d, J = 0.9 Hz, 1H), 6.83 (s, 1H), 6.82 (s, 1H), 5.09 (d, J =
13.8 Hz, 1H), 5.04 (d, J = 13.8 Hz, 1H), 4.68 (m, 1H), 3.9? (s, 3H), 2.46 (d, J = 0.9 Hz, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.14 (d, J = 6.6 Hz, 3H).

a Example 3(21) N- [4-tr ifluoromethyl-2- [4-(5-tetrazolyl)p henylmethyloxy]phenyl] ~ N-isopr opyl-3-TLC : Rf 0.47 (chloroform : methanol = 3 : 1)~
NMR(DMSO-ds) : b 8.91 (dd, J = 2.4, 0.6 Hz, 1H), 8.73 (dd, J = 4.5, 1.8 Hz, 1H), 8.14 (ddd, J = 8.4, 2.4, 1.8 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.57 (s, 1H), 7.55 (d, J
= 8.4 Hz, 2H), 7.47 (ddd, J = 8.4, 4.5, 0.6 Hz, 1H), 7.43-7.38 (m, 2H), 5.28 (d, J = 12.3 Hz, 1H), 5.21 (d, J
= 12.3 Hz, 1H), 4.45-4.25 (m, 1H), 1.04 (d, J = 6.6 Hz, 3H), 1.00 (d, J = 6.6 Hz, 3H).
Example 3(22) N-[4-trifluornmethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-~N
TLC : Rf 0.47 (chloroform : methanol = 3 : 1)~
NMR : 8 8.89 (d, J = 1.5 Hz, 1H), 8.46 (dd, J = 4.8, 1.5 Hz, 1H), 8.00 (d, J =
8.4 Hz, 2H), 7.83 (dt, J = 8.1, 1.5 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.35 (dd, J = 8.4, 0.9 Hz, 1H), 7.26-7.20 (m, 1H), ?.19 (d, J = 0.9 Hz, 1H), 7.14 (d, J = 8.4 Hz, 2H), 4.95 (brs, 1H), 4.?7 (brs, 1H), 3.56 (brs, 1H), 3.40 (brs, 1H), 1.70-1.60 (m, 1H), 0.94 (brs, 6H).
Example 3(23) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl] ~N-isopropyl-2-pyridylsulfonylamide pyridylsulfonylamide pyridylsulfonylamide n ngv w y TLC : Rf 0.4? (chloroform : methanol = 3 : 1)~
NMR : S 8.69 (d, J = 4.8 Hz, 1H), 8.02 (d, J = 8.4 Hz, 2H), ?.92-?.76 (m, 2H), 7.52 (d, J =
8.4 Hz, 2H), ?.46-?.38 (m, 1H), ?.30-?.26 (m, 3H), 5.08 (d, J = 12.0 Hz, 1H), 5.01 (d, J =
12.0 Hz, 1H), 4.?5-4.55 (m, 1H), 1.11 (d, J = ?.5 Hx, 3H), 1.08 (d, J = ?.5 Hz, 3H).
Example 3(24) N-[4-trifluoromethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide N..N
I ~~N
N
F3C \ O \ ~ H .
/ N'S~O Nw H3C ( /

TLC : Rf 0.38 (chloroform : methanol = 3 : 1)~
NMR : 8 8.60-8.45 (m, 1H), 8.10 (d, J = 8.4 Hz, 2H), ?.80-?.70 (m, 2H), 7.49 (d, J = 8.1 Hz, 1H), ?.38 (d, J = 8.4 Hz, 2H), ?.38-?.31 (m, 1H), ?.30-?.20 (m, 1H), 7.14 (d, J = 1.8 Hz, 1H), 4.91 (brs, 2H), 3.63 (brd, J = 6.3 Hz, 2H), 1.?0-1.55 (m, 1H), 0.89 (d, J =
6.6 Hz, 6H).
Example 3(25) N-[4-trifluoromethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide N NON

F3C ~ O r ~ H
/ N'S~O Nw H3C"CH3 J
TLC : Rf 0.24 (chloroform : methanol = 3 : 1)~
NMR : 8 8.69 (d, J = 4.8 Hz, 1H), 7.92-?.?5 (m, 4H), 7.58 (d, J = 7.8 Hz, 1H), ?.48-7.39 (m, 1H), ?.31-?.18 (m, 3H), 5.03 (s, 2H), 4.72-4.58 (m, 1H), 2.3? (s, 3H), 1.11 and 1.09 (each d, J = 6.6 Hz, each 3H).
Example 3(26) N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-pyridylsulfonylamide N-N
H3C / ~ N,N
HsC \ O \ ~ H
H C~N~O N\

HsC

TLC : Rf 0.40 (chloroform : methanol : water = 8 : 2 : 0.2);
MS (FAB, Pos.) : 507 (M + H)+.
Example 3(27) N-[4,5-dimethyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-pyridylsulfonylamide Nf NN

HsC~ \ 0 \ ~ H
~O~O
H3C~/ N~ I ~N

TLC : Rf 0.44 (chloroform : methanol : water = 8 : 2 : 0.2);
MS (FAB, Post : 507 (M + H)+.
Example 3(28) N-[4-chloro-5-methyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide ci, ~ .o_ ~~ J "
oho ~ ~N
/
TLC : Rf 0.28 (chloroform : methanol : water = 8 : 2 : 0.2);
NMR(DMSO-ds) : s s.s9 (d, J = 1.s Hz, 1H), 8.64 (dd, J = 4.8, 1.8 Hz, 1H), 8.00 (d, J = s.1 Hz, 2H), 7.98-7.92 (m, 1H), 7.40 (dd, J = 8.1, 4.8 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), ?.27 (s, 1H), 7.24 (s, 1H), 5.1'7-4.68 (m, 2H), 3.46-3.16 (m, 2H), 2.28 (s, 3H), 1.60-1.42 (m, 1H), 1.00-0.73 (m, 6H).
Example 3(29) N' [4,5-dimethyl-2-[2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-TLC : Rf 0.22 (chloroform : methanol : water = 40 : 10 : 1)~
NMR : b 8.52 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.79 (dt, J = 1.5, 8.1 Hz, 1H), 7.71 (d, J = 8.1 Hz, 1H), ?.47 (d, J = 7.8 Hz, 1H), 7.35-7.30 (m, 1H), 7.04 (s, 1H), 6.63 (s, 1H), 4.90 (br, 1H), 4.64 (br, 1H), 3.67 (br, 1H), 3.57 (br, 1H), 2.21 (s, 3H), 2.15 (s, 3H), 1.80-1.60 (m, 1H), 0.91 (br, 6H).
Example 3(30) N-[4,5-dimethyl-2-[2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-3-pyridylsulfonylamide N NN
CI
HaC ~ p ~ ~ H
/ O~O
H3C ~ ~ ~ N

TLC : Rf 0.22 (chloroform : methanol : water = 40 : 10 : 1)~
NMR : b 9.11 (d, J = 1.8 Hz, 1H), 8.61 (dd, J = 4.8, 1.5 Hz, 1H), 8.20-8.10 (m, 2H), 7.88 (dd, J = 7.8, 1.5 Hz, 1H), 7.42 (dd, J = 8.1, 4.8 Hz, 1H), 7.33 (d, J = 7.8 Hz, 1H), 7.01 (s, 1H), 6.79 (s, 1H), 4.96 (d, J = 13.5 Hz, 1H), 4.93 (d, J = 13.5 Hz, 1H), 4.60-4.45 (m, 1H), 2.29 (s, 3H), 2.23 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.11 (d, J = 6.6 Hz, 3H).
Example 3(31) N-[4,5-dimethyl-2-(2-chloro-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-TLC : Rf 0.22 (chloroform : methanol : water = 40 : 10 : 1)~

pyridylsulfonylamide pyridylsulfonylamide NMR : 8 8.9? (d, J = 1.8 Hz, 1H), 8.55-8.45 (m, 1H), 8.15 (d, J = 1.5 Hz, 1H), 7.89 (d, J =
?.8 Hz, 1H), 7.83 (dt, J = 8.1, 1.8 Hz, 1H), ?.31 (dd, J = 8.1, 4.8 Hz, 1H), 7.24 (s, 1H), 7.07 (d, J = 7.8 Hz, 1H), 6.75 (s, 1H), 4.89 (d, J = 12.5 Hz, 1H), 4.63 (d, J =
12.5 Hz, 1H), 3.70-3.60 (m, 1H), 3.45-3.30 (m, 1H), 2.30 (s, 3H), 2.26 (s, 3H), 1.80-1.60 (m, 1H), J = 6.6 Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H).
Example 3(32) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide N_NN
N
HsC ~ p ~ ~ H
H3C~N'S~O IVw H3C"CH3 J
TLC : Rf 0.23 (chloroform : methanol = 5 : 1)~
MS (APCI, Neg. 20V) : 4?? (M - H)'.
Example 3(33) N-[4,5-dimethyl-2-[4-(5-tetrazoly~phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide TLC : Rf 0.23 (chloroform : methanol = 5 : 1)~
MS (APCI, Neg. 20V) : 491 (M - H)'.
Example 3(34) N-[4,5-dimethyl-2-[4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide h O~p N~ ~N
I/
H

TLC : Rf 0.23 (chloroform : methanol = 5 : 1)~
MS (APCI, Neg. 20~ : 491 (M - H)'.
Example 3(35) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide NINN

CI ~ O ~ I H
H3C ~ / N~O Nw H3C"CH3 J
TLC : Rf 0.30 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : 8 8.6? (d, J = 3.6 Hz, 1H), 7.98-7.88 (m, 2H), 7.85-?.?8 (m, 2H), ?.55-7.48 (m, 2H), ?.3? (s, 1H), 7.04 (s, 1H), 5.10 (ABd, J = 13.2 Hz) and 5.04 (ABd, J = 13.2 Hz) total 2H, 4.49 (sept, J = 6.9 Hz, 1H), 2.36 (s, 3H), 2.23 (s, 3H), 1.02 (d, J = 6.9 Hz) and 0.99 (d, J = 6.9 Hz) total 6H.
Example 3(36) N-[4-chloro-5-methyl-2-[2-methyl-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide TLC : Rf 0.26 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR(DMSO-ds) : 8 8.48 (m, 1H), 7.93-7.85 (m) and 7.90 (dd, J = 7.8, 1.8 Hz) total 2H, ?.81 (d, J = 8.1 Hz, 1H), ?.68 (d, J = 8.1 Hz, 1H), 7.44 (ddd, J = 7.8, 4.8, 1.2 Hz, 1H), 7.29 (s) and 7.27 (d, J = 7.8 Hz) total 2H, 7.20 (s, 1H), 4.92 (m, 2H), 3.47 (m, 2H), 2.31 (s, 3H), 2.23 (s, 3H), 1.50 (m, 1H), 0.81 (d, J = 6.6 Hz, 6H).

r Example 3(37) N-[4, 5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide TLC : Rf 0.23 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Pos.) : 523 (M + I-~+.
Example 3(38) N-[4,5-dimethyl-2-[2-methoxy-4-(5-tetrazolyl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide TLC : Rf 0.23 (chloroform : methanol = 10 : 1).
Reference example 5 N-[4,5-dimethyl-2-[2-methyl-4-(N-hydroxyamidino)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide ...OH
N.5~0 O
J I ~ cH3 To a solution of N-[4,5-dimethyl-2-(2-methyl-4-cyanophenylmethyloxy)phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide prepared in reference example 4 (70 mg) in ethanol (2 ml), triethylamine (42 ~I) and hydroxylamine hydrogen chloride salt (21 mg) were added at room temperature, then mixture was reffuxed for 5 hours. After termination of reaction, the reaction mixture was poured into ethyl acetate -water. The organic layer was washed, dried and concentrated under reduced pressure to give the title compound (80 mg) having the following physical data.
TLC : Rf 0.38 (n-hexane : ethyl acetate = 2 : 3).
Example 4 N- [4, 5-dimethyl-2- [2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide N-o H3C I ~O
~N
H3C O ~ ~ H .
H3C~N~0 O

To a solution of N-[4,5-dimethyl-2-[2-methyl-4-(N-hydroxyamidino)phenylmethyloxy] phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide prepared in reference example 5 (78 mg) in N,N-dimethylformamide (1 ml), pyridine (16 u1) and chloro formic acid 2-ethylhexyl ester (30 p1) were added and the mixture was stirred for 1 hour at 0°C. After termination of reaction, the reaction mixture was poured into ethyl acetate - water. The organic layer was washed, dried and concentrated under reduced pressure. To the residue, xylene (2 ml) was added, and the mixture was refluxed for 6 hours at 140°C. After termination of reaction, the reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (hexane - ethyl acetate) to give the title compound (42 mg) having the following physical data.
TLC : Rf 0.43 (chloroform : methanol = 19 : 1) NMR : 8 10.69 (br, 1H), 7.62 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.54 (d, J =
8.1 Hz, 1H), 6.97 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 6.00 (d, J = 3.3 Hz, 1H), 4.94 (br, 2H), 3.46 (d, J = 7.5 Hz, 2H), 2.39 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 1.70-1.55 (m, 1H), 0.89 (d, J = 6.6 Hz, 6H).
Example 4(1) ~ Example 4(22) By the same procedures as described in reference examples 1 - 5 and example 4, the compounds having the following physical data were obtained.

Example 4(1) N-[4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide N_O
~O
~N
CI ~ p ~ ~ H
H C~N~O O
3 ~ ~ CH3 H3C"CH3 TLC : Rf 0.40 (chloroform : methanol = 19 : 1)~
NMR : 8 10.81 (br, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.63 (d, J = 8.3 Hz, 2H), 6.97 (s, 1H), 6.92 (s, 1H), 6.84 (d, J = 3.3 Hz, 1H), 6.10-6.00 (m, 1H), 5.07 (s, 2H), 4.55-4.35 (m, 1H), 2.34 (s, 3H), 2.28 (s, 3H), 1.10 (d, J = 6.6 Hz, 3H), 1.07 (d, J = 6.6 Hz, 3H).
Example 4(2) N-[4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide N-O
~0 ~N
CI ~ O ~ I H
H3C'~N~O O

H3C\ J
'C~H3 TLC : Rf 0.38 (chloroform : methanol = 19 : 1)~
NMR : 8 11.01 (br, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H), 7.10 (s, 1H), 6.92 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.05-5.95 (m, 1H), 5.02 (br, 2H), 3.45 (d, J = 7.2 Hz, 2H), 2.29 (s, 3H), 2.20 (s, 3H), 1.70-1.55 (m, 1H), 0.90 (d, J = 6.9 Hz, 6H).
Example 4(3) N-[4,5-dimethyl-2-[2'methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide TLC : Rf 0.43 (chloroform : methanol = 19 : 1) NMR : 8 10.34 (br, 1H), 7.71 (d, J = 8.1 Hz, 1H), 7.65-7.55 (m, 2H), 6.86 (d, J = 3.3 Hz, 1H), 6.79 (s, 1H), 6.74 (s, 1H), 6.10-6.05 (m, 1H), 4.93 (s, 2H), 4.50-4.40 (m, 1H), 2.37 (s, 3H), 2.34 (s, 3H), 2.26 (s, 3H), 2.17 (s, 3H), 1.09 (d, J = 6.6 Hz, 3H), 1.07 (d, J
= 6.6 Hz, 3H).
Example 4(4) N-[4,5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide N_O
t ~N
HsC ~ p ~ ~ H
H3C~N~0 O
CH3 .
H3C\ J
'C~H3 TLC : Rf 0.53 (chloroform : methanol = 9 : 1)~
NMR : S 11.10-10.50 (br, 1H, NH), 7.78 (d, J = 8.7 Hz, 2H), 7.52 (d, J = 8.7 Hz, 2H), 6.97 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 6.69 (s, 1H), 6.01-5.98 (m, 1H), 5.15-4.85 (m, 2H), 3.46 (d, J
= 7.2 Hz, 2H), 2.22 (s, 3H), 2.20 (s, 3H), 2.17 (s, 3H), 1.73-1.60 (m, 1H), 0.90 (d, J = 6.9 Hz, 6H).
Example 4(5) N-[4,5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(5-methyl-2-furyl)sulfonylamide TLC : Rf 0.46 (dichloromethane : methanol = 10 : 1).
MS (FAB, Pos.) : 542 (M + H)+.
Example 4(6) N-[4,5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(5-methyl-2-furyl)sulfonylamide N_O
H3C0 / ~ N~O
H3C \ 0 \ ~ H _ H C~N'~O O
3 ~ / CH3 H3C"CH3 TLC : Rf 0.44 (dichloromethane : methanol = 19 : 1)~
NMR : b 7.68 (d, J = 8.1 Hz, 1H), 7.35 (dd, J = 8.1, 1.5 Hz, 1H),-7.24 (d, J =
1.5 Hz, 1H), 6.91 (d, J = 3.3 Hz, 1H), 6.77 (s, 1H), 6.72 (s, 1H), 6.11 (dd, J = 3.3, 0.6 Hz, 1H), 4.92 (d, J
= 14.7 Hz, 1H), 4.83 (d, J = 14.? Hz, 1H), 4.49 (m, 1H), 3.93 (s, 3H), 2.3?
(s, 3H), 2.25 (s, 3H), 2.17 (s, 3H), 1.09 (d, J = 6.9 Hz, 3H), 1.07 (d, J = 6.9 Hz, 3H).
Example 4(7) N-[4-triffuoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylsulfonylamide TLC : Rf 0.23 (n-hexane : ethyl acetate = 1 : 1)~
NMR : 8 7.96 (d, J = 3.3 Hz, 1H), 7.82 (d, J = 8.4 Hz; 2H), 7.65 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 3.3 Hz, 1H), 7.34-7.22 (m, 3H), 5.19 (s, 2H), 4.68 (sept, J = 6.6 Hz, 1H), 1.15 and 1.14 (each d, J = 6.6 Hz, each 3H).
Example 4(8) N-[4-trifluoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide N-O
~N
F3C ~ O \ I H
~ 0'S~ ~
N ~~CHs H3C"CH3 /
TLC : Rf 0.60 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 7.82 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.4 Hz, 2H), 7.32-7.24 (m, 3H), ?.11 (d, J =
0.9 Hz, 1H), 5.19 (s, 2H), 4.68 (quint, J = 6.6 Hz, 1H), 2.51 (d, J = 0.9 Hz, 3H), 1.14 (d, J =
6.6 Hz, 6H).

Example 4(9) N- [4-trifluoromethyl-2- [4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide H
~N.~.S~~N
~' ,>---CH3 H3~, J
TLC : Rf 0.60 (chloroform : methanol : water = 8 : 2 : 0.2)~
NMR : 8 7.83 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.4 Hz, 2H), ?.45 (d, J = 7.8 Hz, 1H), ?.2? (m, 1H), ?.18 (d, J = 1.5 Hz, 1H), 7.04 (d, J = 0.6 Hz, 1H), 5.05 (br, 2H), 3.60 (d, J = 6.9 Hz, 2H), 2.38 (d, J = 0.6 Hz, 3H), 1.66 (sep, J = 6.9 Hz, 1H), 0.92 (d, J = 6.9 Hz, 6H).
Example 4(10) N-[4-chloro-5-methyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide c1 TLC : Rf 0.37 (chloroform : methanol = 19 : 1)~
NMR : 8 10.89 (br, 1H), 7.79 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.4 Hz, 2H), 7.1? (s, 1H), 7.01 (s, 1H), 6.92 (s, 1H), 4.99 (br, 1H), 4.87 (br, 1H), 3.57 (br, 2H), 2.36 (s, 3H), 2.27 (s, 3H), 1.80-1.60 (m, 1H), 0.93 (d, J = 6.6 Hz, 6H).
Example 4(11) N- [4-chloro-5-methyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide N-O
H3C I ~O
/ ~N
CI ~ O ~ I H
H3C ~ / N~~ N
~~CH3 H3C~ ~S

TLC : Rf 0.43 (ethyl acetate) NMR(DMSO-dc) : b 7.6? (s, 1H), ?.64 (d, J = 8.1 Hz, 1H), ?.50 (s, 1H), ?.34 (s, 1H), 7.32 (d, J = 8.1 Hz, 1H)> 7.21 (s, 1H), 5.06 (brs, 1H), 4.8? (brs, 1H), 3.45 (brs, 2H), 2.33 (s, 3H), 2.2? (s, 3H), 2.22 (s, 3H), 1.?0-1.50 (m, 1H), 0.86 (brd, J = 6.3 Hz, 6H).
Example 4(12) N-[4,5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide N' O
J
i TLC : Rf 0.45 (chloroform : methanol = 19 : 1)~
NMR : 8 10.56 (br, 1H), 7.64 (d, J = 8.1 Hz, 1H), ?.62 (s, 1H), ?.5? (dd, J =
8.1, 1.8 Hz, 1H), 7.0? (s, 1H), 6.83 (s, 1H), 6.?? (s, 1H), 4.98 (s, 2H), 4.?5-4.60 (m, 1H), 2.49 (s, 3H), 2.39 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.14 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H).
Example 4(13) N-[4, 5-dimethyl-2-[2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyl)sulfonylamide TLC : Rf 0.45 (chloroform : methanol = 19 : 1).
NMR : b 10.95 (br, 1H), ?.62 (s, 1H), 7.59 (d, J = 8.1 Hz, 1H), 7.40 (d, J =
8.1 Hz, 1H), ?.03 (s, 1H), 6.99 (s, 1H), 6.71 (s, 1H), 4.91 (br, 1H), 4.82 (br, 1H), 3.57 (br, 2H), 2.37 (s, 3H), 2.34 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H), 1.80-1.60 (m, 1H), 0.93 (br, 6H).
Example 4(14) N-[4,5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide H
N~~N

S
TLC : Rf 0.42 (chloroform : methanol = 10 : 1)~
NMR : 8 ?.77 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.06 (d, J = 0.9 Hz, 1H), 6.83 (s, 1H), 6.74 (s, 1H), 5.05 (d, J = 12.9 Hz, 1H), 5.00 (d, J = 12.9 Hz, 1H), 4.68 (m, 1H), 2.49 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.15 (s, 3H), 1.15 (d, J = 6.6 Hz, 3H), 1.13 (d, J = 6.6 Hz, 3H).
Example 4(15) N-[4, 5-dimethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-(4-methyl-2-thiazolyD
H
V 'O/Ji N ~~CHs H3C\ J S
'C~Hg TLC : Rf 0.39 (chloroform : methanol = 10 : 1)~
NMR : b 7.78 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.03 (s, 1H), 6.97 (d, J = 0.9 Hz, 1H), 6.68 (s, 1H), 5.12-4.68 (m, 2H), 3.73-3.42 (m, 2H), 2.35 (d, J = 0.9 Hz, 3H), 2.23 (s, 3H), 2.17 (s, 3H), 1.69 (m, 1H), 1.03-0.86 (m, 6H).
Example 4(16) N-[4,5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yuphenylmethyloxy]phenyl]-N-isopropyl-(4-methyl-2-thiazolyl)sulfonylamide N.-O

/ I ~'N
H
H3C ~ 0 ~~I
H3C~N~0 N
~~CH3 H3C~CH ~3 TLC : Rf 0.3? (dichloromethane : methanol = 19 : 1)~
NMR : s 7.63 (d, J = 7.8 Hz, 1H), 7.33 (dd, J = 7.8, 1.5 Hz, 1H), 7.30 (d, J =
1.5 Hz, 1H), 7.08 (brs, 1H), 6.83 (s, 1H), 6.76 (s, 1H), 5.02 (d, J = 14.4 Hz, 1H), 4.93 (d, J = 14.4 Hz, 1H), 4.69 (m, 1H), 3.93 (s, 3H), 2.49 (d, J = 1.2 Hz, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.14 (d, J =
6.9 Hz, 3H), 1.13 (d, J = 6.9 Hz, 3H).
IIS

Example 4(17) N-[4-trifluoromethyl-2-[4-(5-oxo-1,2,4-thiadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-thiazolylsulfonylamide H
N~~N
.~_..S.J
TLC ~ Rf 0.44 (n-hexane : ethyl acetate = 1 : 1)~
NMR : b 11.41 (brs, 1H), 7.94 (d, J = 8.4 Hz, 2H), ?.94 (d, J = 3.0 Hz, 1H), ?.60 (d, J = 8.4 Hz, 2H), 7.54 (d, J = 3.0 Hz, 1H), 7.34-7.20 (m, 3H), 5.16 (s, 2H), 4.69 (sept, J = 6.6 Hz, 1H), 1.15 (d, J = 6.6 Hz, 6H).
Example 4(18) N-[4-trifluoromethyl-2-[4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide H
~N~O Nw TLC : Rf 0.46 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 8.60-8.50 (m, 1H), ?.90 (dt, J = 1.8, ?.8 Hz, 1H), ?.81 (d, J
= 8.4 Hz, 2H), 7.72 (d, J = ?.5 Hz, 1H), ?.55-?.35 (m, 6H), 5.08 (brs, 2H), 3.52 (brd, J
= ?.5 Hz, 2H), 1.60-1.40 (m, 1H), 0.83 (d, J = 6.6 Hz, 6H).
Example 4(19) N-[4,5-dimethyl-2' [2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide HsC ~ p ~ ~ H
H3C~N~o Nw u_r~ru TLC : Rf 0.33 (chloroform ~ methanol = 19 : 1)~

NMR : b 10.41 (br, 1H), 8.75-8.70 (m, 1H), ?.90 (dd, J = 7.8, 0.9 Hz, 1H), 7.80 (dt, J = 0.9, 7.8 Hz, 1H), 7.65-7.50 (m, 3H), 7.41 (ddd, J = 7.8, 4.8, 0.9 Hz, 1H), 6.78 (s, 1H), 6.72 (s, 1H), 4.87 (d, J = 13.4 Hz, 1H), 4.83 (d, J = 13.4 Hz, 1H), 4.75-4.60 (m, 1H), 2.34 (s, 3H), 2.25 (s, 3H), 2.13 (s, 3H), 1.10 (d, J = 6.6 Hz, 6H).
Example 4(20) N-(4,5-dimethyl-2-(2-methyl-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-3-pyridylsulfonylamide N-O
H3C I ~O
HsC~/ \\~O \ ~ ,H .
~O~O
H3C~/ N~ ~~N
HaC\J //
C~H3 TLC : Rf 0.30 (chloroform : methanol = 19 : 1)~
NMR : 8 11.28 (br, 1H), 8.84 (d, J = 1.8 Hz, 1H), 8.49 (dd, J = 4.8, 1.8 Hz, 1H), 7.87 (dt, J =
8.1, 1.8 Hz, 1H), 7.62 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), ?.19 (dd, J = 8.1, 4.8 Hz, 1H), 7.15 (s, 1H), 6.97 (d, J = 7.8 Hz, 1H), 6.69 (s, 1H), 4.82 (br, 1H), 4.62 (br, 1H), 3.53 (br, 1H), 3.34 (br, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.22 (s, 3H), 1.80-1.60 (m, 1H), 1.00 (br, 3H), 0.87 (br, 3H).
Example 4(21) N-(4,5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isobutyl-2-pyridylsulfonylamide N-O
H3C0 ~ ~O
/ I ~N
HgC \ O \ H
H3C ~ / N\cu'O Nw HaC

TLC ~ Rf 0.36 (dichloromethane : methanol = 10 : 1)~
MS (FAB, Pos.) : 539 (M + H)+.
Example 4(22) N- [4,5-dimethyl-2-[2-methoxy-4-(5-oxo-1,2,4-oxadiazol-3-yl)phenylmethyloxy]phenyl]-N-isopropyl-2-pyridylsulfonylamide H3C \ C~ H
H C~N~O N~

H3C"CHg v TLC : Rf 0.37 (dichloromethane : methanol = 19 : 1)~
NMR : b 8.73 (ddd, J = 4.8, 1.5, 0.9 Hz,1H), 7.91 (ddd, J = 7.8, 1.2, 0.9 Hz, 1H), 7.82 (ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.43 (ddd, J = 7.8, 4.8, 1.2 Hz, 1H), 7.32 (dd, J = 7.8, 1.5 Hz, 1H), 7.26 (m, 1H), 6.76 (s, 1H), 6.72 (s, 1H), 4.88 (d, J = 14.1 Hz, 1H), 4.78 (d, J = 14.1 Hz, 1H), 4.71 (m, 1H), 3.91 (s, 3H), 2.24 (s, 3H), 2.13 (s, 3H), 1.10 (d, J =
6.6 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H).
Example 5(1) ~ Example 5(63) By the same procedure as described in reference examples 1 ~ 3 and example 2, the compounds of the present invention having the following physical data were obtained.
Example 5(1) 3,5-dimethyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-5-acid TLC : Rf 0.49 (chloroform : methanol = 10 : 1)~
NMR : b 7.82 (s, 2H), 7.40-7.20 (m, 3H), 6.70 (d, J = 3.3 Hz, 1H), 6.00-5.95 (m, 1H), 5.07 (s, 2H), 3.35 (d, J = ?.5 Hz, 2H), 2.43 (s, 6H), 2.19 (s, 3H), 1.60-1.45 (m, 1H), 0.?9 (d, J = 6.6 Hz, 6H).
Example 5(2) 3-methyl-4~ [6-[N-(5-methyl-2-furylsulfonyl)-N-(2-methyl-2-propenyl)amino]indan-5-yloxymethyl]benzoic acid .~N~g- o _ ~% ~ , ~ CH3 TLC : Rf 0.54 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 ?.80-7.70 (m, 2H), 7.37 (d, J = 7.8 Hz, 1H), 7.05 (s, 1H), 6.99 (s, 1H), 6.8? (d, J = 3.3 Hz, 1H), 6.17 (d, J = 3.3 Hz, 1H), 4.99 (br, 2H), 4.72 (s, 2H), 4.13 (br, 2H), 2.83 (t, J = 7.4 Hz, 2H), 2.7? (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.08 (s, 3H), 2.05-1.90 (m, 2H), 1.65 (s, 3H).
Example 5(3) 4-[6-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzoic acid ~CH3 TLC : Rf 0.54 (chloroform : methanol = 9 : 1)a NMR(DMSO-ds) : b 7.77 (s, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.38 (d, J = 8.1 Hz, 1H), 7.09 (s, 1H), 7.02 (s, 1H), 6.85 (d, J = 3.3 Hz, 1H), 6.20-6.15 (m, 1H), 5.01 (br, 2H), 3.41 (br, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.79 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 2.10-1.95 (m, 2H), 0.90-0.70 (m, 1H), 0.35-0.25 (m, 2H), 0.05-(-0.05) (m, 2H).
Example 5(4) 4-[3-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphthalen-2-yloxymethyl]
TLC : Rf 0.55 (ethyl acetate : methanol = 9 : 1)~
NMR : 8 8.14 (d, J = 8.4 Hz, 2H), 7.85 (s, 1H), ?.78 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.1 Hz, 1H), ?.51-7.3? (m, 4H), 7.18 (s, 1H), 6.93 (s, 1H), 5.1? and 4.96 (each br-m, total 2H), 3.85-3.62 (br-m, 2H), 2.34 (s, 3H), 1.82-1.69 (m, 1H), 0.9? (br-s, 6H).

benzoic acid Example 5(5) 4-[3-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino] naphthalen-2-yloxymethyl]
benzoic acid COOH_ / \ O
/ N.a''~'O S

TLC : Rf 0.55 (ethyl acetate : methanol = 9 : 1)~
NMR : 8 8.15 (d, J = 8.4 Hz, 2H), 7.72 (d, J = 9.0 Hz, 2H), 7.61 (s, 1H), 7.60 (d, J = 9.0 Hz, 2H), 7.51-7.46 (m, 1H), 7.44-7.35 (m, 1H), 7.24 (s, 1H), ?.03 (s, 1H), 5.24 (s, 2H), 4.84-4.?5 (m, 1H), 2.52 (s, 3H), 1.26 (d, J = 6.6 Hz, 3H), 1.17 (d, J = 6.6 Hz, 3H).
Example 5(6) , 4-[3-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphthalen-2-yloxymethyl]-3-TLC : Rf 0.63 (ethyl acetate : methanol = 9 : 1)~
NMR : 8 ?.98-7.96 (m, 2H), 7.84 (s, 1H), 7.78 (d, J = 8.1 Hz, 1H), ?.72 (d, J
= 8.1 Hz, 1H), 7.52-7.47 (m, 1H), ?.42-?.3? (m, 2H), ?.21 (s, 1H), 6.95 (s, 1H), 5.10 and 4.96 (each br-m, total 2H), 3.84-3.60 (br-m, 2H), 2.41 (s, 3H), 2.34 (s, 3H), 1.82-1.68 (m, 1H), 0.96 (br-s, 6H).
Example 5(7) 4-[3-[N-isopropyl-N-[2-(4-methylthiazolyl)sulfonyl]amino]naphthalen-2-yloxymethyl]-3-methylbenzoic acid 0 \
\ / N.~O S

TLC : Rf 0.56 (ethyl acetate : methanol = 9 : 1)~
NMR : 8 8.00-7.97 (m, 2H), ?.76-7.65 (m, 3H), 7.61 (s, 1H), 7.52-7.47 (m, 1H), 7.40-7.35 (m, 1H), 7.26 (s, 1H), 7.04 (s, 1H), 5.22 (d, J = 15.0 Hz, 1H), 5.1? (d, J = 15.0 Hz, 1H), 4.83-methylbenzoic acid 4.73 (m, 1H), 2.53 (s, 3H), 2.46 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.16 (d, J
= 6.6 Hz, 3H).
Example 5(8) 4-[3-(N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphthalen-2-yloxymethyl]
TLC : Rf 0.6? (ethyl acetate : methanol = 9 : 1)~
NMR : 8 7.84-7.69 (m, 4H), 7.58 (d, J = 8.1 Hz, 2H), 7.51'7.45 (m, 1H), 7.41-?.35 (m, 3H), 7.18 (s, 1H), 6.93 (s, 1H), 6.49 (d, J = 16.2 Hz, 1H), 5.02 and 4.91 (each br-m, total 2H), 3.84-3.62 (br-m, 2H), 2.33 (s, 3H), 1.82-1.68 (m, 1H), 0.91 (br-s, 6H).
Example 5(9) 4-(3-(N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)aminolnaphthalen-2yloxymethyl]
TLC : Rf 0.61 (ethyl acetate : methanol = 9 : 1)~
NMR : b ?.80 (d, J = 16.9 Hz, 1H), 7.71 (d, J = 8.7 Hz, 2H), 7.61-7.46 (m, 6H), 7.39-7.34 (m, 1H), 7.24 (s, 1H), 7.03 (s, 1H), 6.48 (d, J = 16.9 Hz, 1H), 5.19 Cs, 2H), 4.85-4.72 (m, 1H), 2.51 (s, 3H), 1.25 (d, J = 6.6 Hz, 3H), 1.16 (d, J = 6.6 Hz, 3H).
Example 5(10) 3-methyl-4-[6-(N-methyl-N-(5-methyl-2-furylsulfonyDamino]indan-5-yloxymethyl]benzoic acid \ O \
NCO O
i ~ ~ CHs TLC : Rf 0.58 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : s 7.77 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H), 7.36 (d, J = 7.s Hz, 1H), 7.09 (s, cinnamic acid cinnamic acid 1H), 6.99 (s, 1H), 6.90 (d, J = 3.3 Hz, 1H), 6.25-6.15 (m, 1H), 5.02 (s, 2H), 3.15 (s, 3H), 2.84 (t, J = ?.4 Hz, 2H), 2.?8 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.12 (s, 3H), 2.10-1.95 (m, 2H).
Example 5(11) 4-(6-[N-ethyl-N~(5-methyl-2-furylsulfonyDamino]indan-5-yloxymethyl]-3-methylbenzoic acid H3~~COOH
O y~, / N~O O

~CH3 TLC : Rf 0.59 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.77 (s, 1H), 7.74 (d, J = 7.8 Hz, 1H),7.38 (d, J = ?.8 Hz, 1H), ?.10 (s, 1H), 6.95 (s, 1H), 6.86 (d, J = 3.3 Hz, 1H), 6.16 (d, J = 3.3 Hz, 1H), 5.01 (br, 2H), 3.58 (br, 2H), 2.86 (t, J = 7.4 Hz, 2H), 2.79 (t, J = 7.4 Hz, 2H), 2.32 (s, 3H), 2.10 (s, 3H), 2.10-1.95 (m, 2H), 0.99 (t, J = ?.2 Hz, 3H).
Example 5(12) 4-[6-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid / ~ COOH
O
/ NCO O

TLC : Rf 0.53 (chloroform : methanol = 9 : 1)~
NMR : 8 7.?? (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), ?.14 (s, 1H), 6.80 (s, 1H), 6.79 (d, J = 3.6 Hz, 1H), 6.4? (d, J = 15.9 Hz, 1H), 5.97 (d, J = 3.6 Hz, 1H), 4.98 (s, 2 H), 3.31 (s, 3H), 2.90-2.80 (m, 4H), 2.17 (s, 3H), 2.08 (quint, J = 7.5 Hz, 2H).
Example 5(13) 4-[6-[N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5yloxymethyl]cinnamic acid / ~ COOH
.~ O
/ N~O O

~CH3 TLC : Rf 0.53 (chloroform : methanol = 9 : 1);
NMR : b 7.77 (d, J = 16.2 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), ?.08 (s, 1H), 6.80 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 16.2 Hz, 1H), 5.94 (d, J = 3.3 Hz, 1H), 4.9? (s, 2 H), 3.82-3.65 (m, 2H), 2.90-2.80 (m, 4H), 2.15 (s, 3H), 2.08 (quint, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H).
Example 5(14) 4-(6-(N-(5-methyl-2-furylsulfonyl)-N-propylamino]indan-5-yloxymethyl]cinnamic acid / ~ COOH
.~ O
/ N~O O
CHa TLC : Rf 0.54 (chloroform ~ methanol = 9 : 1)~
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.1 Hz, 2H), ?.37 (d, J = 8.1 Hz, 2H), 7.08 (s, 1H), 6.79 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.94 (brd, J = 3.3 Hz, 1H), 4.97 (br s, 2H), 3.65-3 .61 (m, 2H), 2.90-2.80 (m, 4H), 2.15 (s, 3H), 2.08 (quint, J = 7.5 Hz, 2H), 1.53 (sext, J = 7.2 Hz, 2H), 0.89 (t, J = 7.2 Hz, 3H).
Example 5(15) 4-(4,5-dimethyl-2-[N-(5-methyl-2-furylsulfonyl)-N-(2-methyl-2-propenyl)amino]phenoxy TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : 8 8.00-7.93 (m, 2H), 7.44 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 6.75 (d, J
= 3.3 Hz, 1H), 6.69 (s, 1H), 5.96 (m, 1H), 4.94 (s, 2H), 4.77 (s, 2H), 4.27 (s, 2H), 2.38 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H), 1.78 (s, 3H).
Example 5(16) 4-(6-(N-(5-methyl-2-furylsulfonyl)-N-(2-methyl-2-propenyl)amino]indan-5-yloxymethyl]
cinnamic acid / ~ COOH
~I
/ N ~~5'''O 0 H3C' J
~CHZ
l23 methyl]-3-methylbenzoic acid TLC : Rf 0.61 (chloroform : methanol = 9 : 1)~
NMR : b 7.78 (d, J = 15.9 Hz, 1H), ?.56 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 6.76 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.94 (d, J = 3.0 Hz, 1H), 4.95 (brs, 2H), 4.77 (s, 2H), 4.384.18 (m, 2H), 2.90-2.75 (m, 4H), 2.14 (s, 3H), 2.07 (quint, J = 7.5 Hz, 2H), 1.78 (s, 3H).
Example 5(17) 4-[6-[N-cyclopropylmethyl-N-(5-methyh2-furylsulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.51 (chloroform : methanol = 9 : 1)~
NMR : 8 7.79 (d, J = 15.9 Hz, 1H), 7.55 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.15 (s, 1H), 6.?9 (s, 1H), 6.74 (d, J = 3.3 Hz, 1H), 6.47 (d, J = 15.9 Hz, 1H), 5.94 (d, J = 3.3 Hz, 1H), 4.9? (brs, 2H), 3.65-3.50 (m, 2H), 2.92-2.70 (m, 4H), 2.15 (s, 3H), 2.0$
(quint, J = 7.5 Hz, 2H), 1.00-0.85 (m, 1H), 0.45-0.36 (m, 2H), 0.20-0.05 (m, 2H).
Example 5(18) 4-[6-[N-(5-methyl-2-furylsulfonyl)-N-(2-propenyl)amino]indan-5-yloxymethyl]cinnamic acid / ~ COOH
.~ 0 / N~O 0 TLC : Rf 0.57 (chloroform : methanol = 9 : 1)~
NMR : b 7.79 (d, J = 15.9 Hz, 1H), 7.56 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.07 (s, 1H), 6.78 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.4? (d, J = 15.9 Hz, 1H), 5.96 (d, J = 3.3 Hz, 1H), 5.96-5.77 (m, 1H), 5.13-5.03 (m, 2H), 4.97 (s, 2H), 4.42-4.20 (m, 2H)>
2.90-2:80 (m, 4H), 2.16 (s, 3H), 2.07 (quint, J = 7.5 Hz, 2H).
Example 5(19) 3-methyl-4-[6-[N-(5-methyl-2-furylsulfonyl)-N-propylamino]indan-5-yloxymethyl]benzoic cinnamic acid aCld O \
N%~~O 0 , TLC ~ Rf 0.40 (chloroform : methanol = 10 : 1)~
NMR = b 7.95 (d, J = 7.8 Hz, 1H), 7.93 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), ?.10 (s, 1H), 6.81 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 5.95 (dd, J = 3.3, 0.9 Hz, 1H), 4.96 (s, 2H), 3.76-3.4? (m, 2H), 2.92-2.82 (m, 4H), 2.37 (s, 3H), 2.13 (s, 3H), 2.15-2.03 (m, 2H), 1.60-1.47 (m, 2H), 0.89 (t, J
= 7.5 Hz, 3H).
Example 5(20) 3-methyl-4-(6-(N-(5-methyl-2-furylsulfonyl)-N-(2-propenyl)amino]indan-5-yloxymethyl]
TLC ~ Rf 0.41 (chloroform ~ methanol = 10 : 1);
NMR : 8 7.95 (d, J = 7.8 Hz, 1H), 7.94 (s, 1H), 7.47 (d, J = 7.8 Hz, 1H), 7.08 (s, 1H), 6.80 (s, 1H), 6.78 (d, J = 3.3 Hz, 1H), 5.97 (d, J = 3.3 Hz, 1H), 5.85 (m, 1H), 5.10 (dd, J = 16.8, 1.2 Hz, 1H), 5.05 (dd, J = 9.9, 1.2 Hz, 1H), 4.9? (s, 2H), 4.43-4.18 (m, 2H), 2.91-2.81 (m, 4H), 2.37 (s, 3H), 2.15 (s, 3H), 2.13-2.03 (m, 2H).
Example 5(21) 4-[4,5-dimethyl-2-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid H3C \ O \
H G ~ ~ N'S~O S

CH3 ~~

TLC ~ Rf 0.49 (dichloromethane : methanol = 10 ~ 1);
NMR : 8 7.94-7.90 (m, 2H), 7.31 (d, J = 9.0 Hz, 1H), 7.13 (s, 1H), 6.94 (m, 1H), 6.73 (s, 1H), 4.88 (s, 2H), 3.42 (s, 3H), 2.35 (s, 3H), 2.34 (d, J = 0.9 Hz, 3H), 2.24 (s, 3H), 2.19 (s, 3H).

benzoic acid Example 5(22) 4-[4,5-dimethyl-2-[N~ethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid TLC : Rf 0.49 (dichloromethane : methanol = 10 : 1)~
NMR : 8 7.96-7.90 (m, 2H), ?.32 (d, J = 8.1 Hz, 1H), ?.06 (s, 1H), 6.90 (m, 1H), 6.?4 (s, 1H), 4.87 (brs, 2H), 3.85 (br, 2H); 2.34 (s, 3H), 2.32 (d, J = 0.9 Hz, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 1.18 (t, J = ?.2 Hz, 3H).
Example 5(23) 4-[4, 5-dimethyl-2-[N-(4-methyl-2-thiazolylsulfonyl)-N-propylamino]phenoxymethyl]-3-TLC : Rf 0.49(dichloromethane : methanol = 10 : 1)~
NMR(DMSO-ds) : b 12.88 (s, 1H), 7.78-?.?2 (m, 2H), ?.49 (m, 1H), ?.25 (d, J =
7.8 Hz, 1H), ?.03 (s, 1H), 6.95 (s, 1H), 4.88 (br, 2H), 3.59 (br, 2H), 2.28 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.13 (s, 3H), 1.44-1.35 (m, 2H), 0.81 (t, J = 7.2 Hz, 3H).
Example 5(24) 4-[4, 5-dimethyl-2-[N-(4-methyl-2-thiazolylsulfonyl)-N-(2-propenyDamino]phenoxymethyl]-3-methylbenzoic acid H3C .,~ O
H3C~N~0 S
~H CH3 TLC : Rf 0.49 (dichloromethane : methanol = 10 : 1)~
NMR(DMSO-ds) : 8 12.88 (s, 1H), ?.78-?.?2 (m, 2H), ?.50 (s, 1H), ?.26 (d, J =
7.5 Hz, 1H), ?.O1 (s, 1H), 6.95 (s, 1H), 5.74 (m, 1H), 5.09 (d, J = 1?.1 Hz, 1H), 5.04 (d, J = 9.9 Hz, 1H), methylbenzoic acid r 4.89 (br, 2H), 4.27 (br, 2H) , 2.29 (s, 3H), 2.21 (s, 3H), 2.18 (s, 3H), 2.12 (s, 3H).
Example 5(25) 4-[2-[N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino-4,5-dimethyl]phenoxy methyl]-3-methylbenzoic acid TLC : Rf 0.49 (dichloromethane : methanol = 10 : 1)~
NMR(DMSO-ds) : b 12.87 (br, 1H), ?.78-7.72 (m, 2H), ?.48 (s, 1H), 7.25 (d, J =
?.5 Hz, 1H), 7.03 (s, 1H), ?.00 (s, 1H), 4.90 (br, 2H), 3.45 (br, 2H), 2.2? (s, 3H), 2.23 (s, 3H), 2.1? (s, 3H), 2.14 (s, 3H), 0.82 (m, 1H), 0.38-0.30 (m, 2H), 0.10-0.02 (m, 2H).
Example 5(26) 4- [4, 5-dimethyl-2- [N-(2-hydroxy- 2-methylpropyl)-N-(4-methyl-2-thiazolylsulfonyD amino]
phenoxymethyl]-3-methylbenzoic acid TLC : Rf 0.49 (dichloromethane : methanol = 10 : 1)~
NMR : b 7.99-7.94 (m, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.04 (m, 1H), 6.?9 (s, 1H), 6.?7 (s, 1H), 5.06 (d, J = 12.3 Hz, 1H), 4.95 (d, J = 12.3 Hz, 1H), 3.95 (d, J = 15.3 Hz, 1H), 3.73 (d, J =
15.3 Hz, 1H), 2.420 (s, 3H), 2.41? (s, 3H), 2.23 (s, 3H), 2.11 (s, 3H), 1.25 (s, 3H), 1.21 (s, 3H).
Example 5(27) 4-[4,5-dimethyl-2-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]benzoic acid / COOH
H3C ~ O
HsC ~ / N.~O O
~ CH3 TLC : Rf 0.46 (chloroform : methanol = 9 : 1)~

NMR : S 8.11 (d, J = 8.4 Hz, 2H), 7.42 (d, J = 8.4 Hz, 2H), 7.08 (s, 1H), 6.79 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 5.99-5.95 (m, 1H), 5.03 (s, 2H), 3.31 (s, 3H), 2.22 (s, 3H), 2.18 (s, 3H), 2.16 (s, 3H).
Example 5(28) 4-(4,5-dimethyl-2-[N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]benzoic acid COOH
H3C ~ O
H C~N~O O
s ' ~ CH3 ~CH3 TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : 8 8.10 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.71 (s, 1H), 5.965.93 (m, 1H), 5.02 (s, 2H), 3.83-3.65 (m, 2H), 2.23 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H).
Example 5(29) 4-(4,5-dimethyl-2-(N-(5-methyl-2-furylsulfonyl)-N-propylamino]phenoxymethyl]benzoic acid TLC : Rf 0.43 (chloroform : methanol = 9 : 1)~
NMR : s 8.11 (d, J = 8.4 Hz, 2H), 7.43 (d, J = s.4 Hz, 2H), 7.02 (s, 1H), s.74 (d, J = 3.o Hz, 1H), 6.70 (s, 1H), 5.96-5.93 (m, 1H), 5.01 (s, 2H), 3.75-3.53 (m, 2H), 2.22 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 1.60-1.46 (m, 2H), 0.90 (t, J = 7.2 Hz, 3H).
Example 5(30) 4-C6-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]indan~5-yloxymethyl]benzoic acid t28 COOH
O
~N~O S
/%H3C ~~

CHz TLC : Rf 0.36 (dichloromethane : methanol = 19 : 1)~
NMR : 8 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.14 (s, 1H), 6.92 (brs, 1H), 6.74 (s, 1H), 5.10-4.70 (brs, 2H), 4.80 (brs, 2H), 4.60-4.20 (brs, 2H), 2.88-2.82 (m, 4H), 2.32 (d, J
= 0.9 Hz, 3H), 2.07 (m, 2H), 1.83 (s, 3H).
Example 5(31) 4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yloxymethyl]benzoic acid COOH
O
//NCO S

z TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1)~
NMR : b 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.? Hz, 2H), ?.13 Cs, 1H), 6.93 (brs, 1H), 6.76 (s, 1H), 5.89 (ddt, J = 17.1, 10.2, 6.3 Hz, 1H), 5.17-5.06 (m, 2H), 4.92 (brs, 2H), 4.70-4.10 (brs, 2H), 2.89-2.83 (m, 4H), 2.34 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H).
Example 5(32) 4-[6-[N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
benzoic acid TLC : Rf 0.36 (dichloromethane : methanol = 19 : 1) NMR : b 8.10 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.22 (s, 1H), 6.89 (brs, 1H), 6.78 (s, 1H), 5.10-4.70 (m, 2H), 3.90-3.50 Cm, 2H), 2.90-2.85 (m, 4H), 2.32 (d, J =
0.9 Hz, 3H), 2.09 (m, 2H), 1.00 (m, 1H), 0.43 (m, 2H), 0.20 (brs, 2H).

Example 5(33) 4-[3-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]-methylbenzoic acid / ~ \ O
\ / N.S''O O

H3C"CH3 TLC : Rf 0.52 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 7.92-7.80 (m, 3H), 7.77 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.63 (s, 1H), 7.60 (s, 1H), 7.57-7.50 (m, 1H), 7.45-7.36 (m, 1H), 6.95 (d, J =
3.3 Hz, 1H), 6.29 (d, J = 3.3 Hz, 1H), 5.26 and 5.24 (each d, J = 13.5 Hz, each 1H), 4.34 (sept, J = 6.6 Hz, 1H), 2.42 (s, 3H), 2.34 (s, 3H), 1.06 and 1.00 (each d, J = 6.6 Hz, each 3H).
Example 5(34) 4-(3-(N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]-3-methylbenzoic acid \ / N~0 O

H3C' J
'C~Hg TLC : Rf 0.50 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 7.88 (d, J = 7.8 Hz, 1H), 7.86-7.74 (m, 4H), 7.59 (s, 1H), ?.56-7.36 (m, 3H), 6.86 (d, J = 3.3 Hz, 1H), 6.19 (d, J = 3.3 Hz, 1H), 5.40-4.90 (br, 2H), 3.4? (brd, J = 6.9 Hz, 2H), 2.39 (s, 3H), 2.12 (s, 3H), 1.65-1.50 (m, 1H), 0.83 (brd, J = 6.3 Hz, 6H).
Example 5(35) 4-[3-(N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]cinnamic acid / \ COOH
/ \ 0 \
\ I / N:~O 0 H3C"CH3 TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.87 (d, J = 7.8 Hz, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.73 (d, J = 8.4 Hz, 2H), 7.67-7.46 (m, 6H), 7.44-7.34 (m, 1H), 6.94 (d, J = 3.3 Hz, 1H), 6.56 (d, J = 15.9 Hz, 1H), 6.28 (d, J = 3.3 Hz, 1H), 5.2? and 5.21 (each d, J = 13.2 Hz, each 1H), 4.36 (sept, J =
6.6 Hz, 1H), 2.33 (s, 3H), 1.08 and 1.03 (each d, J = 6.6 Hz, each 3H).
Example 5(36) 4-(3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]cinnamic acid TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.88 (d, J = 8.4 Hz, 1H), 7.81 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 7.8 Hz, 2H), 7.61 (d, J = 15.9 Hz, 1H), 7.55-?.34 (m, 2H), 7.50 (s, 1H), 7.44 (d, J = 7.8 Hz, 2H), 6.82 (d, J = 3.6 Hz, 1H), 6.56 (d, J = 15.9 Hz, 1H), 6.16 (d, J = 3.6 Hz, 1H), 5.40-4.90 (br, 2H), 3.49 (d, J = 6.6 Hz, 2H), 2.13 (s, 3H), 1.64-1.48 (m, 1H), 0.85 (d, J = 6.6 Hz, 6H).
Example 5(37) 4-[3-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]-methylcinnamic acid H3C / \ COOH
/ I ~. O \
\ / N%

H3C"CH3 TLC : Rf 0.46 (chloroform : methanol = 9 : 1);
NMR(DMSO-ds) : 8 7.87 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.64-7.48 (m, 7H), 7.44-7.36 (m, 1H), 6.93 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 15.9 Hz, 1H), 6.29 (d, J = 3.6 Hz, 1H), 5.23 and 5.18 (each d, J = 14.4 Hz, each 1H), 4.33 (sept, J = 6.6 Hz, 1H), 2.39 (s, 3H), 2.34 (s, 3H), 1.06 and 1.00 (each d, J = 6.6 Hz, each 3H).
Example 5(38) 4-[3-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]naphthalen-2-yloxymethyl]-3-methylcinnamic acid H3C / ~ COOH
/ \ O \ I
\ I / N~O O
cH3 H3C\ J
'C~H3 TLC : Rf 0.46 (chloroform : methanol = 9 : 1);
NMR(DMSO-ds) : b 7.88 (d, J = 8.1 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.78 (s, 1H), 7.62-7.4? (m, 5H), 7.44-7.35 (m, 2H), 6.84 (d, J = 3.6 Hz, 1H), 6.54 (d, J = 16.2 Hz, 1H), 6.20 (d, J = 3.6 Hz, 1H), 5.35-4.90 (br, 2H), 3.4? (d, J = 7.2 Hz, 2H), 2.35 (s, 3H), 2.14 (s, 3H), 1.63-1.49 (m, 1H), 0.83 (d, J = 6.3 Hz, 6H).
Example 5(39) 4- [3- [N-isob utyl-N- [2-(4-methylthiazolyl) sulfonyl] amino] nap hthalen-2-yloxymethyl]-3-TLC : Rf 0.71 (ethyl acetate : methanol = 9 : 1)~
NMR : b 7.82-7.? 1 (m, 4H), 7.51-7.46 (m, 1H), ?.43-7.32 (m, 4H), 7.21 (s, 1H), 6.95 (s, 1H), 6.48 (d, J = 16.2 Hz, 1H), 5.04 and 4.91 (each br-m, total 2H), 3.83-3.60 (br-m, 2H), 2.38 (s, 3H), 2.34 (s, 3H), 1.81-1.67 (m, 1H), 0.95 (br-s, 6H).
Example 5(40) 4-[3-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]naphthalen-2-yloxymethyl]-3-TLC : Rf 0.71 (ethyl acetate : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.88-7.83 (m, 2H), 7.65-7.47 (m, 8H), 7.42-7.3? (m, 1H), 6.55 (d, J =
15.9 Hz, 1H), 5.16 (s, 2H), 4.62-4.49 (m, 1H), 2.42 (s, 3H), 2.36 (s, 3H), 1.13 (d, J = 6.6 Hz, 3H), 1.03 (d, J = 6.6 Hz, 3H).

methylbenzoic acid methylbenzoic acid Example 5(41) 4-[6-[N-ethyl-N-(4-methyl-2~thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1) NMR : 8 8.10 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.14 (s, 1H), 6.90 (brs, 1H), 6.79 (s, 1H), 4.92 (m, 2H), 4.20-3.60 (m, 2H), 2.90-2.83 (m, 4H), 2.33 (s, 3H), 2.09 (m, 2H), 1.20 (t, J = 7.2 Hz, 3H).
Example 5(42) 4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-propylamino]indan-5-yloxymethyl]benzoic acid COOH
O
N:S~O S

TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1)~
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.15 (s, 1H), 6.90 (brs, 1H), 6.78 (s, 1H), 5.10-4.70 (m, 2H), 4.00-3.50 (m, 2H), 2.90-2.84 (m, 4H), 2.32 (s, 3H), 2.09 (m, 2H), 1.58 (m, 2H), 0.93 (t, J = ?.5 Hz, 3H).
Example 5(43) 4-[4,5-dimethyl-2-(N-(5-methyl-2-furylsulfonyl)-N-(2-propenyl)amino]phenoxymethyl]
benzoic acid COOH
H3C ~ O
H C ( ~ N'~O O
3 ~ ~ CH3 CHZ
TLC : Rf 0.44 (chloroform : methanol = 9 : 1);
NMR : b 8.12 (d, J = 8.4 Hz, 2H>, 7.43 (d, J = 8.4 Hz, 2H), 7.01 (s, 1H>, 6.77 (d, J = 3.0 Hz, 1H), 6.68 (s, 1H), 5.99-5.94 (m, 1H), 5.92-5.75 (m, 1H), 5.16-5.03 (m, 2H), 5.02 (s, 2H), 4.42-4.20 (m, 2H), 2.21 (s, 3H), 2.17 (s, 3H), 2.15 (s, 3H).

Example 5(44) 4-(4,5-dimethyl-2-[N-methyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid H3C ~ O
H3C~N~0 O

TLC : Rf 0.42 (chloroform : methanol = 9 : 1);
NMR : b 7.98-7.91 (m, 2H), 7.43 (d, J = 8.7 Hz, 1H), 7.08 (s, 1H), 6.?9 (d, J
= 3.3 Hz, 1H), 6.?4 (s, 1H), 5.98 (m, 1H), 4.98 (s, 2H), 3.30 (s, 3H), 2.38 (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.15 (s, 3H).
Example 5(45) 4-(4,5-dimethyl-2-(N-ethyl-N-(5-methyl-2-furylsulfonyl)amino]phenoxymethyl]-3-methylbenzoic acid H,c ~ o ~~1 H3C~N~0 O

~CH3 TLC : Rf 0.42 (chloroform : methanol = 9 : 1);
NMR : b 7.97-?.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.01 (s, 1H), 6.76 (s, 1H), 6.75 (d, J =
3.3 Hz, 1H), 5.95 (m, 1H), 4.96 (s, 2H), 3.82-3.66 (br, 2H), 2.37 (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 1.14 (t, J = 7.2 Hz, 3H).
Example 5(46) 4-(4,5-dimethyl-2-(N-(5-methyl-2-furylsulfonyl)-N-propylamino]phenoxymethyl]-3-TLC : Rf 0.42 (chloroform : methanol = 9 : 1);
NMR : 8 7.98-?.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.02 (s, 1H), 6.?8-6.70 (m, 2H), 5.95 (m, 1H), 4.95 (s, 2H), 3.? 1-3.55 (br, 2H), 2.3? (s, 3H), 2.24 (s, 3H), 2.19 (s, 3H), 2.12 (s, 3H), 1.60-1.44 (m, 2H), 0.88 (t, J = ?.5 Hz, 3H).

methylbenzoic acid , f Example 5(47) 4- [4, 5-dimethyl-2-(N-(5-methyl-2-furylsulfonyl)-N-(2-propenyl)amino]phenoxymethyl]-3-TLC : Rf 0.45 (chloroform : methanol = 9 : 1).
NMR : 8 7.98-7.90 (m, 2H), 7.45 (d, J = 8.1 Hz, 1H), 7.01 (s, 1H), 6.77 (d, J
= 3.3 Hz, 1H), 6.71 (s, 1H), 5.96 (m, 1H), 5.83 (m, 1H), 5.15-5.00 (m, 2H), 4.96 (s, 2H), 4.40-4.20 (br, 2H), 2.38 (s, 3H), 2.23 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H).
Example 5(48) 4-[4,5-dimethyl-2-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyDamino]
phenoxymethyl]-3-methylbenzoic acid H3C ~ O
H C , ~ N'S~0 O
a ~ / CH3 HO~
H3C~CH

TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : 8 8.00-7.94 (m, 2H), 7.53 (d, J = 7.8 Hz, 1H), 6.80 (s, 1H), 6.77 (s, 1H), 6.75 (d, J =
3.3 Hz, 1H), 6.01 (m, 1H), 5.08 (d, J = 12.3 Hz, 1H), 5.00 (d, J = 12.3 Hz, 1H), 3.84 (d, J =
14.4 Hz, 1H), 3.56 (d, J = 14.4 Hz, 1H), 2.42 (s, 3H), 2.23 (s, 3H), 2.21 (s, 3H), 2.14 (s, 3H), 1.25 (s, 3H), 1.18 (s, 3H).
Example 5(49) 4-(6-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.34 (dichloromethane : methanol = 19 : 1);
NMR : 8 8.11 (d, J = 8.7 Hz, 2H), 7.35 (d, J = 8.7 Hz, 2H), 7.20 (s, 1H), 6.94 (brs, 1H), 6.?8 methylbenzoic acid (s, 1H), 4.92 (brs, 2H), 3.44 (s, 3H), 2.89-2.83 (rn, 4H), 2.35 (d, J = 0.9 Hz, 3H), 2.08 (m, 2H).
Example 5(50) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]-3-methylbenzoic acid O
~'''~~/ N'S~O 0 HO~
H3C~CH3 , TLC : Rf 0.32 (chloroform : methanol = 10 : 1)~
NMR : 8 ?.97 (d, J = 7.8 Hz, 1H), 7.95 (s, 1H), 7.53 (d, J = 7.8 Hz, 1H), 6.89 (s, 1H), 6.86 (s, 1H), 6.75 (d, J = 3.3 Hz, 1H), 6.01 (dd, J = 3.3, 0.9 Hz, 1H), 5.08 (d, J =
12.9 Hz, 1H), 5.02 (d, J = 12.9 Hz, 1H), 3.85 (d, J = 14.7 Hz, 1H), 3.58 (d, J = 14.7 Hz, 1H), 2.90-2.78 (m, 4H), 2.42 (s, 3H), 2.21 (s, 3H), 2.13-2.01 (m, 2H), 1.25 (s, 3H), 1.18 (s, 3H).
Example 5(51) 3-methyl-4-[6-[N-methyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b ?.60-7.50 (m, 3H), 7.49 (d, J = 8.1 Hz, 1H), 7.20 (d, J = 8.1 Hz, 1H), ?.09 (s, 1H), 7.04 (s, 1H), 6.53 (d, J = 15.9 Hz, 1H), 4.87 (br, 2H), 3.24 (s, 3H), 2.85 (t, J =
7.4 Hz, 2H), 2.77 (t, J = ?.4 Hz, 2H), 2.25 (s, 3H), 2.23 (s, 3H), 2.10-1.95 (m, 2H).
Example 5(52) 4-[6-[N-ethyl-N-(4-methyl-2~thiazolylsulfonyl)amino]indan-5-yloxymethyl]-3-methylcinnamic acid cinnamic acid . .
H3C / ~ COOH
O
N.S~O S
H3~J

TLC : Rf 0.44 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : b 7.55 (d, J = 16.0 Hz, 1H), 7.50-7.40 (m, 3H), ?.19 (d, J =
8.1 Hz, 1H), ?.09 (s, 1H), 6.98 (s, 1H), 6.52 (d, J = 16.0 Hz, 1H), 4.84 (br, 2H), 3.66 (br, 2H), 2.85 (t, J =
7.4 Hz, 2H), 2.?7 (t, J = 7.4 Hz, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.10-1.90 (m, 2H), 1.01 (t, J
= 7.0 Hz, 3H).
Example 5(53) 4- [2- [N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxy methyl]benzoic acid TLC : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : 8 8.11 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.09 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.70 (s, 1H), 5.96-5.92 (m, 1H), 5.02 (brs, 2H), 3.68-3.40 (m, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.14 (s, 3H), 1.03-0.86 (m, 1H), 0.46-0.35 (m, 2H), 0.21-0.06 (m, 2H).
Example 5(54) 4-[4,5-dimethyl-2-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl)amino]
phenoxymethyl]benzoic acid TLC : Rf 0.34 (chloroform : methanol = 9 : 1)~
NMR : b 8.13 (d, d = 8.4 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 6.81 (s, 1H), 6.?5 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.03-5.98 (m, 1H), 5.22-4.96 (m, 2H), 3.92-3.76 and 3.64-3.48 (each m, total 2H), 2.21 (s, 6H), 2.13 (s, 3H), 1.28 and 1.19 (each brs, each 3H).

Example 5(55) 3-methyl-4-[6-[N-(2-methyl-2-propenyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-TLC : Rf 0.60 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 15.9 Hz, 1H), 7.42-7.34 (m, 2H), 7.27-7.22 (m, 1H), 7.12 (s, 1H), 6.92 (d, J = 0.9 Hz, 1H), 6.78 (s, 1H), 6.4? (d, J = 15.9 Hz, 1H), 4.90-4.72 (m, 4H), 4.50-4.14 (m, 2H), 2.92-2.80 (m , 4H), 2.31 (s, 6H), 2.18-2.00 (m, 2H), 1.81 (s, 3H).
Example 5(56) 4-[6-[N-cyclopropylmethyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]-3-methylcinnamic acid H3C / ~ COON
O
/ NCO S

TLC : Rf 0.60 (chloroform : methanol = 9 : 1)~
NMR : 8 ?.77 (d, J = 15.9 Hz, 1H), 7.42-7.38 (m, 2H), 7.30-7.25 (m, 1H), 7.21 (s, 1H), 6.89 (d, J = 0.9 Hz, 1H), 6.82 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 4.92-4.64 (m, 2H), 3.84'3.42 (m, 2H), 2.95-2.76 (m, 4H), 2.31 (s, 3H), 2.31 (s, 3H), 2.18-2.02 (m, 2H), 1.08-0.90 (m, 1H), 0.46-0.40 (m, 2H), 0.26-0.08 (m, 2H).
Example 5(57) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(5-methyl-2-furylsulfonyl)amino]indan-5-TLC : Rf 0.46 (chloroform : methanol = 9 : 1)~
NMR : 8 7.78 (d, J = 15.9 Hz, 1H), 7.58 (d, J = 8.1 Hz, 2H), 7.47 (d, J = 8.1 Hz, 2H), 6.85 (d, l38 yloxymethyl]cinnamic acid yloxymethyl]cinnamic acid J = 3.6 Hz, 2H), 6.?4 (d, J = 3.6 Hz, 1H), 6.4? (d, J = 15.9 Hz, 1H), 6.01 (d, J = 2.1 Hz, 1H), 5.10 (d, J = 12.0 Hz, 1H), 4.99 (d, J = 12.0 Hz, 1H), 3.85 (d, J = 14.1 Hz, 1H), 3.53 (d, J =
14.1 Hz, 1H), 2.90-2.7? (m, 4H), 2.23 (s, 3H), 2.0? (m, 2H), 1.2? (s, 3H), 1.16 (s, 3H).
Example 5(58) 3-methyl-4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-(2-propenyl)amino]indan-5-yloxymethyl]cinnamic acid H3C / \ CO
\ 0 \
/ N~O S

TLC : Rf 0.42 (dichloromethane ~ methanol = 10 : 1)~
NMR : 8 ?.76 (d, J = 15.9 Hz, 1H), ?.42-?.36 (m, 2H), 7.28 (m, 1H), ?.11(s, 1H), 6.92 (m, 1H), 6.80 (s, 1H), 6.4? (d, J = 15.9 Hz, 1H), 5.8? (m, 1H), 5.11 (dd, J =
1?.1, 1.5 Hz, 1H), 5.0? (dd, J = 8.7, 1.5 Hz, 1H), 4.83 (br, 2H), 4.32 (br, 2H), 2.92-2.82 (m, 4H), 2.33 (d, J =
0.6 Hz, 3H), 2.32 (s, 3H), 2.16-2.04 (m, 2H).
Example 5(59) 4-[6-[N-(2-hydroxy-2-methylpropyD-N-(4-methyl-2-thiazolylsulfonyl)amino]indam5-yloxymethyl]-3-methylcinnamic acid H3C / \ COOH
\. O w, i / N~O S
H3C~
HsC ' H CH3 O
TLC ~ Rf 0.42 (dichloromethane : methanol = 10 : 1)~
NMR : 8 ?.76 (d, J = 15.9 Hz, 1H), ?.44-7.38 (m, 3H), 7.05 (m, 1H), 6.88 (s, 1H), 6.82 (s, 1H), 6.46 (d, J = 15.9 Hz, 1H), 5.03 (d, J = 12.0 Hz, 1H), 4.93 (d, J = 12.0 Hz, 1H), 3.96 (d, J = 14.4 Hz, 1H), 3 .69 (d, J = 14.4 Hz, 1H), 2.87 (t, J = 7.5 Hz, 2H), 2.77 (t, J = ?.5 Hz, 2H), 2.43 (s, 3H), 2.40 (s, 3H), 2.13-2.00 (m, 2H), 1.23 (s, 3H), 1.18 (s, 3H).
Example 5(60) 4-[4,5-dimethyl-2-[N-cyclopropylmethyl-N-(5-methyl-2-furylsulfonyl)amino]
phenoxymethyl]-3-methylbenzoic acid r co _ J 1 ~ cH~
TLC : Rf 0.45 (chloroform : methanol = 9 : 1)~
NMR : 8 8.00-7.92 (m, 2H), ?.47 (d, J = ?.8 Hz, 1H), 7.09 (s, 1H), 6.78-6.?1 (m, 2H), 5.94 (m, 1H), 4.96 (s, 2H), 3.63-3.45 (br, 2H), 2.3? (s, 3H), 2.25 (s, 3H), 2.19 (s, 3H), 2.13 (s, 3H), 0.95 (m, 1H), 0.44-0.35 (m, 2H), 0.15-0.22 (m, 2H).
Example 5(61) -3-methyl-4-[6-[N-(4-methyl-2-thiazolylsulfonyl)-N-propylamino]indan-5-yloxymethyl]
TLG : Rf 0.41 (chloroform : methanol = 9 : 1)~
NMR : 8 7.76 (d, J = 16.2 Hz, 1H), 7.44-7.34 (m, 2H), 7.32-7.20 (m, 1H), 7.13 (s, 1H), 6.90 (s, 1H), 6.82 (s, 1H), 6.46 (d, J = 16.2 Hz, 1H), 4.90- 4.70 (m, 2H), 3.90-3.50 (m, 2H), 2.89 (t, J = 7.5 Hz) and 2.86 (t, J = 7.5 Hz) total 4H, 2.31 (s) and 2.30 (s) total 6H, 2.09 (quint, J = 7.5 Hz, 2H), 1.58 (m, 2H), 0.91 (t, J = 7.5 Hz, 3H).
Example 5(62) 4-[6-[N-(2-hydroxy-2-methylpropyl)-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-yloxymethyl]benzoic acid J

TLC : Rf 0.29 (dichloromethane : methanol = 19 : 1).
NMR : b 8.13 (d, J = 7.8 Hz, 2H), 7.48 (d, J = 7.8 Hz, 2H), 7.02 (brs, 1H), 6.90 (s, 1H), 6.83 (s, 1H), 5.12 (d, J = 12.6 Hz, 1H), 4.95 (d, J = 12.6 Hz, 1H), 3.96 (d, J =
15.0 Hz, 1H), 3.77 (d, J = 15.0 Hz, 1H), 2.88-2.75 (m, 4H), 2.42 (s, 3H), 2.06 (m, 2H), 1.29 (s, 3H), 1.22 (s, 3H).

cinnamic acid Example 6 3-methyl-4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]
To a suspension of the compound prepared in example 2(74) (213 g) in ethanol (2 L), 5N aqueous solution of sodium hydroxide (74.7 ml) was added. The mixture was stirred for 0.5 hour at 80 °C. The reaction solution was filtered under heating to remove the insolubles, then the mixture was cooled, and the precipitate was collected. The mother liquor was concentrated and the residue was dissolved in ethanol (500 ml) and water (25 ml) under heating. The mixture was filtered under heating to remove the insolubles, then the mixture was cooled, and the precipitate was collected.
Under heating, all collected solids were dried under reduced pressure to give the compound of the present invention (165 g) having the following physical data.
TLC : Rf 0.52 (chloroform : methanol = 9 : 1)~
NMR(DMSO-ds) : 8 7.49 (s, 1H), 7.29 (s, 1H), 7.26 (d, J = 8.1 Hz, 1H), 7.10-7.00 (m, 4H), 6.38 (d, J = 15.9 Hz, 1H), 4.89 (br-d, J = 10.5 Hz, 1H), 4.63 (br-d, J = 10.5 Hz, 1H), 3.55-3.25 (m, 2H), 2.85 (t, J = 7.2 Hz, 2H), 2.?8 (t, J = 7.2 Hz, 2H), 2.21 (s, 3H), 2.18 (s, 3H), 2.10-1.90 (m, 2H), 1.60-1.45 (m, 1H), 1.00-0.70 (m, 6H).
Example 6(1) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]
benzoic acid sodium salt COONa F3C ~ O
/ N~O O

H3C"CH3 TLC : Rf 0.50 (chloroform : methanol = 9 : 1)~
NMR : 8 7.84 (d, J = 8.1 Hz, 2H), 7.20-6.95 (m, 5H), 6.65 (d, J = 3.3 Hz, 1H), 5.84 (d, J =
3.3 Hz, 1H), 4.75 (brs, 2H), 4.30-4.10 (m, 1H), 2.12 (s, 3H), 0.86 (brd, J =
3.9 Hz, 6H).
Example 6(2) 4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyDamino]-4,5-dimethylphenoxymethyl]benzoic cinnamic acid sodium salt acid sodium salt COONa H3C ~ O
H C I ~ N'~O O
~CHg H3C' J
~CH3 TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR : s 7.83 (d, J = 8.1 Hz, 2H), 7.00 (d, J = 8.1 Hz, 2H), 6.88 (s, 1H), 6.59 (s, 1H), 6.54 (d, J = 3.0 Hz, 1H), 5.74 (s, 1H), 4.90-4.50 (m, 2H), 3.33 (brd, J = 6.3 Hz, 2H), 2.09 (s, 3H), 2.05 (s, 3H), 1.93 (s, 3H), 1.60-1.40 (m, 1H), 0.73 (d, J = 6.3 Hz, 6H).
Example 6(3) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4,5-dimethylphenoxy methyl]benzoic acid sodium salt TLC : Rf 0.41 (chloroform : methanol = 9 : 1)>
NMR(DMSO-ds) : 8 7.70 (s, 1H), 7.66 (d, J = 7.8 Hz, 1H), ?.13 (d, J = 7.8 Hz, 1H), 6.99 (s, 1H), 6.91 (s, 1H), 6.76 (d, J = 3.3 Hz, 1H), 6.14 (d, J = 3.3 Hz, 1H), 4.88 (brs, 2H), 3.36 (d, J = 6.9 Hz, 2H), 2.26 (s, 3H), 2.22 (s, 3H), 2.14 (s, 3H), 2.10 (s, 3H), 1.60-1.45 (m, 1H), 0.81 (brd, J = 6.3 Hz, 6H). .
Example 6(4) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid TLC : Rf 0.40 (chloroform : methanol = 9 : 1)~
NMR(CDaOD) : 8 7.91 (d, J = 8.1 Hz, 2H), 7.19 (s, 1H), 7.18 (d, J = 8.1 Hz, 2H), ?.13 (s, 1H), 6.93 (s, 1H), 5.00-4.80 (m, 1H), 4.65-4.58 (m, 1H), 3.65-3.48 (m, 2H), 2.95-2.80 (m, 4H), 2.21 (d, J = 0.9 Hz, 3H), 2.09 (quint, J = 7.5 Hz, 2H), 1.66 (m, 1H), 1.03-0.85 (m, 6H).

sodium salt Example 6(5) 4-[6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid potassium salt vN
l'~CH3 ~S
TLC : Rf 0.37 (chloroform : methanol = 9 : 1)~
NMR.(DMSO-dc~ : 8 7.81 (d, J = 8.0 Hz, 2H), 7.4? (q, J = 0.4 Ha, 1H), 7.06 (d, J = 8.0 Hz, 1H), 7.03 (s, 2H), 6.95 (s, 1H), 5.104.80 (m, 1H), 4.80'4.50 (m, 1H), 3.43 (brs, 2H), 2.80 (q, J = ?.0 Hz, 4H), 2.23 (d, J = 0.4 Hz, 3H), 2.01 (qn, J = 7.0 Hz, 2H), 1.53 (sept, J = 6.6 Hz, 1H), 0.85 (brs, 6H).
Example 6(6) 4-[6-[N-isobutyl-N-(5~methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl)cinnamic acid sodium salt °:'s''° 0 J I / cH3 TLC : Rf 0.51 (chloroform : methanol = 9 : 1)~
NMR : S 7.37 (d, J = 15.9 Hz, 1H), 7.17 (d, J = 7.5 Hz, 2H), 7.10-6.90 (m, 3H), 6.67 (s, 1H), 6.55 (s, 1H), 6.45 (d, J = 15.9 Hz, 1H), 5.74 (s, 1H), 4.80-4.45 (m, 2H), 3.35 (d, J = 6.3 Hz, 2H), 2.85-2.55 (m, 4H), 2.10-1.80 (m, 5H), 1.65-1.40 (m, 1H), 0.74 (brs, 6H).
Example 6(7) 3-methyl-4-[6-[N-isobutyl-N-(5-methyl-2-furylaulfonyl)amino]indan-5-yloxymethyl]
TLC : Rf 0.60 (chloroform : methanol = 9 : 1)~
NMR(CD30D) : 8 7.78 (s) and 7.75 (d, J = 8.1 Hz) total 2H, 7.24 (d, J = 8.1 Hz, 1H), 7.07 (s, benzoic acid sodium salt . ' 1H), 6.97 (s, 1H), 6.64 (d, J = 3.3 Hz, 1H), 6.03 (dd, J = 3.3, 0.9 Hz, 1H), 5.08-4.?5 (m, 2H), 3.48 (d, J = 7.5 Hz, 2H), 2.94-2.80 (m, 4H), 2.32 (s, 3H), 2.15-2.00 (m) and 2.04 (s) total 5H, 1.87 (m, 1H), 0.98-0.80 (m, 6H).
Example 6(8) 4-[6-[N-isopropyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid potassium salt / ~ COOK
O ~ I
/ N~O N
~~CH3 H3C~CH
TLC : Rf 0.36 (chloroform : methanol = 9 : 1);
NMR : s 7.27 (d, J = 15.9 Hz, 1H), 7.21 (d, J = 7.5 Hz, 2H), s.98 (d, J = 7.5 Hz, 2H), s.84 (s, 1H), 6.78 (s, 1H), 6.?0 (s, 1H), 6.41 (d, J = 15.9 Hz, 1H), 4.70-4.40 (m, 3H), 2.85-2.60 (m, 4H), 2.24 (s, 3H), 2.05-1.90 (m, 2H), 1.01 (d, J = 6.6 Hz, 3H), 0.95 (d, J =
6.6 Hz, 3H).
Example 6(9) 4-[2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]benzoic acid potassium salt COOK
HOC ~ O
H C I / N'S/O N

TLC : Rf 0.32 (chloroform : methanol = 9 : 1)~
NMR : 8 7.82 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 3.0 Hz, 1H), 7.15 (d, J = 3.0 Hz, 1H), 6.94 (s, 1H), 6.89 (d, J = 8.1 Hz, 2H), 6.56 (s, 1H), 4.70-4.55 (m, 1H), 4.45-4.25 (m, 1H), 3.60-3.30 (m, 2H), 2.09 (s, 6H), 1.60-1.45 (m, 1H), 0.78 (brs, 3H), 0.72 (brs, 3H).
Example 6(10) 3-methyl-4-(2-[N-isobutyl-N-(2-thiazolylsulfonyl)amino]-4,5-dimethylphenoxymethyl]
benzoic acid sodium salt H3G / COONa H3C ~ 0 H C ~ ~ N'S/O N

TLC : Rf 0.37 (chloroform : methanol = 10 : 1)~
NMR(DMSO-ds) : 8 7.98 (d, J = 3.0 Hz, 1H), 7.82 (d, J = 3.0 Hz, 1H), ?.64 (s, 1H), ?.60 (d, J = 7.8 Hz, 1H), 6.99 (d, J = ?.8 Hz, 1H), 6.9? (s, 1H), 6.91 (s, 1H), 5.00-4.54 (m, 2H), 3.42 (d, J = 6.3 Hz, 2H), 2.20 (s, 3H), 2.20 (s, 3H), 2.11 (s, 3H), 1.50 (m, 1H), 0.90-0.?3 (m, 6H).
Example 7 4-[5-trifluoromethyl-2-[N-(5-methyl-2-furylcarbonyl)~N-isopropylamino]phenoxymethyl]
By the same procedures as described in specification of WO 98/27053 as Example 59(2) using the corresponding compound, the title compound having the following physical data was obtained.
TLC : Rf 0.38 (chloroform : methanol = 10 : 1) NMR : s 7.?5 (d, J =15.9 Hz, 1H), ?.50 (d, J = s.1 Hz, 2H), ?.3?-?.ls (m, 5H), s.45 (d, J =
15.9 Hz, 1H), 5.98 (m, 1H), 5.81 (d, J = 3.3 Hz, 1H), 5.12-4.90 (m, 3H), 2.05 (s, 3H), 1.33-0396 (m, 6H).
Formulation example 1: preparation of capsules The following components were admixed and granulated in conventional method, and then they were filled in second hard capsules to obtain 100 capsules each containing 100 mg of active ingredient.
~ The compound A ............................................................
10.0 g ~ Lactose ......................................................................... 6.09 g ~ Microcrystalline cellulose ................................................
2.61 g ~ Low-substituted hydroxypropylcellulose ............................ 2.0 g ~ Hydroxypropylcellulose ...................................................
1.0 g cinnamic acid ~ light silicic anhydride...................................................... 0.1 g ~ Magnesium stearate .......................................................
0.2 g Formulation example 2: preparation of tablets The following components were admixed, granulated and punched out in conventional method and then they were coated to obtain film-coated 100 tablets each containing 100 mg of active ingredient.
~ The compound B ............................................................
10.0 g ~ Lactose ..........................................................................
5.88 g ~ Corn Starch ................:.................................................. 2.52 g ~ Low-substituted hydroxypropylcellulose ............................. 1.00 g ~ Hydroxypropylcellulose ....................................................
0.60 g ~ Magnesium stearate ........................................................
0.20 g Coating Composition ~ Hydroxypropylmethylcellulose ........................................... 0.3 g , ~ Polyethyleneglycole ......................................................... 0.03 g ~ Titanium oxide ................................................................ 0.10 g

Claims (22)

Claims:

1. A pharmaceutical composition for the treatment and/or prevention of depression, which comprises the EP1 antagonist as active ingredient.

2. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is benzenesulfonamide derivative of formula (IA) wherein R1A is hydroxy, C1-4 alkoxy or a group of formula in which R6A and R7A each independently, is hydrogen or C1-4 alkyl, R2A is hydrogen or C1-4 alkyl, R3A and R4A are C1-4 alkyl, halogen atom or trifluoromethyl, R5A is hydrogen, C1-4 alkyl, halogen atom or trifluoromethyl, Y is cis-vinylene or trans-vinylene ~ is a single bond or a double bond:
a non-toxic salt thereof or a cyclodextrin clathrate thereof.

3. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 2, wherein EPA antagonist is 6-[(2S, 3S)-3-(4-chloro-2-methylphenylsulfonylaminomethyl)-bicyclo[2.2.2]octan-2-yl]-5Z-hexenoic acid, or a non-toxic salt thereof, an acid addition salt thereof or a cyclodextrin clathrate thereof.

4. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is benzenesulfonamide or carbamide derivative of formula (1B) wherein and each independently, is C5-15 carbocyclic ring or 5-7 membered heterocyclic ring containing 1 or 2 of oxygens, sulfurs or nitrogens, Z1 is -COR1B, -C1-4 alkylene-COR1B, -CH=CH-COR1B, -C.ident.C-COR1B, -O-C1-3 alkylene-COR1B, in which R1B is hydroxy, C1-4 alkoxy or NR6B R7B in which R6B and R7B each independently, is hydrogen or C1-4 alkyl; or -C1-5 alkylene-OH, Z2 is hydrogen, C1-4 alkyl, C1-4 alkoxy, nitro, halogen atom, trifluoromethyl, trifluoromethoxy, hydroxy or COR1B in which R1B as hereinafter defined Z3 is a single bond or C1-4 alkylene, Z4 is SO2 or CO, Z5 is (1) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (2) phenyl, C3-7 cycloalkyl or 5-7 membered heterocyclic ring containing 1-2 of oxygens, sulfurs or nitrogens, (3) C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl substituted by phenyl or C3-7 cycloalkyl, in the above (2) and (3), phenyl, C3-7 cycloalkyl and 5-7 membered heterocyclic ring containing 1-2 of oxygens, sulfurs or nitrogens may be substituted by 1-5 of R5B in which multiple R5B each independently, is hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, nitro, halogen atom, trifluoromethyl, trifluoromethoxy or hydroxyl;
R2B is CONR8B, NR8B CO, CONR8B-C1-4 alkylene, C1-4 alkylene-CONR8B, NR8BCO-C1-alkylene, C1-4 alkylene-NR8B CO, C1-3 alkyleen-CONR8B-C1-3 alkylene, C1-3 alkylene-NR8B CO-C1-3 alkylene, in which R8B is hydrogen or C1-4 alkyl oxygen, sulfur, NZ8 in which Z6 is hydrogen or C1-4 alkyl; -Z7-C1-4 alkylene, C1-4 alkylene-Z7, C1-3 alkylene-Z7-C1-3 alkylene in which Z7 is oxygen, sulfur or NZ6 in which Z6 is as hereinbefore defined CO, CO-C1-4 alkylene, C1-4 alkylene-CO, C1-3 alkylene-CO-C1-3 alkylene, C2-4 alkylene, C2-4 alkenylene, C2-4 alkynylene, R3B is hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, nitro, halogen atom, trifluoromethyl, tritluoromethoxy, hydroxy or hydroxymethyl, R4H is (1) hydrogen, (2) C1-8 alkyl, C2-8 alkenyl or C2-8 alkynyl, (3) C1-6 alkyl substituted by 1-2 of COOZ8, CONZ9Z10, OZ8 in which Z8, Z9 and Z10 each independently, is hydrogen or C1-4 alkyl; and C1-4 alkoxy-C1-4 alkoxy, (4) C3-7 cycloalkyl, (5) C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl substituted by phenyl or C3-7 cycloalkyl, in the above (4) and (5), phenyl, C3-7 cycloalkyl may be substituted by 1-5 of R5B in which R6B is as hereinbefore defined, n and t each independently, is 1-4, with the proviso that (1) R2B bond to atom of only 1-position in B2 ring and R3B bond to atom of only 2-position in B2 ring, (2) when A2 ring is benzene and (Z2)t is not COR1B, then Z1 bond only 3 or 4-position in benzene of A2 ring;
or a non-toxic salt thereof.

5. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 4, wherein EP1 antagonist is (1) 4-[2-(N-isobutyl-2-furanylsulfonylamino)-5-trifluoromethylphenoxymethyl]
cinnamic acid, (2) 4-[5-trifluoromethyl-2-[N-(5-methy;-2-furylcarbonyl)-N-isopropylamino]
phenoxymethyl]cinnamic acid, or a non-toxic salt thereof.

6. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (IC) wherein R1C is hydrogen, halogen atom or -CF3, R2C is hydrogen, halogen atom, -OH or -OCH3, Z C is oxygen, sulfur, -S(O)- or -S(O)2-, X C is -CH=CH-, -CF2-, -CHF-, -(CH2)nc- or -(CH2)pc -CH=CH-, Y C is -CH(OH)-, -NR3C-, sulfur, -S(O)-, -S(O)2- or oxygen, q C is 0 or 1, r C is 0 or 1, with the proviso that in the case of following (1), (2) or (3), r C is not 0:
(1) X C is -CH=CH-, -(CH2)nc or -(CH2)pc -CH=CH-, q C is 1 and Ar C is imidazole or phenyl, (2) X C is -(CH2)nc-, q C is 1, nc is 1 and Ar C is ethylphenyl substituted by halogen atom, methyl or alkoxy, (3) q C is 1, m C is 1, 2, 3, 4, 5 or 6 and Ar C is imidazole or phenyl, m C is 0-6, with the proviso that when X C is -(CH2)nc-, q C is 1, Y C is oxygen, sulfur, -S(O)-or -S(O)2- and Ar C is phenyl, and then m C is not 0, n C is 1-6, p C is 1-6, R3C is hydrogen or t-butyloxycarbonyl, Ar C is aryl, alkyl-substituted aryl or aryl-substituted aryl.

7. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (ID) wherein A D is an optionally substituted: 8-10 membered bicyclic heteroaryl, 5-membered heteroaryl, naphthyl or phenyl, with the proviso that -OCH(R3D)- and X D-linking group are positioned in a 1, 2 relationship to one another on ring carbon atoms, B D is an optionally substituted 5-6 membered heteroaryl ring system or optionally substituted phenyl, D D is optionally substituted: pyridyl, pyrazinyl, pyrimidyl, pyridazyl, pyrrolyl, thienyl, furyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl or phenyl, X D is -(CHR4D)nD- or -(CHR4D)p D CR4D=CR4D(CHR4D)qD-, in which n D is 1-3, and p D and q D
are either both 0 or one of p D and q D is 1 and the other is 0, R1D is positioned on ring B D in a 1, 3 or 1,4 relationship with the -OCH(R3D)-linking group in 6-membered rings and in a 1, 3 relationship with -OCH(R3D)- linking group in 5-membered rings and carboxy, carboxy-C1-3 alkyl, tetrazolyl, tetrazolyl-C1-3 alkyl, tetronic acid, hydroxamic acid or sulphonic acid, or R1D is -CONR aD R a1D in which R aD is hydrogen or C1-6 alkyl, R a1D is hydrogen, or optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-6 alkyl, C3-7 cycloalkyl-C2-6 alkenyl, C3-7 cycloalkyl-C2-6 alkynyl, C5-7 cycloalkenyl, C3-7 cycloalkenyl-C1-6 alkyl, C5-7 cycloalkenyl-C2-6 alkenyl, C5-cycloalkenyl-C2-6 alkynyl, C1-3 alkyl substituted by 5-6 membered saturated or partially saturated heterocyclic ring, 5-6 membered saturated or partially saturated heterocyclic ring or 5-6 membered heteroaryl, or R aD and R a1D together with the amide nitrogen to which they are attached (NR aD R a1D) form an amino acid residue or ester thereof, or R1D is -CONHSO2R bD in which R bD is optionally substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl-C1-6 alkyl, C3-7 cycloalkyl-C2-6 alkenyl, C3-7 cycloalkyl-C2-6 alkynyl, C3-7 cycloalkenyl-C1-6 alkyl, C3-7 cycloalkenyl-C2-6 alkenyl, C3-7 cycloalkenyl-C2-6 alkynyl, 5-6 membered heteroaryl, 5-6 membered heteroaryl-C1-6 alkyl, phenyl, phenyl-C1-6 alkyl, 5-6 membered saturated or partially saturated hetrocyclic ring or 5-6 membered saturated or partially saturated hetrocyclic ring-C1-6 alkyl, R3D is hydrogen or C1-4 alkyl, R4D is hydrogen or C1-4 alkyl, with the proviso that 4-(2-benzyl-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid and 4-(2-(3-phenylprop-2-ene-1-yl)-3-hydroxy-4-formyophenoxymethyl-3-methoxybenzoic acid are excluded or N-oxide thereof, or S-oxide of sulfur containing rings, or a pharmaceutically acceptable salt thereof or in vivo hydrolyzable ester or amide thereof.

8. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (IE) wherein A E is optionally substituted: phenyl, naphthyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidyl, thienyl, thiazolyl, oxazolyl or thiadiazolyl having at least two adjacent ring carbon atoms, with the proviso that -CH(R3E)N(R2E)B E-R1E and -OR4E are positioned in a 1, 2 relationship to one another on ring carbon atom and the ring atom position ortho to the OR4E linking group (and therefor in the 3-position relative to the -linking group) is not substituted, B E is optionally substituted: phenyl, pyridyl, thiazolyl, oxazolyl, thienyl, thiadiazolyl, imidazolyl, pyrazinyl, pyridazinyl or pyrimidyl, R1E is positioned on ring B E in a 1, 3 or 1, 4 relationship with -CH(R3E)N(R2E)- linking group and is carboxy, carboxy-C1-3 alkyl, tetrazolyl, tetrazolyl-C1-3 alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or R1E is -CONR aE R a1E in which R aE is hydrogen or C1-6 alkyl, R a1E is hydrogen, C1-6 alkyl (optionally substituted by halogen atom, amino, C1-4 alkylamino, di-C1-4 alkylamino, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy or C1-4 alkoxycarbonyl), C2-6 alkenyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond is not in the 1-position), carboxyphenyl, 5-6 membered heterocyclyl-C1-3 alkyl, 5-6 membered heteroaryl-C1-3 alkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl, or R aE and R a1E together with the amide nitrogen to which they are attached (NR aE R
a1E) form an amino acid residue or ester thereof, or R1E is -CONHSO2R bE in which R bE is C1-6 alkyl (optionally substituted by halogen atom, hydroxy, nitro, cyano, trifluoromethyl, C1-4 alkoxy, amino, C1-4 alkylamino, di-C1-4 alkylamino or C1-4 alkoxycarbonyl), C2-6 alkenyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond is not in the 1-position), 5-6 membered heterocyclyl-C1-3 alkyl, 5-6 membered heteroaryl-C1-3 alkyl, 5-6 membered heterocyclyl or 5-6 membered heteroaryl or phenyl, wherein any heterocyclyl or heteroaryl group in R a1E is optionally substituted by halogen atom, hydroxy, nitro, amino, cyano, C1-6 alkoxy, C1-6 alkyl-S(O)p E- (p E is 0, 1 or 2), C1-6 alkylcarbamoyl, C1-4 alkylcarbamoyl, di(C1-4 alkyl)carbamoyl, C2-6 alkenyl, C2-alkynyl, C1-4 alkoxycarbonylamino, C1-4 alkanoylamino, C1-4 alkanoyl(N-C1-4 -alkyl)amino, C1-4 alkanesulfonamide, benzenesulfonamide, aminosulfonyl, C1-4 alkylaminosulfonyl, di(C1-4 alkyl)aminosulfonyl, C1-4 alkoxycarbonyl, C-4 alkanoyloxy, C1-6 alkanoyl, formylC1-4 alkyl, hydroxyimino-C1-6 alkyl, C1-4 alkoxyimino-C1-6 alkyl or C1-6 alkylcarbamoylamino, or R1E is -SO2N(R cE)R c1E in which R cE is hydrogen or C1-4 alkyl and R c1E is hydrogen or C1-4 alkyl, or R1E is the formula (E A), (E B) or (E C):

wherein X E is CH or nitrogen, Y E is oxygen or sulfur, Y'E is oxygen or NR dE and Z E is CH2, NR dE or oxygen, with the proviso that there is no more than one ring oxygen and there are at least two ring heteroatoms and wherein R dE is hydrogen or C1-4 alkyl, R2E is hydrogen, C1-6 alkyl optionally substituted by hydroxy, cyano or trifluoromethyl, C2-6 alkynyl (the double bond is not in the 1-position), C2-6 alkynyl (the triple bond in not in the 1-position), phenyl-C1-3 alkyl or pyridyl-C1-3 alkyl, R3E is hydrogen, methyl or ethyl, R4E is optionally substituted: C1-6 alkyl, C3-7 cycloalkyl-C1-3 alkyl or C3-7 cycloalkyl, with the proviso that 2-(2-methoxybenzylamino]pyridine-5-carboxylic acid, 4-(2-methaxybenzylamino]benzoic acid, 5-[2, 5-dimethoxybenzylamino]-2-chloro-3-aminosulfonylbenzoic acid and 5[2, 5-dimethoxybenzylamino]-2-hydroxybenzoic acid are excluded;
or N-oxide of -NR 2E-, or S-oxide of sulfur containing rings, or a pharmaceutically acceptable salt thereof or in vivo hydrolyzable ester or amide thereof.

9. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (1F) wherein HET F is 5-12 membered mono- or bi-cyclic aromatic ring containing 0-3 heteroatoms selected from oxygen, S(O)n F and N(O)m F, in which m F is 0 or 1, n F is 0, 1 or 2, A F is -W F-, -C(O)-, -C(R7F)-W F-, -W F-C(R7F)2-, -CR7F(OR20F)-, -C(R7F)2-, -C(R7F)2-C(OR20F)R7F-, -C(R7F)2-C(R7F)2- or -CR7F=CR7F-, in which W F is oxygen, S(O)n F or NR17F, X F is 5-10 membered mono- or bi-cyclic aryl or heteroaryl having 1-3 heteroatoms selected from oxygen, , S(O)n F and N(O)m F, and optionally substituted by R14F and R15F, and A F and B F are attached to the aryl or heteroaryl ortho relative to each other, Y F is O, S(O)n F, NR17F, a bond or -CR18F=CR18F-;
B F is -(C(R18F)2)p F- Y F-(C(R18F)2)q F-, in which p F and q F are independently 0-3, such that when Y F is O, S(O)n F, NR17F or -CR18F=CR18F-, p F+q F is 0-6, and when Y F
is a bond, p F+q F
is 1-6;
Z F is OH, NHSO2R19F;
R1F, R2F and R3F each independently, is hydrogen, halogen atom, lower alkyl, lower alkenyl, lower alkynyl, lower alkenyl-HET F(R aF)4-9, -(C(CR4F)2)p F)SR5F, -(C(R4F)2)p F OR8F, -(C(R4F)2)p F N(R6F)2, CN, NO2, -(C(R4F)2)p F C(R7F)3, -COOR9F, -CON(R6F)2 or -(C(R4F)2)p F S(O)n F R10F, each R4F is hydrogen, F, CF3, lower alkyl or two R4F, taken together, is a ring of up to six atoms, optionally containing one heteroatom selected from O, S(O)n F and N(O)m F, each R6F is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, lower alkyl-HET F, lower alkenyl-HET F, -(C(R18F)2)p F Ph(R11F)0-2, each R6F is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph, Bn or two R6F together with N to which they are attached, is a ring of up to six atoms, optionally containing an additional heteroatom selected from O, S(O)n F and N(O)m F, each R7F is independently hydrogen, F, CF3, lower alkyl, or two R7F taken together, is 3-6 membered aromatic or aliphatic ring containing 0-2 heteroatom selected from O, S(O)n F
and N(O)m F, each R8F is hydrogen or R5F, each R9F is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, Ph or Bn, each R10F is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, Ph(R11F)0-3, CH2Ph(R11F)0-3 or N(R6F)2, each R11F is independently lower alkyl, SR20F, OR20F, N(R6F)2, -COOR12F, -CON(R6F)2, -COR12F, CN, CF3, NO2 or halogen atom , each R12F is independently hydrogen, lower alkyl or benzyl, each R13F is independently hydrogen, halogen atom, lower alkyl, O-lower alkenyl, S-lower alkyl, N(R6F)2, COOR12F, CN, CF3 or NO2, R14F and R15F are independently lower alkyl, halogen atom, CF3, OR16F, S(O)n F
R16F or C(R16F)2OR17F, each R16F is independently hydrogen, lower alkyl, lower alkenyl, Ph, Bn or CF3, each R17F is independently hydrogen, lower alkyl or Bn, each R18F is independently hydrogen, F or lower alkyl, or two R18F taken together, is 3-6 membered ring optionally containing one heteroatom selected from oxygen, S(O)n F and nitrogen, each R19F is independently lower alkyl, lower alkenyl, lower alkynyl, CF3, HET(R aF)4-9, lower alkyl-HET(R aF)4-9, lower alkenyl-HET(R aF)4-9, each R20F is independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CF3 or Ph(R13F)2, each R aF is independently selected from the following group:
hydrogen, hydroxy, halogen atom, CN, NO2, amino, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, C1-6 alkylamino, di(C1-6 alkyl)amino, CF3, C(O)C1-6 alkyl, C(O)C2-6 alkenyl, C(O)C2-6 alkynyl, COOH, COO(C1-6)alkyl, COO(C2-6)alkenyl and COO(C2-6)alkynyl, said alkyl, alkenyl, alkynyl, and alkyl portions of alkylamino and dialkylamino being optionally substituted by 1-3 of hydroxy, halogen atom, aryl, C1-6 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, CF3, CO(C1-6)alkyl, CO(C2-6)alkenyl, CO(C2-6)alkynyl, COOH, COO(C1-6)alkyl, COO(C2-6)alkenyl, COO(C2-6)alkynyl NH2, NH(C1-6)alkyl and N(C1-6alkyl)2;
or a non-toxic salt thereof.

10. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (IG) Ar1G-W G-Ar2G-X G-W G (IG) wherein Ar1G is aryl or heteroaryl, optionally substituted by R1G or R3G, R1G is Y G mG-R2G, Y G mG-Ar3G, halogen atom, N(R5G)2, CN, NO2, C(R6G)3, CON(R5G)2, S(O)n G R7G or hydroxy, Y G is a linker between R2G or Ar3G and Ar1G containing 0-4 carbon atoms and not more than one heteroatom selected from oxygen, nitrogen and sulfur, said linker optionally containing CO, S(O)n G, -C=C- or acetylenic group, and said linker being optionally substituted by R2G, m G is 0 or 1, n G is 0, 1 or 2, R2G is hydrogen, F, CHF2, CF3, lower alkyl or hydroxy(C1-6)alkyl, or two R2G
taken together, is carbocyclic ring of up to six members, said ring containing not more than one heteroatom selected from oxygen, nitrogen or sulfur , Ar3G is aryl or heteroaryl, optionally substituted by R3G, R3G is R4G, halogen atom, halo(C1-6)alkyl, N(R5G)2, CN, NO2, C(R6G)3, CON(R5G)2, OR4G, SR4G or S(O)n G R7G, R4G is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, CHF2 or CFs, R5G is R4G, Ph or Bn, or two R5G taken together, is a ring of up to six members containing carbon atoms and 0-2 heteroatoms selected from oxygen, nitrogen or sulfur, R6G is hydrogen, F, CF3 or lower alkyl, or two R6G taken together, is a ring of up to six members containing carbon atoms and 0-2 heteroatoms selected from oxygen, nitrogen or sulfur, R7G is lower alkyl, lower alkenyl, lower alkynyl, CHF2, CF3, N(R5G)2, Ph(R8G)2 or CH2Ph(R8G)2, R8G is R4G, OR4G, SR4G or halogen atom, W G is a 3-6 membered linking group containing 0-2 heteroatoms selected from oxygen, nitrogen and sulfur, said linking group optionally containing CO, S(O)mG, C=C, acetylenic group, and optionally being substituted by R9G, R9G is R2G, lower alkyl, lower alkynyl, OR4G or SR4G, Ar2G is aryl or heteroaryl, optionally substituted by R3G, R10G is R4G, halogen atom, N(R5G)2, CN, NO2, C(R6G)3, OR4G, SR4G or S(O)n G
R7G, X G is a linker which is attached to Ar2G ortho to the attachment of W G, said linker containing 0-4 carbon atoms and not more than one heteroatom selected from oxygen, nitrogen and sulfur, said linker further optionally containing CO, S(O)n G, C=C or acetylenic group, and said linker being optionally substituted by R11G, R11G is R9G, Q G is a member selected from the group consisting of COOH, tetrazole, SO3H, hydroxamic acid, CONHSO2R12G and SO2NHCOR12G, R12G is a member selected from the group consisting of CF3, lower alkyl, lower alkenyl, lower alkynyl and Z G Ar4G, Z G is a linker containing 0-4 carbon atom, optionally substituted by R13G, R13G is R9G, Ar4G is aryl or heteroaryl, optionally substituted by R14G, R14G is R10G or NHCOMe;
or an non-toxic salt thereof.

11. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (IH) wherein y H and z H are independently 0-2, with the proviso that y H + z H =
2, R aH is 1) heteroaryl, wherein heteroaryl is selected from the group (a) - (n):
(a) fury, (b) diazinyl, triazinyl or tetrazinyl, (c) imidazolyl, (d) isoxazolyl, (e) isothiazolyl, (f) oxadiazolyl, (g) oxazolyl, (h) pyrazolyl, (i) pyrrolyl, (j) thiadiaxolyl, (k) thiazolyl, (l) thienyl, (m) triazolyl and (n) tetrazolyl, wherein heteroaryl is optionally substituted by one or more substituents independently selected from R11H and C1-4 alkyl;
2) -COR6H, 3) -NR7HR8H, 4) -SO2R9H, 5) hydroxy, 6) C1-6 alkoxy, optionally substituted by one or more substituents independently selected from R11H, and 7) C1-6 alkyl, C2-6 alkenyl or C3-6 cycloalkyl, optionally substituted by one or more substituents independently selected from R11H, and further substituted by 1-3 substituents independently selected from the group of (a) - (h):
(a) -COR6H, (b) -NR7HR8H, (c) -SO2R9H, (d) hydroxy, (e) C1-6 alkoxy or haloC1-6 alkoxy, and (f) heteroaryl;

R aH is positioned on the phenyl ring to which it is bonded in a 1, 3 or 1, 4 relationship relative to the thienyl group of formula (IH), R1H, R2H, R3H, R4H and R5H are independently selected from the following group:
1) hydroxy, 2) halogen atom, 3) C1-6 alkyl, 4) C1-6 alkoxy, 5) C1-6 alkylthio, 6) nitro, 7) carboxy, and 8) CN, wherein groups of 3) - 5) are optionally substituted by one or more substituents independently selected from R11H, R6H is hydrogen, hydroxy, C1-6 alkyl, C1-6 alkoxy and NR7HR6H, wherein C1-6 alkyl and C1-6 alkoxy are optionally substituted by one or more substituents independently selected from R11H, R7H and R8H are independently selected from the group: 1) hydrogen, 2) hydroxy, 3) SO2R9H, 4) C1-6 alkyl, 5) C1-6 alkoxy, 6) phenyl, 7) naphthyl, 8) furyl, 9) thienyl and 10) pyridyl, wherein groups of 4) - 5) are optionally substituted by one or more substituents independently selected from R11H and groups of 6) -10) are optionally substituted by one or more substituents independently selected from R11H or C1-4 alkyl, R9H is selected from the group:
1) hydroxy, 2) N(R10H)2, 3) C1-6 alkyl, optionally substituted by one or more substituents independently selected from R11H, 4) phenyl, 5) naphthyl, 6) furyl, 7) thienyl, and 8) pyridyl, groups of 4) - 8) are optionally substituted by one or more substituents independently selected from R11H and C1-4 alkyl, R10H is hydrogen or C1-6 alkyl, R11H is halogen atom, hydroxy, C1-3 alkoxy, nitro, N(R10H)2, and pyridyl;
or a pharmaceutically acceptable salt, hydrate or ester thereof.

12. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is a compound of formula (IJ) wherein y J and z J are independently 0-2, with the proviso that y J + z J =
2, R aJ is 1) heteroaryl, wherein heteroaryl is selected from the group (a) - (n):

(a) fury, (b) diazinyl, triazinyl or tetrazinyl, (c) imidazolyl, (d) isoxazolyl, (e) isothiazolyl, (f) oxadiazolyl, (g)oxazolyl, (h) pyrazolyl, (i) pyrrolyl, (j) thiadiazolyl, (k) thiazolyl, (l) thienyl, (m) triazolyl and (n) tetrazolyl, wherein heteroaryl is optionally substituted by one or more substituents independently selected from R11J and C1-4 alkyl;
2) -COR6J, 3) -NR7J R8J, 4) -SO2R9J, 5) hydroxy, 6) C1-6 alkoxy, optionally substituted by one or more substituents independently selected from R11J, and 7) C1-6 alkyl, C2-8 alkenyl or C3-6 cycloalkyl, optionally substituted by one or more substituents independently selected from R11H, and further substituted by 1-3 substituents independently selected from the group of (a) - (f):
(a) -COR6J, (b) -NR7JR8J, (c) -SO2R9J, (d) hydroxy, (e) C1-6 alkoxy or haloC1-6 alkoxy, and (f) heteroaxyl, R aJ is positioned on the pyridyl ring to which it is bonded in a 1, 3 or 1, 4 relationship relative to the thienyl group of formula (IJ), R1J, R2J, R3J, R4J and R5J are independently selected from the following group:
1) hydroxy, 2) halogen atom, 3) C1-6 alkyl, 4) C1-6 alkoxy, 5) C1-6 alkylthio, 6) nitro, 7) carboxy, and 8) CN, wherein groups of 3) - 5) are optionally substituted by one or more substituents independently selected from R11J, R6J is hydrogen, hydroxy, C1-6 alkyl, C1-6 alkoxy and NR7JR8J, wherein C1-6 alkyl and C1-6 alkoxy are optionally substituted by one or more substituents independently selected from R11J, R7J and R8J are independently selected from the group: 1) hydrogen, 2) hydroxy, 3) SO2R9J, 4) C1-6 alkyl, 5) C1-6 alkoxy, 6) phenyl, 7) naphthyl, 8) furyl, 9) thienyl and 10) pyridyl, wherein groups of 4) - 5) are optionally substituted by one or more substituents independently selected from R11J, and groups of 6) - 10) are optionally substituted by one or more substituents independently selected from R11J or C1-4 alkyl, R9J is selected from the group:
1) hydroxy, 2) N(R10J)2, 3) C1-6 alkyl, optionally substituted by one or more substituents independently selected from R11J, 4) phenyl, 5) naphthyl, 6) furyl, 7) thienyl, and 8) pyridyl, groups of 4) - 8) are optionally substituted by one or more substituents independently selected from R11J and C1-4 alkyl, R10J is hydrogen or C1-6 alkyl, R11J is halogen atom, hydroxy, C1-3 alkoxy, nitro, N(R10J)2, and pyridyl;
or a pharmaceutically acceptable salt, hydrate or ester thereof.

13. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, wherein EP1 antagonist is N-arylsulfonylamide compound of formula (IK) wherein R1K is COOH, hydroxymethyl, 5-tetrazolyl, 5-oxo-1,2,4-oxadiazolyl or 5-oxo-1,2,4-thiadiazolyl, R2K is hydrogen, methyl, methoxy or chloro, R3K and R4K are a combination of (1) methyl and methyl, (2) methyl and chloro, (3) chloro and methyl, or (4) trifluoromethyl and hydrogen or R3 and R4 are taken together with the carbon to which R3 and R4 are attached to form (5) cyclopentene, (6) cyclohexene or (7) benzene ring, R5K is isopropyl, isobutyl, 2-methyl-2-propenyl, cyclopropylmethyl, methyl, ethyl, propyl, 2-propenyl or 2-hydroxy-2-methylpropyl, Ar K is thiazolyl optionally substituted with methyl, pyridyl or 5-methyl-2-furyl, n K is 0 or 1, with the proviso that when R1K is 5-tetrazolyl, 5-oxo-1,2,4-oxadiazolyl or 5-oxo-1,2,4-thiadiazolyl, and then n is 0, an alkyl ester thereof or a non-toxic salt thereof.

14. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 13, wherein EP1 antagonist is (1) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-5-trifluoromethylphenoxymethyl]benzoic acid, (2) 4-[2-[N-isopropyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (3) 3-methyl-4-[2-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]-4, 5-dimethylphenoxymethyl]benzoic acid, (4) 4-[6-[N-isobutyl-N-(5-methyl-2-furylsulfonyl)amino]indan-5-yloxymethyl]cinnamic acid, (5) 3-methyl-4-(6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]cinnnamic acid, (6) 4-(4, 5-dimethyl-2-[N-methyl-N-(5-methyl-2-furylsulfonyl)-N-propylamino]
phenoxymethyl]benzoic acid, (7) 4-(6-[N-isobutyl-N-(4-methyl-2-thiazolylsulfonyl)amino]indan-5-yloxymethyl]benzoic acid, a non-toxic salt thereof, or ester thereof.

15. 4-[5-trifluoromethyl-2-[N-(5-methy-2-furylcarbonyl)-N-isopropylamino]
phenoxymethyl]cinnamic acid or a non-toxic salt thereof.

16. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and antianxiety agent.

17. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and antidepressant.

18. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and anticholinergic agent.

19. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and serotonin antagonist.

20. A pharmaceutical composition for the treatment andlor prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and serotonin agonist.

21. A pharmaceutical composition for the treatment andlor prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and calcium antagonist.

22. A pharmaceutical composition for the treatment and/or prevention of depression according to the claim 1, which comprises a combination of EP1 antagonist and phosphodiesterase inhibitor.